Oncology-focused Ascelia Pharma strengthens its board of directors to support international expansion

”With our two strong drug candidates – Mangoral® and Oncoral – we are ready to take Ascelia Pharma to the next level. We are very pleased that Helena Wennerström and Hans Maier will be joining the board and sharing their valuable expertise and experience, not least in the areas of life science, corporate development and internationalisation,” says Peter Benson, chairman of Ascelia Pharma’s board of directors. Over his 25-year career Hans Maier has held senior positions at Schering AG and Bayer AG, including Head of the Global Business Unit Diagnostic Imaging in both companies. He has spent almost a decade in Asia serving as Managing Director for Schering AG in Korea and in Japan. He is a co-founder and managing partner of the Berlin based life science consulting and transaction advisory firm BGM Associates GmbH. Hans holds a PhD in Economics and Social Sciences and is a Professor of International Strategic Management at Berlin School of Economics and Law. ” I am excited to join the board of Ascelia Pharma, which, I believe, has the potential to develop into a successful specialty pharma and oncology company. I look forward to contributing with my experience in the pharmaceutical and diagnostic imaging industries to first of all successfully develop and market Mangoral®, Ascelia Pharma’s lead compound. Mangoral® is likely to become the contrast agent of choice for liver imaging in patients with severely impaired kidney function and thus provides a welcome medical alternative to gadolinium-based imaging agents,” says Hans Maier. Helena Wennerström is CFO and Deputy CEO of Bulten. Her previous experience includes similar positions at Finnveden and FinnvedenBulten, Dicentia and Topcon. Helena holds a Master in Business Administration and will serve as chair of Ascelia Pharma’s audit committee. She has international experience from Bulten, which has operations in several countries. ”Ascelia Pharma is a pioneer in the development of innovative pharmaceutical products that fill an unmet medical need in cancer treatment. As a director, I am looking forward to using my financial expertise to support Ascelia Pharma in its exciting journey,” says Helena Wennerström. Helena Wennerström and Hans Maier join current Ascelia Pharma board members Peter Benson (chair), Niels Mengel, René Spogárd and Bo Jesper Hansen. About Mangoral®Mangoral® is an oral imaging drug candidate (contrast agent) ready for its final clinical development phase (phase 3). Used for diagnostic purposes as an MRI contrast agent, Mangoral® improves the detection and localisation of liver metastases. Mangoral® fills an unmet medical need for patients with impaired kidney function who should not use the currently marketed contrast agents, which are based on the heavy metal gadolinium, due to the risk of serious side effects. About OncoralOncoral, currently in phase 1 clinical development, is an oral formulation based on irinotecan, which is a widely used chemotherapeutic agent. Oncoral is being developed for treatment of advanced gastric cancer and has the potential to be advantageously combined with other chemotherapies.   For additional information, please contact:Peter Benson, Chairman of the board +45 40 80 48 69 Magnus Corfitzen, CEO+46 735 179 110 About Ascelia PharmaAscelia Pharma is a specialty pharmaceutical company dedicated to the development of novel medicines to improve the life expectancy and quality of life for people living with cancer. The company is located in Malmö, Sweden in the middle of Medicon Valley, a leading European life science cluster. Ascelia Pharma’s largest shareholders are Sunstone Capital and Öresund Healthcare. For more information, please visit www.ascelia.com 

Phase II-trial DIAGNODE-2 ahead of World Diabetes Day now open to include patients

“Given the highly promising data we have seen from DIAGNODE-1, it is of course a great event and a potential opportunity for diabetes patients, and we are particularly pleased that we can start work on patient recruitment right in connection to the World Diabetes Day,” says Professor Johnny Ludvigsson, Coordinating Investigator of DIAGNODE-2. “Our goal with DIAGNODE-2 is to finally confirm the effect of the diabetes vaccine,” says Ulf Hannelius, CEO of Diamyd Medical. About type 1 diabetes and DIAGNODE-2Type 1 diabetes is an autoimmune disease where the beta cells, the cells in the pancreas that produce insulin, are broken down by the immune system. GAD65 (glutamic acid decarboxylase) is an endogenous protein that is expressed by the beta cells. In autoimmune diabetes, the immune system identifies the protein as dangerous and attacks and destroys the insulin-producing cells. GAD65 is the active ingredient in the diabetes vaccine Diamyd®. In the placebo-controlled trial DIAGNODE-2, where the diabetes vaccine Diamyd® is administered directly into the lymph node, approximately 80 patients between the ages of 12-24 are included, newly diagnosed with type 1 diabetes. Patients will be monitored for 15 months to evaluate their remaining insulin producing capacity. The treatment is being tested with the goal to interrupt the autoimmune attack on the beta cells by reducing the immune system's sensitivity to GAD65 and thus preserving the remaining insulin production. The remaining insulin production in newly diagnosed type 1 diabetes patients is important to preserve, as it facilitates life with diabetes, decreases the number of hypoglycemias and leads to fewer long-term complications. Coordinating Investigator for DIAGNODE-2 is Professor Johnny Ludvigsson at Linköping University. About Diamyd MedicalDiamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology. Diamyd Medical develops the diabetes vaccine Diamyd®, for antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Besides the Company’s own European Phase-II trial DIAGNODE-2, where the diabetes vaccine is administered directly into the lymph node, there are four investigator initiated clinical trials ongoing with Diamyd®. Diamyd Medical also develops Remygen®, a proprietary GMP manufactured oral GABA-based study drug. An investigator initiated placebo controlled trial with GABA and Diamyd® in patients recently diagnosed with type 1 diabetes is ongoing at the University of Alabama at Birmingham. Exclusive licenses for GABA and positive allosteric modulators of the GABAA receptor for the treatment of diabetes and inflammatory diseases constitutes alongside with the diabetes vaccine Diamyd® and Remygen® key assets. Diamyd Medical is also one of the major shareholders in the stem cell company NextCell Pharma AB and has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA. Diamyd Medical’s B-share is traded on Nasdaq First North under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.

Moberg Pharma AB interim report January - September 2017

NINE-MONTH PERIOD (JAN-SEPT 2017) · Net revenue SEK 348.9 million (244.9) · EBITDA SEK 62.4 million (65.9) · EBITDA excluding capital gains* SEK 49.4 million (24.7) · EBITDA for current product portfolio SEK 75.2 million(76.0) · Operating profit (EBIT) SEK 33.5 million (55.1) · Net profit after tax SEK 1.6 million (35.1) · Diluted earnings per share SEK 0.09 (2.45) · Operating cash flow per share SEK 1.40 (-1.64) THIRD QUARTER (JUL-SEPT 2017) · Net revenue SEK 108.3 million (104.1) · EBITDA SEK 36.0 million (29.0) · EBITDA excluding capital gains* SEK 23.0 million (29.0) · EBITDA for current product portfolio SEK 39.6 million(32.6) · Operating profit (EBIT) SEK 26.6 million (23.4) · Net profit after tax SEK 12.3 million (12.8) · Diluted earnings per share SEK 0.71 (0.89) · Operating cash flow per share SEK 3.01 (-1.47) *Excluding a capital gain of SEK 13 million from the divestment of Fiber Choice®. The comparative figures exclude a capital gain in Q2 2016 of SEK 41.1 million from the divestment of the Jointflex®, Fergon® and Vanquish® brands SIGNIFICANT EVENTS DURING THE THIRD QUARTER · Positive data from clinical trial for Kerasal Nail®/Emtrix® · Divestment of Fiber Choice® for SEK 54 million (USD 6.7 million), with a capital gain of SEK 13 million · Torbjörn Wärnheim, Director Pharmaceutical Innovation and Development, joined the management team · Canadian patent granted for BUPI SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER · Update on timeline for MOB-015, patient recruitment expected to be finalized in 2018 STATEMENT FROM THE CEOStrong development for our three largest brands in the US, where the invigoration of New Skin has been a great success with 17% growth in the nine-month period. Recruitment for the MOB-015 Phase 3 studies is estimated to be completed in the summer of 2018 in North America and in the second half of 2018 for the European study. The successful divestment of Fiber Choice releases resources and strengthens our cash reserves. The high season for Kerasal Nail® and New Skin® is ending and the effects of this year’s ad campaigns lasted far into September. Since the acquisition of New Skin®, we have succeeded in driving strong growth, with a sales increase of 17%[1]  in the nine-month period. The positive trend is a result of our efforts to strengthen the brand, behind the breakthrough “Mr. Cut” advertising campaign that launched in June and expanded distribution at Walgreens and Walmart. For Dermoplast®, we are still seeing inventory effects from the takeover from the previous owner, but underlying demand from end customers is strong and we see several possibilities for driving future growth. For both these brands we see potential to further leverage a digital/social media marketing strategy. Kerasal Nail® is developing strongly in the US, with 17% consumer sales growth for the nine-month period. Impactful advertising and the powerful new “one-week claim” launched earlier this year continue to drive positive consumption gains. We successfully extended the television campaign and managed to optimize our marketing mix further. Extending advertising deeper into the season brought the added benefit of a strong halo effect. We delivered positive gains in consumption and strong share versus year ago in the two months since coming off air.   In terms of distributor sales of Kerasal Nail®, revenue levels are lower than they have been historically. The efforts in Asia have not met expectations and we therefore set lower expectations as to the region's contribution to the company's revenue. Profitability is good, however, and we see significant potential for next-generation nail fungus product, MOB-015, in these markets as well. In August, we divested the Fiber Choice® brand for SEK 54 million (USD 6.7 million) plus inventory value, with a capital gain of SEK 13 million. In accordance with our plan, we have now successfully divested both non-strategic brands included in the acquisition from Prestige Brands. By streamlining the product portfolio, resources are released, and we can place greater focus on our larger brands. Through the divestment and strong operating cash flow in the quarter, our cash reserves strengthened significantly to SEK 121 million. Recruitment to the phase 3 studies for MOB-015 continues in parallel in North America and Europe. We are not satisfied with the development of studies with delays and increased costs and have therefore initiated an extensive action program. Our current assessment is, that we in North America will complete recruitment in the summer of 2018 and in the second half of 2018 in Europe, and also that we can complete both studies without additional external financing. My presence in the US creates new opportunities to expand our contacts with new investors and potential partners, with some of the major American players in the field nearby. I expect an exciting year to continue with further development of the company's portfolio and network in our largest market. Peter Wolpert, CEO Moberg Pharma ---------------------------------------------------------------------- [1]  Symphony IRI, U.S. MULO, during the year up to October 8, 2017 CONFERENCE CALLCEO Peter Wolpert will present the report at a telephone conference today, November 13, 2017, at 3:00 p.m. CET. Telephone: SE +46-8-566 425 08, US +1 646 502 51 18 ABOUT THIS INFORMATIONThis information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 a.m. CET on November 13th, 2017. 

NCC to build swimming complex in Varberg

“Varberg is growing and this new swimming complex will be the municipality’s single largest investment to date. It will be designed to meet residents’ need for leisure, recreation and social activities,” says Ann-Charlotte Stenkil (Moderate Party), Chairman of the Municipal Executive Board. The investment also represents a step toward achieving the goal of developing Varberg into a municipality with an exciting and innovative range of cultural and sporting activities. The municipality’s existing pool was opened in the early 1980s and is currently in need of extensive renovations. The new complex, which will be situated in the same location as the old facility, will feature a 50-meter pool and accommodate approximately 300,000 visitors per year. The assignment comprises a turnkey contract divided into two phases. During the first phase, the partners will design the construction project and agree on a target cost for the project. During the second phase they will demolish the existing facility and concentrate on construction. The assignment also includes groundwork and other work related to the outdoor environment, other equipment in the swimming complex and installation work. “We are now continuing our successful partnership with Varberg Municipality, where we are already building a number of schools,” says Henrik Landelius, Head of NCC Building in Sweden. Work on the first phase will begin during autumn/winter 2017 and the new swimming complex is expected to be completed in early 2021. The order is expected to be registered in the third quarter of 2018 in the NCC Building business area.

Medals of War enters Open Beta on Android

“We’re now looking to introduce Medals of War to Android users, as well. There’s been a great demand for the Android version, so we wanted to open up the Google Play Open Beta in countries where the iOS version is already available. This gives the Android players the opportunity to play together with iOS players.” says Jussi Tähtinen, CEO & Co-Founder, Nitro Games Oyj. This launch follows Nitro Games’s strategy where the company is self-publishing it’s games in the western markets. The other markets are to be accessed via publishing partners according to plan. Medals of War has been developed with Nitro Games’ MVP –process, where the game development is closely tied to continuously collecting actual market data and community feedback, as the game is being further developed. Google Play Open Beta version can be accessed by a direct link that will be shared with the core audiences via Social Media and other key channels. “This Open Beta launch means that we’re offering the game for players to test on Android for the first time while we’re still finalizing the Android version. The purpose of this Open Beta launch is for us to validate the game performance on Android as well as to collect feedback from our Android users.” concludes Jussi Tähtinen. Medals of War is a community-focused game that brings players together with their friends. Players are matched with each other in intense PvP combat – in real-time! The aim is to level up and hone your skills to be the best commander in Warland. Find out more and follow us on: Facebook: https://www.facebook.com/MedalsofWar  Twitter: https://twitter.com/MedalsofWar  Website: www.medalsofwargame.com 


INCREASE IN PRODUCTION ACCORDING TO PLAN, RECORD QUARTER AT VALLVIK · Production volume in the third quarter rose by 12% to 102.5 thousand tonnes (91.9). Vallvik Mill set a new quarterly production record. Rottneros Mill underwent its annual maintenance shutdown in September. · Investments in the Agenda 500 development programme are progressing according to plan, in terms of both costs and increased capacity. The new biofuel boiler makes Rottneros Mill’s energy consumption essentially fossil-free. · Financing of the Agenda 500 programme has been secured with a 5-year bond issue of SEK 400 million. This contributes to optimising the Group's capital structure. · Rottneros and RenFuel are beginning collaboration in the use of the residual product, lignin, from Vallvik Mill in the manufacture of Lignol®, a raw material for renewable petrol and diesel. · Net turnover in the third quarter increased by 6% to SEK 472 million (444). Turnover in the January–September period rose by 10% to SEK 1,416 million (1,289). · Profit after financial items in the third quarter totalled SEK 41 million (45) and in the January–September period amounted to SEK 159 million (170). Earnings per share in January–September were SEK 0.81 (0.88). · Cash flow from operating activities in the third quarter totalled SEK 57 million (93). · The list price for NBSK pulp during the third quarter was 10% higher in USD and 5% higher in SEK, compared with the third quarter of 2016. However, compared with the second quarter of 2017, the price in SEK was 4% lower.  COMMENTS BY THE CEO: RECORD QUARTER AT VALLVIK Our focus on profitable and sustainable growth continues to result in a clear trend towards increased production. Vallvik Mill reported a new production record during the third quarter. This proves that our strategic investment in the Agenda 500 programme is increasing the capacity in accordance with plans. Operating profit for the quarter decreased by SEK 2 million to SEK 44 million and was held back by certain unplanned events. The cost development is not satisfactory. We have increased our focus on the costs in order to return to a normal level. We are doing this in the same goal-oriented manner that has led us to the higher production volumes.  The Group’s production rose by 12 per cent to 102,500 tonnes, which represents yet another quarter in which production exceeded 100,000 tonnes. This was all achieved despite the annual maintenance shutdown at Rottneros Mill, which proves that we are gradually moving towards higher production volumes. Potential is there to further increase availability at our mills in the future. However, we are not satisfied with cost development. In the future, we will focus on achieving cost-efficiency in a structured and goal-oriented manner. In this way, we will take the next step towards increasing profitability alongside the expanded volume which we have been intensively working on over the last 15 months. The strong market is creating good conditions for profitability, despite the weaker USDThe market continues to be positive with a good balance between supply and demand. Our outlook for the fourth quarter is thus optimistic. The weakening of the dollar against the krona over the summer has, to some extent, been reversed in the past few months, and has also been counteracted by an increasing USD pulp price. Taken as a whole, the external conditions for achieving both profitability and growth for the Group are good. Sustainability lies at the heart of our operationsSustainability is a key element when we continue to develop Rottneros. A number of important activities were closely linked to this during the quarter. The investment in the fully bio-based, solid-fuel boiler at Rottneros Mill has successfully been brought into operation. The new boiler replaces an old oil-based boiler. The mill’s energy consumption is now essentially fossil-free and more efficient, decreasing the mill’s variable costs by SEK 25 million annually. The agreement with RenFuel, which we signed in September, means that we will start delivering lignin from Vallvik Mill. Lignin shipment will start up during the course of next year and will be used in RenFuel's lignin oil, which in turn can be refined into renewable petrol and diesel. This will undoubtedly be an exciting market in the future. Rottneros Mill carried out its annual maintenance shutdown in September, while Vallvik performed its shutdown at the beginning of the fourth quarter. Both went according to plan, with costs in line with expectations, i.e. SEK 10 million and SEK 55 million, respectively. A new wash press was installed as part of the shutdown at Vallvik Mill, which ensures not only higher production capacity but also a reduction in emissions in order to comply with new, stricter environmental requirements. Financing of Agenda 500 securedIn August, we concluded the financing of our strategic action plan, Agenda 500, through a bond issue of SEK 400 million within a framework of SEK 600 million. This ensures full financing of our expansion investments over the next four years. We will therefore meet our goal of achieving production volume of at least 470 thousand tonnes by the end of 2021. We are also creating a more optimal balance sheet through increased borrowing. This will allow us to raise the potential return on shareholders’ equity, while simultaneously keeping the balance sheet at a solid, strong level. Looking ahead, conditions will remain positive for delivering on our goals. We have excellent opportunities to bring about sustainability, profitable growth through expanded production volumes, and increased efficiency at our facilities. Our focus is on constantly optimising the factors that we can influence while taking advantage of the opportunities the outside world provides us with. Lennart Eberleh  This information is information that Rottneros AB is obliged to publish under the EU Market Abuse Regulation and the Securities Market Act. The information was submitted via the contact person below for publication on 13 November 2017 at 8 a.m. CET. Swedish and English versions of this report have been drawn up. The Swedish version shall prevail in the event of differences between the two reports. For further information, please contact:Lennart Eberleh, President and CEO, Rottneros AB, +46 270 622 65


The third quarter has been characterized by good sales development of several new markets, alongside continued digitization and a focus on efficiency, logistics and deliveries. The biggest development has been in Germany, one of the world’s largest direct sales markets, which in Q3 showed 37% growth compared to the same period last year. Both the Swedish and Finnish markets showed growth in the third quarter and revenues were 29% and 12% higher respectively than for the same period in 2016. The health product segment continues to grow and included the recent launch of a new unique product - BalanceOil Vegan. The omega-3 oil is based on algae instead of fish and is a product long-demanded by vegans and vegetarians. ”Our product range is now so strong that our focus is on education and a very active marketing campaign through social media to increase knowledge about the products and Zinzino. With a new online store, new products and increased presence, we are ready for growth. Also, with an efficient organization and production, profitability grows in line with the 20% per annum growth we expect over the next few years”, writes Dag Bergheim Pettersen, CEO of Zinzino in his comments on the report.   Previous quarter   · Total revenue increased by 3% (20%) and amounted to 120.1 (116.8) MSEK  · The health product segment increased by 8% (17%) amounting to 87.6 (81.1) MSEK  · Gross profit amounted to 38.3 (35.0) MSEK with a profit margin of 31.9% (30.0%).  · EBITDA amounted to 5.8 (5.8) MSEK and an operating margin before amortization amounting to 4.8% (4.9%)  · Good sales development in several new markets as the strong trend for growth continued in the Swedish domestic market.   Cumulative from January – September   · Total revenue increased by 15% (7%) and amounted to 385.6 (334.4) MSEK.  · Zinzino’s production subsidiary Faun Pharma AS increased its external sales by 63% and amounted to 48.3 (29.7) MSEK.  · The health product segment increased by 21% amounting to 270.1 (232.6) MSEK.  · Gross profit amounted to 114.5 (107.8) MSEK with a profit margin of 29.7% (32.2%).  · EBITDA amounted to 13.1 (18.5) MSEK and an operating margin before amortization amounting to 3.4% (5.5%).  · Liquid assets amounted to 38.3 (18.1) MSEK at the time of reporting.   For a copy of the complete interim report use the link provided or visit www.zinzino.se   For more information: Dag Bergheim Pettersen, CEO Zinzino, Tel. +47 93 22 57 00 Pictures for publication free of charge: Marcus Tollbom, Tel. + 46 (0)70-190 03 12 Certified Adviser: Erik Penser, Bank Aktiebolag Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at kl. 08.30 on 13th November, 2017.   Zinzino Nordic AB (publ.) is a direct sales company that operates throughout Europe and North America. Zinzino markets and sells products in two product lines: Zinzino Health, with a focus on long-term health, and Zinzino Coffee, consisting of espresso machines, coffee and tea. Zinzino owns the Norwegian company BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino has more than 120 employees and currently trades in 33 markets across Europe and North America. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Olso, and in Florida, USA. Zinzino is a public company and its shares are listed on Nasdaq First North. In 2016, Zinzino was recognized with the award ‘’Superföretag 2016’’ by Veckans Affärer and the ‘’Gazelle’’ award by Dagens Industri.

Alfa Laval wins SEK 95 million natural gas order

The Alfa Laval Niagara’s evaporative air-cooler systems will be used in two different steps of the process. They will be part of a refrigeration system to separate the natural gas into its individual pure component streams. They will also be part of the cooling process, where these streams are cooled into natural gas liquids and distilled into ethane propane and butane. “Customers in the gas industry put high demands on reliable and safe equipment,” says Susanne Pahlén Åklundh, President of the Energy Division. “This order for our Niagara air-cooler systems proves that we meet these high requirements.” Did you know that… ethane, propane and butane can be separated from the natural gas and then used, for example, as feed stock for petrochemical plants, for household heating or as fuel for vehicles? About Alfa Laval                                                                                                         Alfa Laval is a leading global provider of specialized products and engineering solutions based on its key technologies of heat transfer, separation and fluid handling. The company’s equipment, systems and services are dedicated to assisting customers in optimizing the performance of their processes. The solutions help them to heat, cool, separate and transport products in industries that produce food and beverages, chemicals and petrochemicals, pharmaceuticals, starch, sugar and ethanol. Alfa Laval’s products are also used in power plants, aboard ships, oil and gas exploration, in the mechanical engineering industry, in the mining industry and for wastewater treatment, as well as for comfort climate and refrigeration applications. Alfa Laval’s worldwide organization works closely with customers in nearly 100 countries to help them stay ahead in the global arena. Alfa Laval is listed on Nasdaq OMX, and, in 2016, posted annual sales of about SEK 35.6 billion (approx. 3.77 billion Euros). The company has about 17 000 employees. www.alfalaval.com  For more information please contact:Peter TorstenssonSenior Vice President, CommunicationsAlfa LavalTel: + 46 46 36 72 31Mobile: +46 709 33 72 31Gabriella GrotteInvestor Relations ManagerAlfa LavalTel: +46 46 36 74 82Mobile: +46 709 78 74 82

Motion Display awarded 14 MSEK record order

A leading beverage supplier has placed an order worth 14 MSEK. Delivery will take place between December 2017 and March 2018, with most of the deliveries taking place in the first quarter of 2018. ”Our products are becoming established in the US and are increasingly a frequent alternative to traditional in-store marketing. It’s a natural step for customers to include Motion Display as part of the significant budgets allocated annually for marketing. We are also seeing more customers shift from other technologies to benefit from Motion Display. This is what happened with this purchase. Extensive documentation together with customer's own experience and analysis clearly proves that our products increase both the product's visibility and sales in a cost-effective way,” says Jakob Nilsson, Motion Display US Manager. Anna Engholm, CEO of Motion Display adds: “Our success in the United States continues, especially in the beverage category. This order has been preceded by extensive studies where the benefits of our products have been carefully evaluated. Once again, we see evidence that our product brings a unique new opportunity to be seen on the shelf and grab the consumer´s attention, where 70% of the purchasing decisions are made." Further information Anna Engholm, CEO Motion Display Scandinavia AB, +46 (0) 709 79 35 04 The information in this press release is information which Motion Display Scandinavia AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the above contact persons for publication on November 13, 2017. Motion Display is the leading global manufacturer of Electronic Paper Display based Retail Signage and offers new solutions for efficient in-store-marketing. The company was founded in Uppsala, Sweden, 2005 by Erik Danielsson, former CEO of Pharmacia AB and founder of e.g. Pricer AB, global leader in ESL (Electronic Shelf Labels). www.motiondisplay.com. 

Sectra strengthens presence in Saudi Arabia by establishing regional support office and signing distribution agreement with El Seif

“Sectra is known for delivering high-quality solutions with excellent customer support,” says Dr. Torbjörn Kronander, President and CEO of Sectra. “The combination of establishing a regional Sectra support organization and utilizing the strong market knowledge and network of El Seif gives us the right conditions to support healthcare providers in Saudi Arabia in their efforts to improve the quality of care”. Saudi Arabia has a population of about 33 million and the Saudi Arabian government aims to make significant efficiency and quality improvements in the healthcare sector in the coming years. Today, there are about 470 hospitals in the country and 2,300 primary care centers. The distribution agreement with El Seif includes Sectra’s Enterprise Image Management solutions, comprising PACS (Picture Archiving and Communication System) for imaging-intense departments including radiology, breast imaging, pathology and cardiology, VNA (Vendor Neutral Archive), solutions for sharing and collaborating around medical images and tools for orthopaedic pre-operative planning in 2D and 3D. About El Seif DevelopmentEl Seif Development Company is a leading Saudi healthcare company in the fields of pharmaceuticals and medical systems supply. With more than 37 years of experience in medical diagnostic imaging systems, radiation oncology systems, clinical laboratory diagnostics, digital operating theaters, digital pathology, medical waste and healthcare IT, El Seif has executed a wide range of projects including full hospital turnkey projects throughout the Kingdom of Saudi Arabia. El Seif has gained an excellent reputation in the healthcare industry thanks to its internal quality system, dedicated workforce, well-equipped facilities, infrastructure, high-quality after-sales service and technical support to all of its clients, resulting in an outstanding customer satisfaction. Sectra Enterprise Image ManagementSectra’s enterprise imaging portfolio gives healthcare providers a unified strategy for all their imaging needs, enabling improved patient outcome while lowering operational costs. This is delivered through high system availability, a single point of access to all information needed, and by giving clinicians access to the tools they need from a single workstation. Sectra’s complete enterprise imaging offering is modular and supports the most image-intense departments—radiology, pathology, cardiology and orthopaedics. Being built on the same technical platform, customers can easily extend a departmental solution to create a comprehensive VNA and enterprise image management solution without any major investment or replacement of existing components. Experience the solutions at RSNA 2017Meet Sectra at RSNA in booth #6113 where Sectra’s solutions for radiology imaging will be showcased. Read more and book a meeting with Sectra at RSNA .

Boozt AB launches exclusive cooperation with Polarn O. Pyret

Boozt will via its webstore Boozt.com be able to help Polarn O.Pyret to take the next step in their successful digital journey, by offering Polarn O.Pyret’s access to Boozt’s approximately one million customers. The cooperation also means that Boozt will assist Polarn O.Pyret in their geographical expansion since they now, via Boozt.com, will be launched in Denmark, a market where Polarn O.Pyret doesn’t yet have any physical stores. “Boozt does a great job on the Nordic market with the combination of leading brands and fast deliveries. This, in combination with their strong position within children’s clothing in Denmark, makes Boozt an excellent partner for us, “says Nanna Hedlund, CEO of Polarn O. Pyret. Magnus Håkansson, Group CEO of RNB RETAIL AND BRANDS adds, “"We will further strengthen Polarn O. Pyret’s position through our cooperation with Boozt.” “We are very pleased to be able to offer Polarn O. Pyret’s products to our customers. The exclusive cooperation with Polarn O. Pyret is an important complement to our brand portfolio and it will strengthen our kid’s category on Boozt,com,” says Hermann Haraldsson, Group CEO of Boozt AB. The cooperation will start immediately with the first products live end of Q2 2018. For additional information, please contact: Boozt AB (publ)Hermann Haraldsson / Group CEO / Phone: +45 20 94 03 95 / Email: heha@boozt.com Karsten Anker Petersen / Head of IR & Corporate Communications / Phone: +45 53 82 17 54 / Email: kap@boozt.com  The information was submitted for publication, through the agency of the contact person set out above, at 10:00 CET on November 13, 2017.

New CFO for FM Mattsson Mora Group appointed

“With Martin Gallacher as our new CFO, we gain international expertise in corporate finance combined with strategic financial management. Martin has mainly been active in the UK, where he was born, but has been well-established here in Mora for several years. I am very pleased that Martin has chosen to join our team and have high expectations of what his knowledge and skills can contribute to the development of FM Mattsson Mora Group,” said Fredrik Skarp, CEO, FM Mattsson Mora Group. Martin Gallacher was most recently CFO at Morakniv AB. Prior to that, he has held several positions within Corporate Finance and Audit at Grant Thornton in Bristol. Martin Gallacher will join the company not later than 10 February 2018. He succeeds the current CFO, Anna-Carin Bjelkeby, who has announced that she will proceed to assignments outside the group. “I’m excited to join FM Mattsson Mora Group. There are a lot of similarities with Morakniv where I was part of a proud team which took a classic Swedish brand to the world while developing quality, service, product range, profitability and a great working environment. I am looking forward to being part of another successful journey with an even more established Mora brand,” says Martin Gallacher. For further information, please contact:Fredrik Skarp, CEO, Tel: +46 70 541 55 41Patrik Linzenbold, IR Manager, Tel: +46 (0)708 25 26 30  FM Mattsson Mora Group conducts the sale, manufacture and product development of water taps under the strong, well-established brands of FM Mattsson, Mora Armatur and Damixa. The Nordic region is the Group’s principal market. The Group generates sales of more than SEK 1 billion and has more than 550 employees. The company’s Class B share has been listed on Nasdaq Stockholm since 10 April 2017.


Pareto Securities has advised Containerships plc (“Containerships” or the “Company”), a Finnish logistics group offering sea and land-based container transportation, on placing a 4-year EUR 60 million senior secured bond (the “Bonds”). The proceeds from the transaction will be used to refinance in full the Company’s existing bond debt and for general corporate purposes. The Bonds, maturing in November 2021, will bear a floating rate coupon of 3 month Euribor + 6.25 per cent, with interest paid quarterly. The Bonds will be listed on Nasdaq Helsinki within 60 days of the issue date. The transaction was well received by the market, with demand primarily from Finnish institutional investors, coupled with strong participation from Swedish, Norwegian and UK accounts. Altogether, some 50 investors participated in the oversubscribed issue.  “We are pleased with the strong interest shown in the Company from both current and new bond investors. Not only does the bond issue allow Containerships to lower its cost of financing; it will enable the Company to deliver on its ambition of launching Europe’s first fully LNG-based supply chain, positioning it at the vanguard of European short sea logistics” says Kari-Pekka Laaksonen, CEO of Containerships. Pareto Securities acted as Sole Bookrunner in connection with the bond issue. For more information, please contact:   Mats Carlsson, CEO, +46 8 402 52 86 Markus Wirenhammar, Head of Debt Capital Markets, +46 70-872 51 86

Nordic Nanovector to Present at Jefferies Global Healthcare Conference

Oslo, Norway, 13th of November 2017 Nordic Nanovector ASA (OSE: NANO) announces that the company will be presenting at the Jefferies Global Healthcare Conference on 15th of November 2017 in London, UK. The slides presented will be available on Nordic Nanovector’s website (www.nordicnanovector.com) in the investor and media section. For further information, please contact: IR enquiries: Tone Kvåle, Chief Financial Officer Cell: +47 91 51 95 76 Email: ir@nordicnanovector.com Media enquiries: Mark Swallow/David Dible/Marine Perrier (Citigate Dewe Rogerson) Tel: +44 207 638 9571 Email: nordicnanovector@citigatedr.co.uk About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugate (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications. Further information about the Company can be found at www.nordicnanovector.com Forward-looking statements This announcement may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of Nordic Nanovector’s strategy and its ability to further grow, risks associated with the development and/or approval of Nordic Nanovector’s products candidates, ongoing clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector’s potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.

Nomination Committee appointed in respect of AGM 2018 in Alligator Bioscience AB

Lund, Sweden, 13 November, 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on 26 April 2018 has been appointed. Pursuant to the instruction for the Nomination Committee adopted by the AGM on 2 May 2017, the Nomination Committee for the Alligator Bioscience AGM 2018 shall consist of four members, representing the three largest shareholders at the last weekday of September, together with the Chairman of the Board. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights. Based on the above, the Nomination Committee for the AGM 2018 has been established to consist of the following persons, together representing approximately 19.5 per cent of the shares and votes in the company as per the end of September 2017: -           Kirsten Drejer, representing Sunstone Life Science Ventures II K/S;-           Jonas Sjögren, representing own holdings;-           Berit Levy, representing Lars Spånberg; and-           Peter Benson, Chairman of the Board. The task of the Nomination Committee’s prior to AGM is to prepare and submit proposals regarding the Chairman of the AGM, the number of Board members elected by the AGM, the Chairman and other Board members elected by the AGM, the fees and other remuneration for each of the Board members elected by the AGM and for members of Board committees, the number of auditors, the auditors, the fee for auditors and election of a Nomination Committee, or alternatively a decision on principles for appointing a Nomination Committee, as well as instructions for the Nomination Committee. Shareholders wishing to submit comments proposals to the Nomination Committee may do so via email to info@alligatorbioscience.com marked “Att. Nomination committee” or by letter to Alligator Bioscience AB, Nomination Committee, Medicon Village, 223 81 Lund, Sweden. To ensure that the proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but not later than 31 January 2018. The Nomination Committee's proposals will be presented in the notice convening the AGM and on the company's website. For further information:Cecilia Hofvander, Director Investor Relations & CommunicationsPhone +46 46 286 44 95E-mail: cecilia.hofvander@alligatorbioscience.com. The information was submitted for publication, through the agency of the contact person set out above, at 11:15 a.m. CEST on 13 November 2017. About Alligator BioscienceAlligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527) and novel research candidates. ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 45 employees. For more information, please visit www.alligatorbioscience.com .

KEWAB acquired as a sister company to Akeab

Stockholm (Sweden), 12 November 2017 – Funds advised by Triton (“Triton”) have completed an add-on acquisition to its portfolio company Akeab by acquiring the privately held company KEWAB. KEWAB is a leading supplier of excavation work and non-building construction services in the mid-western parts of part Sweden. KEWAB and Akeab will be sister companies in an infrastructure services group owned by Triton and the management teams of the companies. The terms of the acquisition were not disclosed. "We look forward to continuing to support the companies, management and employees in the infrastructure services group by investing in and supporting its growth and development. Our strong industry expertise in the business services sector, gained through other investments and strengthened by senior industry experts, will contribute in taking KEWAB to the next level. We look forward to working together with the management team and the Board of Directors in building a stronger company", said Peder Prahl, the Managing Partner of Triton Partners. “We are very happy to join Akeab in the infrastructure services group. The industry expertise that Triton possess will be of strong importance as we continue our growth. We in the management team of KEWAB are very happy to continue to be significant shareholders in the company together with Triton and the management team of Akeab,” says Fredrik Larsson, CEO of KEWAB. About KEWABKEWAB is a leading provider of excavation services, civil works and power network services with a strong presence and market position in the Värmland region of western Sweden and surrounding regions. The company focuses on medium sized projects with customers ranging from national electrical power network operators to municipalities and larger construction groups. Founded in 1965 by Kenneth Wahlström, KEWAB has around 300 employees and offices in six locations. For further information: www.kewab.se  About AkeabAkeab is a leading provider of excavation services and civil works with a strong presence and market position in southern Sweden. The company focuses on medium sized projects with customers ranging from national fiber operators to municipalities and local energy companies. Akeab has grown significantly in recent years by providing efficient service and maintaining strong customer relationships. Founded in 2008, Akeab has around 230 employees and offices in six locations. For further information: www.akeab.se  About TritonThe Triton funds invest in and support the positive development of medium-sized businesses headquartered in Europe, focusing on businesses in the Industrial, Business Services and Consumer/Health sectors. Triton seeks to contribute to the building of better businesses for the longer term. Triton and its executives wish to be agents of positive change towards sustainable operational improvements and growth. The 33 companies currently in Triton's portfolio have combined sales of around €14.7 billion and around 91,000 employees. The Triton funds are advised by dedicated teams of professionals based in Germany, Sweden, Norway, Finland, Denmark, Italy, the United Kingdom, the United States, China, Luxembourg and Jersey. For further information: www.triton-partners.com  Press Contacts: TritonMarcus Brans                                                 Phone: +49 69 921 02204 KEWABFredrik LarssonPhone: +46 70 312 3851

Nilar leads the way with high-voltage storage solutions for the electrical energy storage market

High-voltage battery systems offer considerable advantages over low-voltage systems, such as lower total cost of ownership, versatile installation, and future-oriented flexibility. This is compelling end users to adopt high-voltage storage solutions for their operations. This year there was a clear increase in high-voltage systems in the submissions for the EES Award, which reflects the current developments in the energy storage industry (1). This trend is much welcomed by Nilar: "Over 10 years ago Nilar realized that low voltage solutions would eventually evolve into high voltage products. Judging by the interest we have seen this year; the market is finally ready. Today, we are positioned better than ever before to embrace this market. Our bi-polar technology is ideally suited for high voltage applications and we have continuously invested in that future. These investments gave Nilar products that are broad reaching, efficient, and safe. Nilar will therefore focus on three high-voltage segments going forward; EV-charge support, home/business storage and grid support", says Marcus Wigren, CEO at Nilar. The emergence of Nilar’s high-voltage batteries has created new energy storage opportunities for various technologies and applications. Due to a unique combination of bi-polar design and Nickel Metal Hydride (NiMH) chemistry, Nilar can offer a high performing storage solution packaged in a safe and environmentally friendly battery. (1). http://www.electrical-energy-storage.events/en/ees-award.html 

Volati’s subsidiary Akademibokhandeln will offer to purchase its bonds which will simplify Volati’s capital structure

Akademibokhandeln, a subsidiary of Volati, has announced that it will offer to purchase its outstanding SEK 500 million bonds with ISIN SE0009690084 due 2021 in a tender offer. Akademibokhandeln has also announced that it is soliciting consent from holders of the bonds to amend certain terms and conditions of the bonds which would enable an early redemption in December of all remaining outstanding bonds. The purchase and early redemption of Akademibokhandeln’s bonds would simplify Volati’s capital structure to better support its strategic objectives. In its financial report for the third quarter 2017, Volati announced its plan to investigate the prerequisites for issuing a senior unsecured bond of not less than SEK 750 million, with the aim of increasing the company’s financial flexibility and acquisition capacity. The proceeds from such a bond issue may be partly used towards repurchase and redemption of Akademibokhandeln’s bonds. Akademibokhandeln’s repurchase of its outstanding bonds is conditional upon a successful bond issue by Volati. Subscribing for Volati bonds A tendering bondholder that wishes to subscribe for bonds in Volati’s bond issue can request from Nordea and SEB, a priority allocation code to receive priority allocation. The further conditions for such priority allocation together with further information about the tender offer and the consent solicitation are set out in a Consent Solicitation and Tender Offer Memorandum dated 13 November 2017. To receive copies of the Consent Solicitation and Tender Offer Memorandum and for questions, please contact Nordea or SEB: Tel: +45 6161 2996 / e-mail: Nordealiabilitymanagement@nordea.com and tel: +46 850623061/ e-mail: sebliabilitymanagement@seb.se. 

Instalco acquires Elkontakt i Borås and strengthens its electrical offering

Elkontakt has its head office in Borås with operations in Gothenburg, Stockholm, Borås and in the Skåne region. The company was founded in 1999 by Rickard Ärlig, and has exhibited favourable organic growth and profitability since inception. For the financial year that ended in August 2017,  net sales amounted to approx. SEK 200 million. The purchase price amounts to approx. SEK 47 million with a possible earnout of a maximum of SEK 34 million based on Elkontakt’s result during next year. The seller is Elkontakt Invest i Borås AB. Elkontakt currently employs approx. 80 people and is a complete provider of electrical, telecommunications and data installation services. The company has specialty expertise in installations at new construction projects, primarily in logistics centres, warehouse and production plants, and apartments. “Elkontakt is a great business and through the acquisition we continue to pursue our strategy to grow with highly specialised units. Elkontakt’s expertise in logistics centres is of particular interest”, says Per Sjöstrand, CEO of Instalco. Elkontakt’s founder and CEO Rickard Ärlig will remain in his role at the company. He will also re-invest part of the purchase sum in Instalco. ”We have built up and operated Elkontakt for almost 20 years. When joining Instalco, we look forward to become part of a larger team that will benefit both ourselves and the other subsidiaries in the group”, says Rickard Ärlig. Instalco will acquire 100% of Elkontakt I Borås AB, Elkontakt Entreprenad i Stockholm AB, Elkontakt i Göteborg AB and Elkontakt i Syd AB. The acquisition is conditional on approval from the Swedish Competition Authority. For more informationPer Sjöstrand, CEO Instalcophone +46 70 724 51 49, e-mail per.sjostrand@instalco.se  Adrian Westman, Head of Investor Relationsphone +46 73 509 04 00, e-mail adrian.westman@instalco.se  This information is information that Instalco is required to disclose under the EU Market Abuse Regulation. The information was made public by the contact person listed above, on 13 November 2017 at 14:00 CET. Instalco is one of the leading installation companies in the Nordic region, active in the areas of heating, plumbing, electricity, cooling and industrial solutions. We work closely with customers, offering all the advantages of a local company, along with efficient collaboration and leadership. The operations are conducted through approximately 30 leading and highly specialised local companies, with the support of a small central organisation. Instalco is listed at Nasdaq Stockholm under the ticker INSTAL. For further information, visit www.instalco.se.

Stena Bulk reorganises, coordinates and opens new office in Copenhagen

“This is a natural transition from the old structure to the new one where we now have total control over our business involving product and chemicals transportation in the MR segment. This and other adjustments will result in a clearer structure as regards our business and organisation”, says Erik Hånell, President and CEO, Stena Bulk. ReorganisationAt the same time as the reorganisation came into force, two new managing directors were appointed, namely, Mats Karlsson (Crude & Fuel) and Johnny Schmolker (Products & Chemicals). “After many years working with, among other things, the creation and development of the successful Sonangol pool, I am looking forward to taking greater responsibility in this business area”, says Mats Karlsson, Managing Director, Crude & Fuel. “I have held a leading position at Stena Weco since it was started up 6,5 years ago and I am happy to have a key role in the incorporation of the two companies’ business into a single business”, says Johnny Schmolker, Managing Director, Products & Chemicals.In other changes, Johan Jävert has been appointed as Vice President, Commercial Operations, and Sofia Eriksson will take on the position of General Manager, Business Control, WW. Björn Stignor continues as Managing Director of Golden Stena Weco in Singapore as does Göran Hermansson as General Manager of the business area LNG.New office in CopenhagenStena Bulk Products & Chemicals, Denmark has moved in to the newly incorporated Stena Rederi AS’ domicile, where also Stena Line, Stena RoRo and Northern Marine Management are present. The office is located in Copenhagen near the Port of Tuborg. Stena Bulk will also continue to have regional offices in Gothenburg, Houston, Singapore, Shanghai and Dubai.Background information on Stena Bulk, Products & ChemicalsEarlier this year, Stena Bulk signed an agreement to acquire the remaining 50% of the shares in Stena Weco from its partner WECO Shipping. This means that Stena Weco has now been incorporated into, and is wholly owned by, Stena Bulk. Together with Stena Weco’s fleet of 65 tankers, Stena Bulk operates around 100 tankers. A third of these are owned and two-thirds are chartered.For further information, please contact: Erik HånellPresident & CEOStena Bulk ABMobile: +46 704 855 002erik.hanell@stenabulk.comWith offices in six countries, Stena Bulk is one of the world’s leading tanker shipping companies. The company controls a combined fleet of around 100 tankers. Stena Bulk is part of the Stena Sphere, which has more than 20,000 employees and sales of SEK 60 billion. www.stenabulk.com    

Kährs Group: Interim Report January–September 2017

Third quarter, July–September · Net sales totalled SEK 729 million (708), an increase of 3 per cent compared with the same period in 2016. Organic sales growth was 3 per cent · Operating EBITA rose 7 per cent and totalled SEK 63 million (59), corresponding to an operating margin of 8.6 per cent (8.3) · Operating profit (EBIT) for the third quarter decreased by SEK 66 million to SEK -16 million (50), corresponding to -2.2 per cent (7.1). The decline can be attributed to items affecting comparability of SEK 78 million (9) in the quarter, primarily related to a provision for tariff costs in the US of SEK 50 million, as well as changes in the production structure in Finland of SEK 13 million · Consolidated profit for the quarter was SEK -20 million (21) · Earnings per share amounted to SEK -662 (701) President and CEO Christer Persson comments:”The Kährs Group continued to show stable sales growth in the third quarter of 2017 at 3 per cent. The resilient flooring segment demonstrated the strongest sales growth, followed by the Nordics segment, while the development for Other Markets was below the previous year. Consolidated operating EBITA increased by 7 per cent during the quarter to SEK 63 million, corresponding to a margin of 8.6 per cent. We continue focusing on increasing the proportion of premium sales in our business. By actively driving design and innovation, Kährs will further strengthen its position as market leader on several of our core markets.” For further information, please contact:Christer Persson, President and CEO, tel: +46 70 271 20 14Peter Ericsson, CFO, tel: +46 70 461 10 39  About Kährs Holding AB (publ)Kährs Holding AB (publ) is a leading European flooring manufacturer in hardwood and resilient flooring with a number of strong brands in its product portfolio, including Kährs, Karelia and Upofloor. The Company’s innovations have shaped the industry throughout history and Kährs Group is dedicated to providing the market with innovative new flooring solutions. Kährs Group, which delivers products to more than 70 countries, is the market leader in Sweden, Finland, Norway and Russia and holds a strong position in other key markets, such as the UK and Germany. The Group has approximately 1,700 employees and annual sales of more than SEK 3 billion. www.kahrsgroup.com

Technical Senior High Scool in Parans light in Ankara, Turkey

Parans has since year 2013 participated in the EU financed project A2PBEER. Within the frames for the project 14 pieces of the SP3 system and one SP4 system (third and fourth product generation Parans system) have been installed. The installation leads natural light to the dining room and kitchen. The dining room has a couple of windows that are not bringing enough natural light to the room. In the dining room 21 pieces of luminaires are spreading the light from the Parans systems and in the kitchen 12 pieces of luminaires are doing the same. When the sun is not shining the LED lighting in the same luminaire could be used. The luminaire is developed toghether with Toshiba. Parans has within the frames of the project cooperated, besides Toshiba, with well-reputated companies as Tecnalia to find solutions for green building. -It feels satisfying that it is relevant installations, in this case a Senior High School, where youths gets natural sunlight within the frames for the project, says Lennart Ahlstedt, COO at Parans.      For more information, please contact: Anders Koritz, CEO at Parans Solar Lighting AB (publ), phone +46 31 20 15 90, anders.koritz@parans.com www.parans.com About Parans Solar Lighting AB (publ) Parans Solar Lighting offers sunlight for indoor environments through an innovative system that captures and leads the rays of the sun. Parans, which developed and patented the technology, turns mainly to property owners, architects and larger employers worldwide. Parans Solar Lighting is quoted on the stock exchange list Aktietorget and has offices in Gothenburg, Sweden.

Management changes in Cloetta

Christian Boas Linde has been appointed President Cloetta Denmark & Norway. He will report to Henri de Sauvage-Nolting, CEO, and be part of Group Management. He will assume his new role 1 January, 2018. Christian Boas Linde has been working at Cloetta since 2013 and is currently General Manager Cloetta Denmark & Norway. He has previously, among others, been working at Mars, PepsiCo, Heinz and Arla. Christian Boas Linde was born in 1968 and holds a Master’s Degree in Economics from Aarhus University. Lars Påhlson, currently President Cloetta Scandinavia, will implement the split of the business responsibilities between Sweden and Denmark & Norway. He has also after nine years in the position decided to retire during 2018. Until then he will continue as President Cloetta Sweden. A recruitment process to find a new President for Cloetta Sweden has been initiated. “The acquisition of Candyking makes our Scandinavian operations significantly larger, especially Denmark and Norway will grow in importance for Cloetta. Therefore, there is a need to split the role of President Cloetta Scandinavia. I am happy that Christian Boas Linde with his broad background from our industry and Cloetta, has accepted his new role”, says Henri de Sauvage-Nolting, President and CEO of Cloetta. “Already after the acquisition of Candyking this spring, Lars Påhlson indicated that he wanted to leave Cloetta when the new integrated Swedish organization had been implemented. I would like to take the opportunity to express our sincere thanks and appreciation to Lars Påhlson for the dedication and excellent work during his nine years with the company”, says Henri de Sauvage-Nolting.

UAE-based Aerospace and Defense technology company, Calidus, selects IFS Applications to support rapid growth

IFS, the global enterprise applications company, today announced that the aerospace and defense technology company Calidus , based in Abu Dhabi, UAE, has selected IFS Applications™ as its core solution to manage key company operations and manufacturing projects. The IFS solution ¬¬¬includes Finance, HR, Supply Chain, Project and Document Management modules to support the development of all major Calidus projects, including the manufacturing of the new B-250 Light Attack aircraft which is currently being unveiled at the Dubai Airshow, November 12th -16th. Following its rapid company and project growth in the last two years, Calidus recognized the need for a solution which could scale alongside and meet the requirements of the fast-moving company. IFS Applications will allow Calidus to automate key end-to-end processes to increase productivity, reduce costs, and provide management with a 360 degree view of operations to make better business decisions. The industry-specific and agile nature of IFS Applications removes the need for customization and a long implementation timeline. One of the recent successful Calidus projects supported by the IFS solution, the B-250 Light Attack aircraft, is being launched during the Dubai Airshow 12th-16th November 2017, stand A34 and A35. Calidus managment selected IFS because of its recognized industry leadership in enterprise software as well as its strong track record with other defense manufacturers. As Calidus is a fast growing technology and development company, it was essential for Calidus to partner with a software provider that could adapt at the same rate as the business. The flexibility and scalability of IFS Applications will scale alongside the agressive Calidus growth strategy. Luis Ortega, Managing Director, Middle East, Africa & South Asia at IFS added, “The selection of IFS to support such a fast moving company demonstrates the agility of IFS Applications. With such quick expansion, it is essential for Calidus to have a 360 degree view of its operational processes to make informed, data-driven business decisions. Aerospace and defense manufacturing and maintenance is a rapidly growing industry in the Middle East, and Calidus joins a growing number of customers in the region which recognize the industry expertise of IFS.” About CalidusCalidus is a new technology development company based in Abu Dhabi. Through partnerships with some of the most innovative companies in the aviation field, Calidus aims at providing cutting-edge, mission-oriented and cost-effective solutions to its clients.

BAKKAFROST: Operational EBIT of DKK 252 Million for the Third Quarter of 2017

The Bakkafrost Group delivered a total operating EBIT of DKK 251.8 mil­lion in Q3 2017. Harvested volumes were 11.6 thousand tonnes gutted weight. The combined farming and VAP segments made an operational EBIT of DKK 212.2 million. The farming segment made an operational EBIT of DKK 216.7 million. The salmon spot prices decreased in Q3 2017, compared to the previous quarter. The price decrease had a neg­ative effect on the operational EBIT in the farming segment. The VAP segment made an operational EBIT of DKK -4.5 million, which is an im­provement due to the decrease in the salmon spot prices in Q3 2017. The EBITDA for the FOF segment was DKK 79.5 million. The total volumes harvested in Q3 2017 were 11.6 thousand tonnes gutted weight. Bakkafrost trans­ferred 3.2 million smolts, and Havsbrún sourced 21.9 thousand tonnes of raw material in Q3 2017. The farming segment made an operational EBIT of DKK 216.7 million for Q3 2017, which corresponds to NOK 23.51 per kg. The VAP segment made an operational EBIT of DKK -4.5 million for Q3 2017. The VAP segment has had a loss since the first quarter of 2016, and although the salmon spot price has decreased in Q3 2017, the VAP segment had a negative margin. At the end of Q3 2017, the margins were positive. The combined farming and VAP segments made an operational EBIT of DKK 212.2 mil­lion for Q3 2017, which corresponds to NOK 23.02 per kg. The FOF segment (fishmeal, oil and feed) made an operational EBITDA of DKK 79.5 million for Q3 2017. Commenting on the result, CEO Regin Jacobsen said: “Although the price of salmon decreased in the quarter, Bakkafrost had a satisfactory result. The sal­mon spot price in the third quarter this year was significantly lower than in the same quarter last year. We still have a good outlook for the salmon market, but there is a risk for lower salmon prices in the future. The farming service vessel, M/S Róland, started operation in this quarter, and Bakkafrost is well equipped to combat sea lice with good solutions. Another positive trend in the quarter was the improvement in the VAP operation, after having experienced start-up issues in the first half of 2017.” In September 2017, farming site A-57 Fuglafjørður was ASC certified. Bakkafrost has been in the pro­cess of getting its farming sites ASC certified since 2014. The goal is to get all farming sites ASC certified by 2020. The Bakkafrost Group’s net interest bearing debt amounted to DKK 355.6 million at the end of Q3 2017. Bakkafrost had undrawn credit facilities of DKK 932.6 million at the end of Q3 2017 and the equity ratio was 68% at 30 September 2017. OUTLOOK Market The salmon prices have been on record high levels since 2016, but as expected, the salmon price de-creased in Q3 2017 as supply of salmon increased. The latest update from Kontali Analyse estimates the global supply of Atlantic salmon to increase around 2% in 2017 and 7-8% in 2018, compared to      -6% in 2016. The market place is one of Bakkafrost’s most significant risk areas. To diversify the geographical mar­ket risk, Bakkafrost sells its products to all the largest salmon markets in the world, USA, the Far East, Europe and Russia. Farming The outlook for the farming segment is good. The estimates for harvesting volumes and smolt releases are dependent on the biological development. The number of sea lice has demanded more effort in Q3 2017 than in Q3 2016 and has caused reduc­tion of growth in the quarter, which will most likely postpone some harvest quantity from Q4 2017 to Q1 2018. Bakkafrost focuses on using non-chemical methods in treatments against sea lice. Bakkafrost has now two service vessels, M/S Martin and M/S Róland, which use lukewarm seawater treatment against sea lice. In addition, M/S Hans á Bakka – whose primary operation is transportation of live fish – can be used in treatment against sea lice with freshwater treatment. Bakkafrost will increase the use of lumpfish in farming in 2018. The confirmed presence of pathogenic ISA-virus at farming site A-73 in March draws attention to the importance of a high quality veterinary system to reduce the biological risk. The harvest of the fish at farming site A-73 was finished on 12th April 2017, and the site has been fallowed for a period of 6 months. Bakkafrost focuses on biological risk continuously and has made several new investments and procedures to diminish this risk. Bakkafrost’s guidance for harvest in 2017 is increased by 1,000 tonnes gutted weight, from 53,500 to 54,500 tonnes gutted weight. In 2018, Bakkafrost expects to harvest 51,000 tonnes gutted weight. Bakkafrost expects to release 10.5 million smolts in 2017, compared with 11.7 million smolts in 2016 and 11.3 million smolts released in 2015. In 2018, Bakkafrost expects to release 13.0 million smolts. The number of smolts released is a key element of predicting Bakkafrost’s future production. The construction of the new hatchery at Strond, Klaksvík, progresses according to plan. The hatchery is expected to be in operation during 2018 and deliver full capacity from 2020. The investments in producing larger smolts will gradually reduce the time needed in the fjords to farm the salmon. This is expected to reduce biological risk and increase the capacity. The capacity growth from this investment program will appear in harvested volumes gradually until 2021. VAP (Value added products) Bakkafrost has signed contracts covering around 53% of the expected harvested volumes for the rest of 2017 and is presently negotiating new contracts for 2018. The VAP contracts are at fixed prices, based on the salmon forward prices at the time they are agreed and the expectations for the salmon spot price for the contract period. The contracts last for 6 to 12 months. The long-term strategy is selling around 40-50% of the harvested volumes of salmon as VAP products at fixed price contracts. Selling the products at fixed prices reduces the financial risk with fluctuating salmon prices. The market price for contracted VAP products follows a more stable pattern instead of short-term fluctuations as in the spot market. FOF (Fishmeal, -oil and feed) The outlook for the production of fishmeal and fish oil is dependent on the availability of raw material. The ICES 2018 recommendation for blue whiting is 1,388 thousand tonnes, compared with 1,342 thou­sand tonnes in 2017. The production of fishmeal and fish oil in 2018 will most likely be at the same level as in 2017. The major market for Havsbrún´s fish feed is the local Faroese market including Bakkafrost’s internal use of fish feed. Havsbrún’s sales of fish feed in 2017 are expected to be at 80,000 tonnes, which is a reduction of 5,000 tonnes from previous expectation for fish feed sales in 2017. The reduction is related to lower growth in Q3 2017, as mentioned under Farming. Depending on external sales, the sales of fish feed in 2018 is expected to be at 85,000 tonnes. Investments In June 2016, Bakkafrost announced a five-year investment plan from 2016 to 2020. The total invest-ments for the period are DKK 2.2 billion, including maintenance CAPEX. Investments of around DKK 100 million in the two service vessels, M/S Martin and M/S Róland during 2017, are not included in the investment plan. The purpose of the investment plan is to continue to have one of the most cost-conscious value chains in the farming industry, to carry out organic growth, increase flexibility and reduce the biological risk to meet the future consumers’ trends and to be more end-customer orientated. Bakkafrost aims at being self-supplied with smolts at a size of 500g each. The benefits are a shorter production time at sea as well as reduced biological risk. To reach this goal, approximately half of Bakkafrost’s total investments from 2016 to 2020 will be in hatcheries. Bakkafrost has started upgrading the harvest operation in Vágur, Suðuroy. The upgrading cost is ex­pected to be around DKK 40 million. Bakkafrost plans to increase the value of offcuts from salmon harvested and processed in the new harvest/VAP factory. The new salmon meal and salmon oil plant, located in Fuglafjørður and operated by Havsbrún, is expected to start operation in the beginning of 2018. The FOF segment will also invest in a new feed line, which will increase the capacity of the feed production. Free cash flow from operations, existing financing facilities and partly new financing if advantageous will finance the investments. The dividend policy will be unchanged. Financial Favourable market balances in the world market for salmon products and cost-conscious production will likely maintain the financial flexibility going forward. A high equity ratio together with Bakkafrost’s bank and bond financing makes Bakkafrost’s financial situation strong. This enables Bakkafrost to carry out its investment plans to further focus on strengthening the Group, M&A’s, organic growth oppor­tunities and fulfil its dividend policy in the future. Please find the Company’s Q3 2017 report and the Q3 presentation enclosed. Contacts: Regin Jacobsen, CEO of P/F Bakkafrost: +298 235001 (mobile) Gunnar Nielsen, CFO of P/F Bakkafrost: +298 235060 (mobile) This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. About Bakkafrost: Bakkafrost is the largest salmon farmer in the Faroe Islands. The Group is fully integrated from feed production to smolt, farming, VAP and sales. The Group has production of fishmeal, fish oil and salmon feed in Fuglafjørður. The Group has primary processing in Glyvrar, Kollafjørður and Vágur, and second­ary pro­cessing (VAP) in Glyvrar. The Group operates sea farming in Norðoyggjar, Eysturoy, Streymoy and Suðuroy. The headquarter is located in Glyvrar, and the company has 820 fulltime employees. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities. The securities referred to herein may not be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933, as amended. Copies of this announcement are not being made and may not be distributed or sent into the United States, Australia, Canada or Japan.

Karl Thedéen appointed new Managing Director and CEO of Edgeware

Karl Thedéen is the former CEO of Transmode AB and is currently a board member of Edgeware. He provides the solid business and management experience that can take Edgeware through its next growth phase. Karl Thedéen currently serves as the SVP of Infinera´s Metro Business Group and before that CEO of Transmode AB from 2007, which he managed from a small company through an IPO in 2011 until it being acquired by Infinera in 2015. Prior to that Karl Thedéen held several leading positions for Ericsson in Sweden and in the UK. Karl Thedéen holds a Master of Science in Systems engineering from the Royal Institute of Technology in Stockholm and is an existing board member of Semcon AB (publ). Joachim Roos will remain as CEO of Edgeware through February 2018. The intention is for him to remain on the Edgeware executive management team in supporting the company and Karl Thedéen in achieving a smooth leadership transition and also to focus on some of the company’s strategic development activities. “I have during almost 14 years led the company through a tremendous growth and now firmly established the company in a listed environment,” says Joachim Roos. “Now the time is right for the company to bring in a new leader who can continue growing the company and expanding the business. It has been a fantastic privilege to lead this great company, which today is leading the market place for purpose-built TV CDN systems thanks to its strong culture and all its engaged and professional employees.” “Joachim has been an excellent CEO leading the company from an innovative start-up to a market-leading, high growth public company,” says Chairman of the Board, Michael Ruffolo. “All of us on the Board appreciate his leadership and invaluable personal contribution to the success of Edgeware. We are very pleased that Joachim is willing to remain on the senior management team leading our strategic development initiatives.” “Karl Thedéen is an experienced and successful CEO with the background and leadership capabilities to rapidly scale the company,” says Chairman of the Board, Michael Ruffolo. Karl has the ideal profile of what the Board is searching for in a new CEO to succeed Joachim. In addition, as a current Board Director, Karl Thedéen has had the opportunity to learn the business at Edgeware and help shape its strategy. With his strong track record of success and his knowledge of Edgeware, he will hit the ground running and be able to achieve our growth goals.” “I am very excited about this opportunity,” says Karl Thedéen. “Edgeware is a fantastic company that operates in a fast growing application area of tech. I am happy to start at Edgeware which I know quite well after having served on the Board for two years. The future is really promising and I really look forward to take on the my new role as CEO to lead Edgeware supported by Joachim and the other members of the executive team.”

Atlas Copco hosts Capital Markets Day 2017

The event will focus on three of Atlas Copco’s business areas: Vacuum Technique, Industrial Technique and Mining and Rock Excavation Technique.   Mats Rahmström, President and CEO, confirms Atlas Copco’s most recent outlook statement, that the overall near-term demand for the Group is expected to remain at current high level.  “This year is very exciting, not the least because the Board of Directors proposed to split the Group so we can be even more focused on creating value for customers,” Mats Rahmström said. “Meanwhile, we keep focusing on innovation, including digitalizing all our processes and the customer journey, and building strong teams. We are happy to see that all business areas are growing this year.” The Capital Markets Day begins with presentations by Mats Rahmström; Hans Ola Meyer, CFO; Sofia Svingby, Vice President Corporate Responsibility; and three of the Business Area Presidents: Helena Hedblom, Mining and Rock Excavation Technique; Henrik Elmin, Industrial Technique; and Geert Follens, Vacuum Technique. The program includes an exhibition at Group Center of the three business areas’ innovations. The event will also provide an update on the proposed split of the Group. Indicative revenue and operating profit margin for the last 12 months period ending September 30, 2017, for the two companies, Atlas Copco and Epiroc, are: BSEK 84, 21%, and BSEK 30, 19%, respectively. Epiroc is a fully-owned subsidiary of Atlas Copco. At Atlas Copco’s Annual General Meeting in April 2018, shareholders will decide whether Epiroc should apply to be listed on the stock exchange. Provided shareholders agree with the proposal, Atlas Copco will stay focused on creating value for industrial customers, while Epiroc will be a leading productivity partner for customers in mining, infrastructure and natural resources. At the Capital Markets Day the investor community and financial journalists are participating.


OSLO, NORWAY - NOVEMBER 14, 2017 - CXENSE ASA TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDING 30 SEPTEMBER 2017. Highlights: Strategic change to focus on Data Management and Personalization* New CEO in place to execute strategy* Sale of non-core assets progressing well Growth in core segments of Data Management and Personalization* 15% YoY and 5.3% sequentially* Sales and churn improvement from Q2, but behind targets* 26 new customer contracts On track to reach post restructuring target EBITDA for Q1 2018 of USD -0.5 million* 83% of OPEX reduction target of USD 3 million is realized* Gross margin improvement of 3% from hosting optimisation Financial runway beyond break-even secured* Completed USD 5 million share issue* Sale of mporium for USD 3.8 million vs USD 2.4 million invested* Q3 2017 adjusted cash position of USD 12.2 million CEO comment: “Cxense is well on its way to become a single-focused provider of our world-class Data Management Platform (DMP) with Intelligent Personalization. To this end, a significant company restructuring has been executed during this quarter. Full concentration on our core business combined with strengthened financial runway, makes a strong starting point for long-term value creation in a large and growing market. While our technology continues to prove its value every day with 165 core customers worldwide, we still need to sharpen our technology vision and refine our go-to-market model to capture the big opportunities in front of us. I believe the massive amount of data that we manage on behalf of our customers is a core competitive advantage and its essential to combine this with truly customer-oriented product development and a streamlined sales approach. I look forward to the next chapter of Cxense’s journey and to create a new growth trajectory for the adoption of our solutions” said Christian Printzell Halvorsen, CEO of Cxense. Material: The Q3 2017 report and presentation are attached to this notice and can also be found under the following link: https://www.cxense.com/investors/financial-reports Webcast: Cxense ASA will present its Q3 2017 results at 08:30 am CET. The presentation will take place at the Felix Conference Center, Bryggetorget 3, Oslo, Norway. A live webcast will be available at: http://webtv.hegnar.no/presentation.php?webcastId=67733412 About Cxense: Cxense helps hundreds of leading publishers and marketers across the globe transform their raw data into their most valuable resource. Cxense's leading Data Management Platform (DMP) with Intelligent Personalization, give companies unprecedented insight about their individual customers, and enables them to action this insight real-time in all marketing and sales channels. Benefits include increased digital revenue and user loyalty. Cxense works with brands such as Aeon, Wall Street Journal, Grupo Clarin, NBC Universal, Aller and many more. Cxense is headquartered in Norway with offices worldwide and the company is listed on the Oslo Stock Exchange with the ticker 'CXENSE.' For more information: www.cxense.com Investor Relations Contact: Jørgen Loeng, Chief Financial Officer Email: ir@cxense.com Mobile: +47 906 60 062

New Swedish study results at SABCS show DiviTum® blood test reduces waiting times for evaluating breast cancer treatment

With imaging methods used for evaluating the effect of treatment, it takes about three months to evaluate whether the given therapy is effective or not. The new study demonstrates that DiviTum® accurately can predict outcome (progression free- and overall survival) already after one month. This dramatic shortening of the evaluation window can be key when making decisions to continue or change treatment and can contribute significantly to improved patient outcome. In addition, using a blood-based biomarker reduces the need for invasive biopsies. DiviTum® measures the activity of the enzyme thymidine kinase (TK) which reflects cell proliferation and associates strongly with tumor growth. At diagnosis in the study, low DiviTum®values correlated significantly and independently with improved progression free- and overall survival (p<0.001). During treatment, DiviTum® was significantly associated with outcome at each of four time points and onwards (Baseline, 1, 3 and 6 months). Patients in the study were treated with standard therapies, including endocrine therapy, chemotherapy and Herceptin®, meaning that the value of DiviTum®is demonstrated in a larger patient population than has previously been reported. Biovica have an ongoing trial program including more than 10 clinical studies and 1,500 patients to document the unique capabilities of the assay to become a new gold standard for early efficacy evaluation of patients with metastatic breast cancer. "The results demonstrate that already after just 1 month of treatment, DiviTum is a highly valuable marker for clinical use regarding accurate prognosis. Throughout the course of therapy DiviTum can provide clinical information for patients with metastatic breast cancer scheduled for 1st line systemic therapy”, says Lisa Rydén, Professor, Department of Surgery, Lund University. "The study provides key documentation for DiviTum as a tool for putative evaluation of efficacy in a peripheral blood sample and we are delighted to publish these results in collaboration with Lund University. The study results contribute towards our objective of supplying DiviTum to oncologists as a standard tool for evaluating metastatic breast cancer treatment to improve patient outcome”, says Anders Rylander, CEO Biovica. Reference: www.sabcs.org, Link to the abstract: http://www.abstracts2view.com/sabcs/view.php?nu=SABCS17L_287


Lund, Sweden, 08.00 CET, 14 November 2017 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform announces the publication of a paper highlighting the anti-biofilm activity of CERAMENT® G in vitro - Colloids and Surfaces B: Biointerfaces 161 (2018) 252–260. Implant-related bone infections caused by microorganisms that grow in biofilms are extremely difficult to treat and cause persistent and recurring infections. The use of resorbable biomaterials, such as CERAMENT®, as a reservoir for the local release of antimicrobials, such as gentamicin, into the bone and onto the implant is considered as a valid option to achieve high local concentrations of the drug and, therefore, avoid infection relapses and microbial resistance. In the study reported in the publication ”In vitro anti-biofilm activity of a biphasic gentamicin-loaded calcium sulfate/hydroxyapatite bone graft substitute” by Maria Eugenia Butini and Mariagrazia Di Luca from the group of Andrej Trampuz from the Center for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, CERAMENT® G beads were assessed for their in vitro antimicrobial activity against bacteria known to cause bone infections, including planktonic and biofilm S. agalactiae, S. aureus, S. epidermidis, E. faecalis and E. coli, using standard methods and ultra-sensitive isothermal microcalorimetry. The authors found that CERAMENT® G possesses a preventive and bactericidal anti-biofilm activity in vitro against some selected bacterial strains that are responsible for bone infections.  The authors also believe that high concentrations of gentamicin achieved through the initial burst release from CERAMENT® G within the first 3 hours of its use, together with the retention of a sustained level of antibiotic for at least 24 hours, could effectively suppress an early infection in the first stages of bacterial replication. They concluded, that their in vitro study “demonstrated the potential of the gentamicin-loaded bone graft substitute to prevent and treat biofilm-related bone and implant infections”. Dr. Andrej Trampuz from Center for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, commenting on his research group’s findings, said, “We are excited with the in vitro data that we have generated on CERAMENT® G. It clearly shows that CERAMENT® G provides a good solution for orthopaedic surgeons to prevent and manage biofilm-related bone infections. I look forward to seeing this potential being confirmed in clinical practice.” Richard Davies, CEO of BONESUPPORT, commented: “This publication demonstrating the in vitro activity of CERAMENT® G against multiple bacteria known to cause bone infections and that grow in biofilms, highlights another important potential clinical benefit of this unique injectable bio-ceramic bone substitute. Our investment in supportive clinical and pre-clinical data is key to the continuing rapid adoption of CERAMENT® G by the orthopedic community.”

Elos Medtech commits to the global orthopaedic market

Orthopaedics is a strategically important business segment for Elos Medtech and today we announce our commitment to focus on and grow this market. We will dedicate resources and develop a strong cross-site platform to further build our competence and capacity in support of our global customers. Elos Medtech announces that Jodie Gilmore, Managing Director Elos Medtech Onyx, will take up a new role as Orthopaedic Business Director and lead our global orthopaedic strategy as we continue our journey focusing entirely on the medical device industry. “Elos Medtech is excited to highlight orthopaedics as one of the primary areas of focus and to execute on our market specific strategies. This is a natural step toward achieving our growth targets and capitalizing on our 2015 acquisition of Onyx Medical”, says Jan Wahlström, CEO and President. “I am truly passionate about orthopaedics and have focused my energy here for more than 20 years”, says Jodie Gilmore. “I am thrilled to champion this market within Elos Medtech and leverage our incredible group capabilities for the benefit of our orthopaedic customers.” Jodie Gilmore will remain in Memphis and continue as the Managing Director of the Elos Medtech Onyx site.  Elos Medtech is one of the leading development and production partners for medical technology products and components in the world, such as dental and orthopaedic implants and instruments. The operations are conducted at facilities in Sweden, Denmark, China and the US. Customers are internationally active medical technology companies. Elos Medtech employs more than 500 people worldwide and generates revenue that exceeds MSEK 550. Elos Medtech has been traded on NASDAQ Stockholm AB since 1989. The Elos Medtech B share is classified as a Health Care company on the Small Cap list. Gothenburg, November 14, 2017 Elos Medtech AB (publ) For further information, contact: Jan Wahlström, President and CEO, +46 70-212 18 89, jan.wahlstrom@elosmedtech.com Jodie Gilmore, Managing Director, +1 901 323 6699, jodie.gilmore@elosmedtech.com This is the type of information that Elos Medtech AB (publ) is obliged to publish in accordance with the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was issued for publication by the contact persons stated above on November 14, 2017, at 08.00. (CET). For additional information about the Elos Medtech Group, visit www.elosmedtech.com

Hansa Medical Interim report July – September 2017

July-September in brief ›› Combined data from three independent clinical Phase II studies with Hansa Medical’s lead candidate IdeS was published in The New England Journal of Medicine 2017;377:442-53, August 3, 2017 issue. Data from these studies show that IdeS effectively reduces HLA antibodies and enables patients with very poor prognosis, who are unlikely to find a kidney donor, to be transplanted. Importantly, patients were doing well with good kidney function at last follow up. ›› Patient enrollment on target to have all patients recruited and treated by the end of 2017 in two ongoing Phase II studies with lead candidate IdeS in highly sensitized patients in the US and Europe. All treated patients will be monitored for six months post treatment. ›› Continued strengthening of the organization in preparation for additional Phase II studies with lead candidate IdeS. Significant events after the end of the reporting period ›› On November 8, 2017, Hansa Medical announced the sudden and unexpected passing of CEO Göran Arvidson. Ulf Wiinberg, chairman of Hansa Medical, will serve as acting CEO and board member Birgit Stattin Norinder will take over the role as chairman of the board until further notice. ›› Updates on the clinical progress of IdeS in kidney transplant program were presented at Hansa Medical’s well attended Capital Markets Days in Stockholm (October 3) and London (October 4). As of October 3, the number of patients treated with IdeS prior to kidney transplantation was 42. Follow-up data on the first patient transplanted after desensitization with IdeS in 2014 was presented, demonstrating continuous normalized creatinine levels three years’ post kidney transplantation. ›› Continued patient enrollment in the investigator initiated Phase II study with IdeS in anti-GBM, a rare kidney disease. As of November 14, five patients had been included in the study. Limited follow-up data is currently available from three of these five patients who have responded favorably. IdeS appears to be well tolerated in these patients so far. Patients enrolled in the study will be monitored for six months. +-----------------------------+-------+-------+--------+------------+--------+| | Q3  |January – September  | Year |+-----------------------------+-------+-------+--------+------------+--------+|KSEK, unless otherwise | 2017 | 2016 | 2017 | 2016 | 2016 ||stated  | | | | | |+-----------------------------+-------+-------+--------+------------+--------+|Net revenue  | 678 | 907| 2 429| 2 036| 2 579|+-----------------------------+-------+-------+--------+------------+--------+|Operating profit/loss  |-37 434|-26 954|-127 162| -77 573|-111 135|+-----------------------------+-------+-------+--------+------------+--------+|Net profit/loss  |-37 527|-26 926|-127 672| -77 573|-111 129|+-----------------------------+-------+-------+--------+------------+--------+|Earnings per share before and| -1,07| -0,83| -3,64| -2,39| -3,39||after   dilution | | | | | |+-----------------------------+-------+-------+--------+------------+--------+|Shareholders’ equity  |167 890|138 806| 167 890| 138 806| 283 693|+-----------------------------+-------+-------+--------+------------+--------+|Cash flow from operating |-38 427|-27 775|-120 963| -67 378| -94 563||activities | | | | | |+-----------------------------+-------+-------+--------+------------+--------+|Cash and cash equivalents |130 871|103 948| 130 871| 103 948| 253 578||including short term | | | | | ||investments | | | | | |+-----------------------------+-------+-------+--------+------------+--------+ CEO statementWe are very grateful for the time we had Göran at the helm of Hansa Medical. Through his inspiring and genuine commitment, he has built a strong growing biopharmaceutical company with clear and ambitious strategic plans and a dedicated organization capable of executing and delivering on milestone targets. Göran will be greatly missed by all of us, as a true professional and as a warm and inspiring person. We are firmly dedicated to continue the development of our company in the direction outlined by Göran and the board of directors. Göran’s work in collaboration with the team in Lund and in the US, has taken us to a very strong position in the development of innovative immunomodulatory enzymes. During the third quarter, we received further evidence that IdeS has great potential as a new and innovative treatment to enable life-saving kidney transplantation. In our ongoing clinical Phase II studies with IdeS a total of 42 patients have been transplanted, which reinforces our view that IdeS could represent an entirely new approach for eliminating HLA antibodies to enable transplantation for highly sensitized patients. In line with the clinical progress, we have also gained increased attention from in the medical research community and among other stakeholders. In August, data was published from three independent clinical Phase II studies with IdeS in the high impact medical journal The New England Journal of Medicine. The article, titled IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation, concludes that treatment with IdeS effectively reduces donor-specific antibodies (DSAs) to levels that enable life-saving transplantation for highly sensitized kidney transplant patients. This is a very important milestone for highly sensitized patients awaiting a kidney transplant and for us as a company. In October, we hosted Capital Markets Days in Stockholm and in London, where we shared these important study results with our shareholders and provided details of our strategy for the company’s next phase of development. During the events, senior management from Hansa Medical and leading transplant experts gave an update on our projects and the latest research findings. The interest from both our shareholders and the research community, further supports the relevance and medical importance of our research and development of immunomodulatory enzymes. This year, in parallel with our innovative work in organ transplantation, we have taken the first important clinical steps to broaden the use of IdeS. We believe there is significant therapeutic potential for the fast and efficient IgG cleaving mechanism of action of IdeS in both serious transplant-related indications and acute autoimmune diseases, such as anti-GBM antibody disease. As of today (November 14, 2017) five patients have been treated with IdeS in an ongoing investigator-initiated Phase II study in severe anti-GBM antibody disease, a rare and acute autoimmune disease in which the kidneys often are irreversibly damaged resulting in the need for dialysis treatment or kidney transplantation. Limited follow-up data is currently available from three of these five patients, who have responded favorably. IdeS appears to be well tolerated so far in these patients. In addition, prior to initiation of this clinical study, three patients with anti-GBM antibody disease were treated on a named patient basis in Sweden. Hence, a total of eight patients with anti-GBM disease have been treated with IdeS as of November 14, 2017. In total, approximately 15 patients will be recruited to the anti-GBM study at up to 15 clinics in Europe. This may provide evidence that IdeS has the potential to be an important treatment in additional serious, acute IgG-mediated diseases for which no approved treatments exist today. During this year, we have continued to build a strong and committed team expanding broadly in both R&D and marketing as well as in the medical department to which we recently hired two seasoned senior medical science liaisons in the US, to support our increasing presence in this important market for future anticipated launches. We have increased the number of co-workers significantly and are now around 40. We have made significant investments in the IdeS production process during 2017 and we continue to prepare product supply for commercialization of IdeS. The processes have been transferred to manufacturers in Europe suitable for commercialization and the product we are preparing for launch is going to be a lyophilized product for easy off the shelf use and for convenient and effective world-wide distribution. Naturally, we still have several milestones to achieve until we have a product on the market, but the overall progress in recent months is very encouraging and has further strengthened our belief in the future of IdeS. Our position to become a pharmaceutical company with important, life-saving products on the market is becoming more prominent for every milestone we reach and I look forward to updating you on our continued development. Ulf WiinbergActing CEO 

Rottneros invests another 117 SEKm within the framework of Agenda 500

As a next step in the capacity development of Rottneros Mill, Rottneros’ Board has granted further investments in the CTMP line. The investment, CTMP Step 2, increases capacity by approximately 18,000 tonnes per year and is expected to be operational in the fall of 2018. The investment follows the strategic development plan Agenda 500, where a first capacity-enhancing investment in the CTMP line was made in 2016. Within Agenda 500, Rottneros Mill has put into operation a bio mass boiler in the third quarter of 2017 that replaces an oil-based boiler and made the mill practically fossil-free. The expansion of the purification plant is an ongoing investment that is expected to be put into operation in 2018. The Rottneros Mill has a strong position as a supplier of high yield pulp. With increased capacity, we ensure that Rottneros can be a reliable supplier of CTMP and an attractive partner for our customers, says Lennart Eberleh, President and CEO of Rottneros AB. The Vallvik Mill was granted a new environmental permit in 2016 which allows production of 255,000 tonnes of chemical pulp per year. The permit also includes increased requirements regarding sulfur emissions. In order to meet the requirements, the mill will invest in a weak gas collection system. Final negotiations with the potential suppliers will begin immediately. The investment is expected to be put into operation in Q4 2018. Agenda 500 includes both environmental and capacity investments. For Vallvik Mill, the investment in the weak gas collection system is another environmental investment to ensure the long-term sustainability of the mill, comments Lennart Eberleh, President and CEO of Rottneros.    For more information, please contact:Lennart Eberleh, President and CEO of Rottneros AB, +46 270 622 65 The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on 14 November 2017. 

Interim report January - September 2017

Third quarter 2017 ·Revenues amounted to SEK 180.7 (127.2) million, an increase by 42 % compared to the same period last year. ·Operating profit amounted to SEK 52.9 (54.6) million, a decrease by 3 %. ·Profit before tax amounted to SEK 52.6 (54.6) million, and profit after tax amounted to SEK 40.6 (42.3) million. ·Cash flow from operating activities amounted to SEK 70.3 (102.7) million, and cash flow from investing activities amounted to SEK -79.2 (-30.8) million. ·By the end of the period cash and short term placements amounted to SEK 244.3 (215.1) million.   ·Earnings per share amounted to SEK 0.38 (0.40) per share. ·Revenue from the third quarter of 2017 are mainly attributable to Stellaris, Cities: Skylines, Cities: Skylines Console, Hearts of Iron IV and Europa Universalis IV. Important events in the third quarter ·The acquisition of game developer Triumph Studios was finalized with a transaction date July 7. The purchase price was set to EUR 4 million plus a performance based earnout of up to EUR 21 million, until December 2025. ·Cities: Skylines PlayStation4 Edition was released to PS4. ·Pillars of Eternity: Complete Edition was released to PS4 and Xbox One. ·Several expansions were released during the period; Second Wave to Steel Division: Normandy 44, Synthetic Dawn Story Pack to Stellaris and Bastard's Wound to Tyranny. ·Steam Summer Sale started June 22 and continued until July 5. ·A decision was made to move the release of Battletech to 2018, instead of as previously communicated 2017. ·It was announced that CFO Andras Vajlok has decided to step down from his role and a process to recruit his successor was initiated. Words from CEO We can do better! As we close the third quarter, we do so with 42% growth compared with the same quarter in 2016 and an operating margin of 29%. While this is good, the figures are significantly lower than the same period last year. This is mainly a consequence of negative exchange rate differences, the writing-off of an as yet unnamed project and increased royalty payments. The quarter is yet another example of the fact that some quarters will always look better than others throughout our ongoing operations. We still managed to see growth in turnover despite the fact that we have actually only had one PC release to full price during 2017. On the other hand, we have released some successful expansions with content and value comparable to other full-priced titles on the market. We have also released some of our current games on consoles. These releases, in addition to earlier releases, are the driving forces behind growth in both revenue and players during the quarter. With all that said, we are still short of giving ourselves a passing grade for what we’ve done so far during 2017. Only one new game per year is just not good enough. The underlying cause for releasing only one game during 2017 are the many decisions that we made a couple of years ago regarding the improvement of the quality of our games. As a result, we tightened the flow of games to a certain degree, with a clearer focus on improved quality. These last few years have shown that this strategy is paying off, in particular when viewed over time, but the real advantages are yet to be revealed. Now that we have more people and teams in place, we are better equipped to meet future challenges and are working with really great developers all over the world. A quick look at what we already know about 2018 reveals two exciting titles, Surviving Mars and Battletech, in our pipeline. Looking back at the past quarter, the acquisition of game developer Triumph Studios has been the most significant event. We have spent the last few months integrating the team into our organization. The smoothness of this transition is an indication that we share many of the same views regarding our communities with gamers, our love for game development and the kind of driven people that we have within our respective organizations. Paradox has a lot to offer in terms of size, marketing muscle, contacts, experience and so on. It is clear, however, that the Triumph team too can teach us a few things about our different disciplines. In Q3 we also became a console publisher “for real.” We previously experimented with consoles but have now released both Cities: Skylines on PS4 and Pillars of Eternity: Complete Edition on PS4 and Xbox One. Looking at the suitability for a console version in our game projects is now a natural part of the production process, even if that doesn’t necessarily mean that console versions of our games will automatically be developed. We have also released a number of expansions during the period. Second Wave for Steel Division: Normandy 44, Synthetic Dawn Story Pack for Stellaris and Bastard's Wound for Tyranny. The content of Stellaris continues to attract new users while reactivating current players. Expansion sales for Steel Division: Normandy and Tyranny: Bastard’s Wound have been slower but, like most DLCs, have contributed to keeping the game active, in particular in view of the sales campaigns that often accompany the release of new content. After careful consideration, a decision was made to delay the release of Battletech until 2018. This is something that seems to have been met positively from both gamers who are anxiously awaiting the release and the market as a whole. Even if we are naturally reluctant to delay a game release, it is something that we are willing to accept if we see that it makes good business sense regarding the quality of the product. As in previous years we had a presence at Gamescom in Germany, one of the world’s biggest gaming conventions that seems to break records year after year. This year more than 350,000 people visited the convention. Our participation consisted of more than 200 meetings with media and our partners and, of course, our annual Paradox Party. This year we also held an informal fan-gathering where we got to meet some of our players. The games that we and our respective developers were able to show the media were Surviving Mars, Battletech, Stellaris: Synthetic Dawn and Tyranny: Bastards Wound. We also gave interviews in connection with the announcement of Cities: Skylines - Green Cities and Crusader Kings 2 - Jade Dragon. The importance of Gamescom as a convention was underlined by the fact that the opening ceremony was attended by none other than Angela Merkel herself. During this period we also announced the decision of CFO Andras Vajlok to step down from his position, and we have begun the process of finding his successor. Andras and I have worked together for more than six years now and have reached many milestones together. Even if I, from a personal point of view, am sorry that we won’t be working together on a daily basis anymore, I am convinced that every change represents an opportunity. Therefore, I am thrilled to be able to share that we have signed with our new CFO, Alexander Bricca. He has a very relevant background, shares my excitement about our future journey and will start within six months. I am sure that with Andras’ help, we will be able to give our new CFO a great introduction to the Paradox of today, so that he in turn will be able to help us achieve our goals for the future. Fredrik Wester, CEO Presentation of interim report Fredrik Wester and Andras Vajlok will host a live stream to answer report and financial related questions on our Twitch channel on November 14 at 12:00 PM CET https://www.twitch.tv/paradoxinteractive. Submit your questions before via our forum https://forum.paradoxplaza.com/forum/index.php?threads/quarterly-report-q3-q-a-stream-tuesday-nov-14-at-12-00-noon-cet.1053635/ by e-mailing them to ir@paradoxplaza.com or directly in the Twitch chat. The Twitch chat is open for anyone to view but to post comments or question you will need to create an account.

Etrion Releases Third Quarter 2017 Results

November 14, 2017, Miami, Florida, United States – Etrion Corporation (“Etrion” or the “Company”) (TSX: ETX) (OMX: ETX), a solar independent power producer, today released its condensed consolidated interim financial statements and related management’s discussion and analysis (“MD&A”) for the three and nine months ended September 30, 2017.  Etrion Corporation delivered strong project-level results in the third quarter of 2017 driven by the Japanese assets. Higher installed capacity and electricity production resulted in a significant increase in revenue and project-level EBITDA compared to the same period in 2016. THIRD QUARTER 2017 HIGHLIGHTS ▪     Strong performance in Japan, with full year results expected to be at or above to the high end of the guidance range. ▪     Revenue more than doubled for this third quarter compared to same period last year. ▪     Significant project cash distributions, enabling the Company to further optimize its capital structure by reducing the amount of its corporate bonds outstanding, while maintaining a strong unrestricted cash position to support the growth of the business. ▪     Deconsolidation of the Chilean solar power subsidiary resulted in a one-time, non-cash extraordinary gain of US$41.0 million. ▪     Construction of the 13.2 MW Komatsu solar project in northern Japan 75% complete, on budget and on schedule, with estimated connection during the second quarter of 2018. ▪     Growth opportunities in Japan remain strong with further projects of 190 MW (on a gross basis) targeted to reach financial close in the next 24 months. Management Comments Marco A. Northland, the Company’s Chief Executive Officer, commented, “Japan continues to deliver very strong results.  We more than doubled our revenues compared to 2016, increased our installed capacity and made significant progress on several projects with aggregate capacity of 190 MW (on a gross basis). We continue to have a strong cash position, giving us flexibility on how to fund our growth.  I am very excited at the prospects over the next 24 months in this market and look forward to bringing new projects to financial close. On the operational side, our plants are performing well above plan, demonstrating superior design, technology and operations. We continue to drive cost down and restructure the business to better support our growth in Japan.” FINANCIAL SUMMARY  Three Nine months months ended endedUS$ thousands (unless Q3-17 Q3-16 Q3-17 Q3-16otherwise stated)Electricity production 49,174 41,705 141,563 119,957(MWh) 1Financial performance2 3Revenues 7,005 3,351 19,245 10,254EBITDA 2,512 (84) 4,474 298Net income (loss) from 35,161 (92,640) 20,732 (102,340)continuing operationsProject cash 4,362 - 7,704 -distributionsCash flow used in (1,493) (1,140) (3,052) (3,419)operationsAdjusted operating 2,732 930 5,043 586cash flowFinancial position Sep 17 Dec 16Unrestricted cash at 41,548 42,286parent levelRestricted cash at 19,597 18,888project levelWorking capital 56,451 45,257Consolidated net debt 126,989 225,700on a cash basisCorporate net debt 5,691 (98)(cash)1 MWh-Megawatt-hour 2Q3-17 financialresults include thefinancial performanceof the Chileansubsidiary, PVSalvador SpA untilSeptember 30, 2017when the Group lostcontrol for IFRSpurposes. 3 2016comparative figureshave been restated toexclude thediscontinued Italianoperation  Management Change  Effective January 1, 2018, the Company has appointed Christian Lacueva as Chief Financial Officer. Mr. Lacueva replaces Paul Rapisarda, who is resigning to pursue other interests. Mr. Rapisarda has been CFO of Etrion since November 2015.  Mr. Lacueva has been Etrion’s Vice President of Asset Management Services and Corporate Treasurer since 2014 and held other finance positions within the Company since 2010. Etrion’s CEO, Marco A. Northland, commented “I am very pleased to appoint Christian as CFO. He has intimate understanding of the business and will play an instrumental role in the Company’s next growth phase. I also want to extend my gratitude to Paul for his invaluable leadership and contributions to the Company, including the successful sale of our Italian assets and restructuring of our Chilean operations. I wish him great success in his future endeavors.” Also, effective January 1, 2018, the Company has promoted Martin Oravec to the position of Chief Investment Officer. Mr. Oravec joined Etrion in 2009 and has been responsible for financing all the solar projects developed by the Company, in an aggregate amount of nearly one billion dollars since inception. Earnings Call A conference call/webcast to present the Company’s third quarter 2017 results will be held on Tuesday, November 14, 2017, at 10:00 a.m. Eastern Daylight Time (EDT) / 4:00 p.m. Central European Time (CET).   Dial-in details: North America: +1-647-788-4919 / Toll Free: +1-877-291-4570 / Sweden Toll Free: 02-079-4343 Webcast: A webcast will be available at https://www.webcaster4.com/Webcast/Page/1297/19086     In addition, the earnings call presentation, along with the Company’s condensed consolidated interim financial statements for the three and nine months ended September 30, 2017, and related management’s discussion and analysis will be available on the Company’s website (www.etrion.com) .  A replay of the telephone conference will be available until December 5, 2017.  Replay dial-in details: North America: +1-416-621-4642 / Toll Free: +1-800-585-8367  Pass code for replay: 43070958 About Etrion Etrion Corporation is an independent power producer that develops, builds, owns and operates utility-scale solar power generation plants. The Company owns 114 MW of installed solar capacity in Chile and Japan. Etrion has 13 MW of solar projects under construction in Japan and is also actively developing additional greenfield solar power projects in Japan. Etrion is listed on the Toronto Stock Exchange in Canada and the NASDAQ OMX Stockholm Exchange in Sweden under ticker symbol "ETX". Etrion's largest shareholder is the Lundin family, which owns approximately 24% of the Company's shares directly and through various trusts. For additional information, please visit the Company’s website at www.etrion.com or contact: Paul Rapisarda – Chief Financial Officer  Telephone: +41 (22) 715 20 90 or +1 (786) 636 6449    Note: The capacity of power plants in this release is described in approximate megawatts on a direct current (“DC”) basis, also referred to as megawatt-peak (“MWp”). Etrion discloses the information provided herein pursuant to the Swedish Securities Market Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication in Sweden at 08:05 Central European Time on November 14, 2017. Non-IFRS Measures: This press release includes non-IFRS measures not defined under IFRS, specifically EBITDA and Adjusted operating cash flow. Non-IFRS measures have no standardized meaning prescribed under IFRS and therefore such measures may not be comparable with those used by other companies.  EBITDA is a useful metric to quantify the Company’s ability to generate cash before extraordinary and non-cash accounting transactions recognized in the financial statements. In addition, EBITDA is useful to analyze and compare profitability between companies and industries because it eliminates the effects of financing and accounting policy decisions. The most comparable IFRS measure to EBITDA is net income (loss). In addition, adjusted operating cash flow is used by investors to compare cash flows from operating activities without the effects of certain volatile items that can positively or negatively affect changes in working capital and are viewed as not directly related to a company’s operating performance. The most comparable IFRS measure to adjusted operating cash flow is cash flow used in operations. Refer to Etrion’s MD&A for the three and nine months ended September 30, 2017, for a reconciliation of EBITDA and adjusted operating cash flow reported during the period.  Forward-Looking Information:   This press release contains certain “forward-looking information”. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements relating to the Company’s projects in Japan under construction and in development) constitute forward-looking information. This forward-looking information reflects the current expectations or beliefs of the Company based on information currently available to the Company as well as certain assumptions including, without limitation, the ability of the Company to execute on its projects in Japan under construction or in development on economic terms and in a timely manner. Forward-looking information is subject to a number of significant risks and uncertainties and other factors that may cause the actual results of the Company to differ materially from those discussed in the forward-looking information, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on the Company. Factors that could cause actual results or events to differ materially from current expectations include, but are not limited to, the risk that the Company may not be able to obtain all applicable permits for the development of projects in Japan and the associated project financing required for the development of such projects on economic terms and the risk of unforeseen delays in the development and construction of its projects under construction or in development. Reference is also made to the risk factors disclosed under the heading “Risk factors” in the Company’s AIF for the year ended December 31, 2016 which has been filed on SEDAR and is available under the Company’s profile at www.sedar.com. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein. 

OmniCar holding AB announces new board member

Andreas Klainguti has worked for more than 25 years in Investment Banking for Merrill Lynch, Standard Chartered Bank and Citigroup in Zurich, London and Hong Kong. As a Manging Director he was Head of Derivatives EMEA and Asia, Head of Global Equity Trading and Head of Global Strategic Risk. Since moving to Denmark in 2013 he has been advising various Banks and Hedge Funds on Business set up, risk and manager selection while running his own investment company. The above is subject to approval by next the general meeting. Jens Aaløse, Chairman of the board of OmniCar Holding AB, says: "We are excited about welcoming Andreas Klainguti as a board member. It is crucial to have a constant focus on all the financial aspects of running a company, including future funding, budgeting, cash flow and financial reporting. With Andreas Klainguti, we now have an experienced resource as a board member with extensive global experience” Jens Aaløse, says. For more information about OmniCar Holding AB, please contact  Claus T. Hansen, CEO  E-mail: cth@omnicar.dk Telephone: +45 26 75 66 66http://www.omnicar.com/ This information is insider information that OmniCar AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 26 October 2017. About OmniCar Holding AB OmniCar Holding AB (559113-3987) OmniCar is a 100% ‘plug-and-play’ online solution. No more time-consuming management and manual invoicing. Omnicar allows you to manage your service agreements digitally with a layout that is fully customised to meet your business’s individual requirements and specifications. You save time and administrative resources thanks to the automated system management of all processes.

Schörling & Partners AB announces an unconditional cash offer of SEK 569 per share to the shareholders of Melker Schörling AB

The Schörling family has together with Stefan Persson, Carl and Martin Bek-Nielsen and Mikael Ekdahl decided to continue to operate Melker Schörling AB (“MSAB” or the “Company”) in a non-listed environment. The decision is a consequence of an altered situation in MSAB since Melker Schörling left his operational position in the Company. “Considering the new situation in MSAB, it is our opinion that the Company could be more efficiently operated in a non-listed environment. Going forward, we intend, together with our closest long term partners, to do our outmost to contribute to the best possible development of the holding companies”, says Melker Schörling, Märta Schörling Andreen and Sofia Schörling Högberg. “Our hope is that all shareholders in MSAB have an understanding for this change and continue their commitment by investing directly in the successful listed companies which make up MSAB’s portfolio companies. Since the IPO in 2006, we have consistently used the net asset value as a benchmark of the value development in MSAB and therefore consider it logical that the offer is now also based on current net asset value”, says Mikael Ekdahl, the chairman of the board of directors of MSAB. The buy-out is made by Goldcup 15638 AB (u.n.c.t. Schörling & Partners AB) (”Schörling & Partners”), jointly owned by the Schörling family’s holding company Melker Schörling Tjänste AB (“MSTAB”), Stefan Persson, UIE Malta Holding Ltd. (a wholly owned subsidiary of United International Enterprises Ltd. which is controlled by Carl and Martin Bek-Nielsen) and Mikael Ekdahl AB, announcing an unconditional cash offer to the shareholders of MSAB to tender all their shares in MSAB to Schörling & Partners (the ”Offer”). Schörling & Partners holds approximately 92.6 percent of the shares and votes in MSAB. The shares in MSAB are admitted to trading on Nasdaq Stockholm, Large Cap. · Schörling & Partners offers SEK 569 in cash per share in MSAB (the “Offer Price”).[1]  The Offer Price exceeds the net asset value in MSAB as of 13 November 2017, SEK 568, and corresponds to the volume-weighted average purchase price for the MSAB share on Nasdaq Stockholm during the last 20 trading days prior to the announcement of the Offer.[2]  The total Offer Price amounts to approximately SEK 5,005 million, and the Offer represents a value of MSAB of approximately SEK 67,767 million.[3]  · The Offer Price represents a premium of: - approximately 5.1 percent compared to the volume-weighted average purchase price of SEK 541.3 for the MSAB share on Nasdaq Stockholm during the last 90 trading days prior to the announcement of the Offer; and - approximately 3.9 percent compared to the closing price of SEK 547.5 for the MSAB share on Nasdaq Stockholm on 13 November 2017, which was the last trading day prior to the announcement of the Offer. · The Company has obtained a fairness opinion from Ernst & Young AB, according to which the Offer is fair to the MSAB shareholders from a financial perspective. · Schörling & Partners is the Company’s largest shareholder, holding approximately 92.6 percent of the shares and votes in the Company and intends to, as soon as possible, initiate a compulsory acquisition procedure in respect of the remaining shares in the Company. · Schörling & Partners expects to publish an offer document regarding the Offer around 15 November 2017. The acceptance period for the Offer is in such case expected to commence on 16 November 2017 and run until 14 December 2017. · The Offer is not subject to any completion condition and settlement to those having accepted the Offer will occur weekly during the acceptance period, with the first settlement estimated on 24 November 2017. · In order to, on a continuous basis, provide liquidity to MSAB’s shareholders, Schörling & Partners intends to acquire, or enter into arrangements to acquire, shares in MSAB outside the Offer through Skandinaviska Enskilda Banken AB (publ) (“SEB”), whereby purchase orders are intended to be placed on the market for MSAB shares, at a price not higher than the Offer Price. Please note, however that sale of shares in the market may entail a cost for shareholders in the form of commission. Such acquisitions made or arranged will be in accordance with Swedish law and the Nasdaq Stockholm’s Takeover Rules (the “Takeover Rules”) and will be disclosed in accordance with applicable rules. ---------------------------------------------------------------------- [1]  If MSAB pays dividends or makes any other distributions to the shareholders, for which the record date occurs prior to settlement of the Offer Price, the Offer Price will be reduced accordingly. [2]  The net asset value in MSAB as per 13 November 2017 amounted to SEK 568 per share. The bidder has also considered it relevant to observe the obligation to offer a price corresponding to the volume-weighted average purchase price during the last 20 trading days prior to the announcement of a public offer that a bidder under certain circumstance have to adhere to in a mandatory bid, the application of which in this case results in an offer price of SEK 569 per share. [3]  Based on 119,097,595 shares, which is the total number of issued shares in MSAB.

Patent cases dismissed

In October 2013, Accumulate AB filed a lawsuit against Seamless Distribution AB (publ) for alleged patent infringement. In August 2014, Seamless filed a lawsuit against Accumulate where Seamless claimed that Accumulate’s patent should be declared invalid. On September 15, 2017, the Swedish Patent and Market Court announced its judgements in both cases. The judgements were appealed by Accumulate to the Swedish Patent and Market Court of Appeal, and the court has now decided to dismiss both cases. The reason behind the dismissal of the cases is that the parties have reached a settlement with the purpose to final, and without any further delay, regulate the issues that have been dealt with in both cases. The settlement provides that the parties shall withdraw the action and that the parties agree on the understanding that Seamless has not committed a patent infringement and that Accumulates patent (SE1050585-7, SE537539) will continue to be valid. The settlement also provides for financial compensation to Seamless related to legal costs.  For more information, please contact:  Martin Schedin, CFO, martin.schedin@seamless.se, +46 8 564 878 00  This is information that Seamless Distribution AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 8:50 a.m. CET on November 14, 2017. About Seamless Since 2001 Seamless has been providing its proprietary solutions and systems for mobile phone transactions. Seamless operates in two main business areas; mobile phone payment solutions (provided through the brands SEQR© and MeaWallet™) and distribution of e-products. www.seamless.se

Arcam news at Formnext 2017

EBM systems momentum EBM technology continues to find wider acceptance in the Additive Manufacturing community. The aerospace and medical industries have increased the demand for Arcam EBM systems as the technology proves itself to be effective. As a result, Arcam is committed to evolving and developing products that support our customers and focus in the future. Presenting EBMobile, an app for remote monitoring of EBM machines.With EBMobile, we give our customers the ability to monitor their EBM machines at a distance. EBMobile is an app built with our customers in mind. Through research and development, Arcam EBM has identified the need to give the user on-time information regarding the status of their EBM machine while gathering and analyzing statistical data. The EBMobile app will help our customers obtain an optimal overview of ongoing processes in their EBM machines in real time. Expanding Metal Powder Range & Capacity AP&C, the largest titanium powder supplier for the additive manufacturing industry, continues to secure long-term supply agreements with key customers. AP&C supplies a range of powders to the AM industry, including Ti6Al4V, Ti Grade 2 and Inconel 718. Recently AP&C opened its new state-of-the-art metal powder manufacturing plant in Saint-Eustace, Canada. With the new facility AP&C will have an initial production capacity of 750 tons, rising eventually to 1,250 tons at full capacity. AP&C is certified to ISO13485, ISO9001 and AS9100. Traction in the Medical Implants Sector Volume production of EBM-manufactured, CE-certified orthopedic implants is now a reality. Well over 100,000 orthopedic implants produced with EBM technology have been implanted. At present, Arcam’s customers offer a wide range of implants; acetabular cups, femoral stems, spinal and CMF. With the use of EBM machines, the implants are cost-efficiently manufactured with integrated, designed network structures for improved bone in-growth. DiSanto (DTI) is increasingly active in the medical implant sector and continues to add new customers and projects to the Arcam EBM contract manufacturing business.  

Episealer® 24 months’ clinical study results accepted for publication in peer-reviewed scientific journal

Episurf Medical (NASDAQ: EPIS B) today announces that a peer-reviewed article with clinical data on 10 Episealer® knee implant patients with 24 months’ follow-up now is accepted for publication. The publication with the title “A customized femoral resurfacing metal implant for focal chondral lesions - radiostereometric analysis and subjective outcome of the first ten patients” by Stålman, A., Sköldenberg, O., Martinez-Carranza, N., Högström, M. and Ryd, L. will be published in the journal Knee Surgery, Sports Traumatology, Arthroscopy and is shortly available online. The study behind the publication is a multi-center clinical study conducted in Sweden with Dr Anders Stålman as principal investigator. The surgeries were performed between 2012 and 2014. The patients were followed-up with subjective outcome measures (VAS, Tegner, EQ5D and KOOS) and implant fixation was studied with RSA. The subjective outcome measures showed improvements that reached significance for VAS (p=<0,001), Tegner (p=0,034) and the KOOS sub-scores Activities of Daily Living (p=0,0048), Sport and Recreation (p=0,034) and Quality of Life (p=0,037). “This first publication from a clinical multi-center study with Episealer®, a customized focal knee resurfacing system, shows short-term implant safety and the patient related outcome measures show good to excellent results” says Anders Stålman, PhD, Senior Consultant, Capio Artro Clinic, Stockholm. “This publication is very welcome for us, as high-quality peer-reviewed clinical evidence is a must for orthopaedic surgeons in their treatment decisions. This is a further and very important step forward to gain market shares for the Episealer®” comments Pål Ryfors, CEO, Episurf Medical.  For more  information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 09.15 CET on 14 November 2017.

MATPAX-project completed with positive outcome

The main focus of the project was to develop a system solution comprising a tailored resin, with embedded reactive functionality (cross-linkers), and a production process to manufacture crosslinked parts from this resin. The test results displayed significantly enhanced mechanical properties. These results create opportunities for new applications where, for instance product performance could be retained in parts made with less material than existing products – enabling weight reduction. “The MATPAX-project was successful and the participants are optimistic about this technology. We are developing a new solution with an interesting future and we have gained a lot new knowledge about plastics materials development”, says Dane Momcilovic, CTO. For more information about the project visit www.vinnova.se  (only in Swedish). Nexam Chemical has received half of the project cost as contribution from Vinnova. Total contribution received during the project amounts to approximately SEK 2.4 million. Note: This news has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version. For further information please contact: Anders Spetz, CEO, +46-703 47 97 00, anders.spetz@nexamchemical.com  ____________________________________________________________________________ About Nexam Chemical Nexam Chemical develops technology and products that make it possible to significantly improve the production process and properties of most types of plastics in a cost-effective manner and with retained production technology. The improved properties include strength, toughness, temperature and chemical resistance as well as service life. The improvements in properties that can be achieved by using Nexam Chemical's technology make it possible to replace metals and other heavier or more expensive materials with plastics in a number of applications. In applications where plastic is already used, Nexam Chemicals products can improve the manufacturing process, reducing material use and enable more environmental friendly alternatives. Example of commercial applications: pipe manufacturing, foam production and high-performance plastics. More information about the business will be found on www.nexamchemical.com . The company´s Certified Adviser is FNCA Sweden AB.

Loudspring - strategy update, next steps & outlook

In January 2015, we set out to become the leading European Cleantech accelerator by the end of 2017. As year-end is approaching we see a number of things we can do that would bring shareholder value but that are dependent on us updating our strategy. We have consequently taken the decision to already now publish this strategy update. This document sheds light on the background of the updated strategy, and sets the scene and targets for the coming three years. Executive Summary Traditional industrial companies typically consume more natural resources when they grow. Cleantech Invest (later referred to as: “Loudspring”) is unique in that, the more our energy and resource efficiency businesses grow the more natural resources (minerals, renewable resources, clean air and climate, clean water and biodiversity) we save. We have decided to transform from an investor-accelerator into a company saving natural resources through maximizing growth, with holdings varying from (the current) minority venture holdings to majority holdings forming the core of our group’s operations in the future. This means that instead of always seeking an exit for a portfolio company, we will also aim to consolidate selected companies into our group, resulting in majority ownerships or even wholly-owned business units. We may also consider acquiring external businesses into our company’s core. We will look to acquire a majority in companies that are profitable in the short to medium term, and that require relatively limited additional capital injections. We will continue to invest into current and new firms, and in many cases, we will ultimately seek an exit. In our venture portfolio, we will accept higher risk, as returns when successful can be high, as we see in our current portfolio. As we have recently communicated, we have generated a 11,3x partial exit and we see potential for even higher returns among current holdings. But at the same time, out of our own operations, we will be creating a global enterprise focused on saving natural resources and which directly influences the vision, strategy and revenue of its businesses. We believe that building and managing our own businesses enables us to generate much more value in the long term, compared to a traditional investment company approach. The transition will be gradual and we will work together with our current entrepreneurs and possible acquisition targets to see if there is an economic, strategic and cultural fit with our core business. Consolidation will generate a myriad of opportunities ranging from synergies in customer acquisition to efficient sourcing, cost of capital and talent acquisition. Traditional industrial companies consume more natural resources, the more they grow. Loudspring is unique in that, the more we grow the more natural resources we save and as an end result, we seek to form a leading industrial actor in selected business areas, saving the maximum amount of natural resources while maximizing value to our shareholders. Where We Are Coming From  Ecosystem deterioration through human activity is a universal problem facing our generation. Cleantech Invest has been combating this through sourcing, investing in and deploying Nordic solutions on the global markets where they can have maximum positive impact.  Since our last strategy update, we have already prioritized our current portfolio companies’ international growth. This approach has allowed us to get more involved with our portfolio companies, heavily influencing a wide range of managerial and strategic decisions made by our portfolio companies. We no longer take a high-level approach to our portfolio but get involved in tasks such as talent acquisition, business modeling, funding, and executing international growth and communications. Furthermore, our more focused approach has allowed us to allocate a more significant portion of our available capital to the current portfolio companies. We have been able to dramatically accelerate portfolio company growth (portfolio company combined annual revenue growth over 110% on average since 2014) thus maximizing also their positive environmental impact by saving maximal amount of natural resources according to our strategy. The main form of shareholder value creation is the value appreciation of our share. Since Cleantech Invest IPO in 2014 the share price has increased more than 50% per year and we acknowledge that the market expects us to achieve high growth in value. In addition to shareholder value we aim to deliver societal value. The main form, which we also measure and communicate, is the positive environmental impact our companies have through achieving savings in natural resources; energy, carbon emissions and fresh water; decreased pesticide use; increased use of renewable energy; and decreased use of minerals and agricultural land. In order to continue to achieve and exceed our ambitious growth targets,we are implementing the following strategic changes. New Name and New Identity: Loudspring We have published a separate release on the new name and identity on November 7th 2017. A new mode of operating: A company with its own vision for the future, saving natural resources Our track record shows that our direct operational engagement in our portfolio firms has been crucial to their financing, management and successful growth. Our operational involvement has steadily increased over the years and we now intend to intensify it. To date we have avoided owning more than 50% of any holding. We believe that this has not generated maximal returns for our shareholders, especially when seen in relation to our contribution in our companies. We have also been seen as a holding company, or an investment firm, with the related stigma of being valued as such, despite the pivotal role of our own operations in creating portfolio company success. We are now changing strategy and will be actively looking to significantly increase our exposure in a number of fast-growing market opportunities and direct an increased portion of our focus and capital on our current portfolio of companies active in these markets. We have carefully identified those companies where we see the largest opportunity for growth and are actively looking for opportunities to increase our ownership in those firms. This shift in policy and ownerships will over time result in Loudspring becoming an operational company that saves natural resources through revenue growth. The more we are able to grow, the more natural resources will be saved. Loudspring will no longer be a standard holding company with a portfolio of companies, but an operational company with business units (or daughter companies) as well as a venture investment arm. In addition to increased ownership in select portfolio companies, we will also begin to work in parallel with the management teams and take a more hands-on approach to operations. From the portfolio companies’ perspective, through Loudspring they will gain crucial growth competences such as internationalization, sales, investor relations, and communications, as well as access to capital. In addition to executive support, consolidated portfolio companies will also benefit from resource sharing and collaboration between each other, as they will all operate closely together. We have carefully made this decision moving forward in order to fully capture the economic benefit that will be created as a result of the foundational work we have done with our current portfolio. We are confident that the timing to initiate this change is now. Markets ready for disruption: High potential for saving natural resources We believe there is a transitional change happening across several markets. This transition opens up opportunities to disrupt legacy industries with capital-light, innovative solutions. There are new modes of operating and a shift towards more environmentally-friendly solutions on the markets where our companies operate and are experiencing strong growth. During the last five years, the cost of more environmentally-friendly alternatives to traditional solutions have radically dropped and we clearly see through the growth of companies such as ResQ Club, Swap.com and Plugsurfing that consumer willingness to adopt these solutions has increased steadily. Examples of markets ready for disruption are: · Manufacturing, where the decreasing cost of sensors, processing power and Internet connectivity has made it possible to measure, manage and optimize energy use remotely, opening huge energy efficiency pockets that have not been available up until now; · Real Estate, where the smart building is now finally replacing what was previously only regarded as ‘property’; · Energy, where installing renewables is in several scenarios now the most economically viable option for much of the new power that is built [https://www.lazard.com/media/438037/lazard-lcoe-100-executive-summary.pdf], and where Africa, with increasing population and strong GDP growth coupled with extremely low access to electricity (currently 43% of population), is leading the way; · Food production and distribution, where around a staggering 88 million tonnes of food is wasted annually in the EU alone, with associated costs estimated at 143 Billion Euros; and · Fast fashion, where 85 billion worth of pre-owned clothing goes to waste every year in the US. Our current portfolio is, and we state this with great pride, leading the charge on many of these fronts. We see (to mention a few) that Swap.com can lead the transition into a radically different way to shop, pro-longing the lifetime of clothes significantly. We also see ResQ Club offering flawless meals that would otherwise have been wasted; Nocart progressing rural electrification in Africa; and Nuuka, increasing property value while decreasing energy use. We see similar growth in other focus areas within energy and resource efficiency and we continue to believe that by any metric, the Nordics are the technological growth engine of the world when it comes to environmentally-friendly technologies, rivalled only by California ( http://nordic.businessinsider.com/denmark-finland-and-sweden-are-the-worlds-best-at-clean-technology-innovation-2017-6/). The Nordic region provides us with a unique platform for our business operations. Next steps and outlook No single geographic location can tackle our global environmental challenges in isolation. Therefore, we have chosen to maximize our impact through making this a global effort in saving natural resources. Loudspring will continue to increase its international reach either through our own presence or partnerships. We will, however, remain Nordic-focused in our sourcing. What you measure is what you get. We have started to measure and communicate the positive environmental impact we are having and we see Loudspring as a company where the core value proposition is tangible positive impact on our ecosystems in the form of saving natural resources, and where the business idea is to make that positive environmental impact as big as possible.  Our shareholder base has grown to 5000 + and an increasing number of people are also followers of our activities. In 2018, we intend on focusing more time and effort reaching out to new potential investors and interested stakeholders.  We have set among other things, the following strategic targets to be achieved by the end of 2020: · Own businesses: Target global leadership in carefully selected market pockets by consolidating two or more portfolio companies into majority or fully-owned daughter companies/ business units; · Turn one or more of our business units into high profitability and source of significant dividends; · Venture portfolio: Achieve three or more successful exits with very high returns on invested capital. · Impact: Continue to rapidly increase our positive environmental impact and transform Loudspring into an internationally recognized role model in impact creation; · Shareholder value: Continued focus on share price appreciation as the main form of shareholder value creation; · Evaluate a possible switch to the main list of Stockholm and/or Helsinki Stock Exchange; · Establish a presence in additional growth markets around the globe; and · Seek and quickly monetize new natural resource efficiency opportunities. From looking at companies that we aspire to emulate we have seen that only by taking an active role have leaders in their respective space been able to dictate and create their vision for the future. Our new strategy allows us to do just that. Over time, the growth of a number of our companies has corresponded to the amount of influence we have had over them, and the amount of resources we have applied. Our record speaks for itself, and through increased ownership in a select number of our firms, we see that our record for growth and impact can even be further improved. Through this strategy change we are now moving to the next level of growth by step-wise transforming into a group that directly influences the vision, strategy and revenue of its business holdings. In 2020, Loudspring aims to be a company with one shared purpose: saving natural resources. We believe when we do this shareholder value will follow.

Loudspring - Beyond ‘Cleantech’ and ‘Investment’

As we have continued to grow, we will not allow our success to turn into complacency. We have only just started, and we understand the potential we have and are now shifting gears towards global status. Our strengthened position has allowed us to take a longer-term approach to our operations, and we are now able to ask ourselves - where do we want to be in 10 years? We have taken the decision to avoid comfort and embrace change as we have done for over 10 years. The world needs businesses to be flexible and willing to challenge the status quo. Being nimble has already allowed us to capitalize on new opportunities, and remaining nimble will help us steer the firm in the right direction, whichever direction that may be. A week ago, we announced the change of our company name to Loudspring and today we have announced significant changes to our strategy moving forward. This strategic shift is something I am really proud of, and is the culmination of years of insight and careful consideration about how we continue to provide value to shareholders as well as remaining ahead of the curve. You can read our new strategy outlook here , but the following is my own elaboration on what all this means. What’s in a name? Everything. As many traditional companies have branded themselves as cleantech, the term has diluted during the past decade. And it is true that many successful companies have focused more and more on efficiency and reducing negative environmental impact. Loudspring, however, has a clear goal of a big positive environmental impact - the more we succeed the more natural resources saved. We want to communicate this more clearly through our new identity. We are not interested in us being a part of a ‘pack’. We are interested in remaining ahead of it. Loudspring is a forward-looking company that will continue to support ‘clean technologies’ of course, but will not lean on the term ‘cleantech’ to prove it. Sharpening the point, when everything is cleantech, nothing really is. ‘Investing’ doesn’t optimally reflect what we do today either. Sure, we have invested in our companies and will continue to make investments in solutions that solve global challenges, but investing for quite some time has not been our core activity. Growing the portfolio companies is what we see ourselves as doing mostly, as well as making bold strategic moves like our California and other international expansion. Our involvement in the portfolio companies has steadily increased over the years and we intend to step up this trend as Loudspring. The identity of Loudspring is based on the desired end result of our work, which is the improved wellbeing of the Earth’s ecosystems. Deploying new technologies is one, but not the only, tool for us to help achieve that result. Why ‘Loudspring’? Loudspring takes inspiration from Rachel Carson’s famous book ‘Silent Spring’. Carson wrote about the use of environmentally harmful pesticides such as DDT, raising the prospect of a ‘silent spring’ without the sound of birds in nature. It may seem far-fetched today, but back 50 years ago, our ecosystems were facing some very grave prospects due to pesticide and chemical use. Carson was a quiet revolutionary in many ways, and her book sounded the alarm. She can be credited with being one of the founders of the mainstream environmental movement. This type of game-changing effort appeals to us and Loudspring pays respect to her efforts. A related vision is that of a ‘loud’ spring, where nature and biodiversity truly thrives. Healthy ecosystems that are brimming with life, overwhelming the senses, bringing joy and wellbeing to societies. The name matches our vision of maximizing our positive environmental impact and encourages and reminds us to use our own voices and actions to best achieve that vision. As you have seen recently with our own increased communications, we like to be bold and thrive when we are pushing the limits and changing the game. Loudspring is about being loud and proud about what we are doing, and even shouting from the top of a mountain when there is a need to challenge the, old status quo. A Strategic Shift - Growth in value equals growth in impact. As mentioned in our strategy update, the Nordics are the technological growth engine of the world, rivaled only by California. We believe this more than ever. We have been able to do our part in combating climate change and solving global challenges by growing and deploying Nordic solutions to the markets where they make the most impact. The results speak for themselves: since the Cleantech Invest IPO in 2014, the share has shown over 50% return per annum to investors. Our ambition is to continue a high growth track and we are focused on getting results. We are continuously evaluating new ways to increase the main form of shareholder value creation, which is the continued value appreciation of our share. We are ambitious and optimistic about the opportunities ahead of us, but we are realistic about the challenges as well. Not every company we invested in as Cleantech Invest turned out as successful as others. This is the reality of the journey ahead - there will be ups and downs. We will openly communicate these ups and downs, and learn from them as we grow. Loudspring is an impact company, focused on saving the Earth’s natural resources, with holdings varying from minority venture holdings to majority holdings forming the core of our operations in the future. Instead of seeking an exit for a portfolio company, we will also consider consolidating a specific company’s operations into our group, having a majority ownership or even a wholly-owned business. This is a big change from the investor/accelerator identity and approach we had as Cleantech Invest and it is the best way for us to play to our strengths while increasing shareholder value. We are out to create a thriving global enterprise, focused on environmental impact by saving natural resoures. This change won’t happen overnight, but it is clear through our increased ownership in Nuuka recently that the ball is rolling. The consolidation of selected holdings will generate a myriad of opportunities for Loudspring, ranging from synergies in customer acquisition to efficient sourcing and talent acquisition. Essentially, our re-focused approach, policy and ownership structure will result in Loudspring becoming an industrial company that is more similar to a ‘Green’ high tech company with a venture arm, than a standard portfolio of companies. Loudspring will be a leading industrial actor in selected business areas, providing real environmental impact while maximizing value for shareholders. Are we building rockets or colonizing Mars? Space X doesn’t just build rockets. No, they are going to colonize Mars. Our aspiration is akin to Space X in that with Loudspring, we don’t want to grow companies that do this or that at the moment, we are going to change the way the world consumes and impacts nature. Taking control of our own destiny will allow Loudspring to free itself from the valuation stigma of a company that does not directly influence its own future revenues, and we trust that the consolidation of certain portfolio companies will eventually allow the market to take a different approach to the valuation of us. We will be able to express our vision for the future, control our revenues and have that be reflected in our share price beyond the sum value of our parts. Through setting bold targets, we can provide a stronger voice to our solutions who will be able to use this claim as their own while continuing to grow. Any progress is considered a step in the right direction. I am proud to be part of a team that is out to disrupt laggard legacy industries. Nothing short of changing the world for the better and creating value for our shareholders is what we are here to do. We will be bold, vocal, and disrupt even ourselves in the process. The best way to predict the future is to create it. We are Loudspring, and we intend on leaving our mark. 

Realfiction completes implementation of rental service concept for their Dreamoc line

An important part of Realfiction’s ongoing global expansion is to offer the company’s customers greater flexibility and lower initial costs. A key element in this development is to go from only selling mixed reality displays to offering complete service solutions. The rental of the required hardware is offered through the company’s global partner network. While purchasing the hardware still remains the most sought after business model by customers, rental offers a flexible way of utilizing the company’s displays and technology for short-term campaigns and other one-off events.      – The possibility to remove the hardware sale from the equation has been well received by our partners as well as end-clients. We are already noticing an increased interest from existing clients, while we are also able to reach a significantly wider customer base than before, says Realfiction's CEO Clas Dyrholm.  During the latter part of 2017, the rental concept has been gradually implemented, and the first rental projects with smaller Dreamoc displays have already been completed. The concept is now fully available for the company's Dreamoc line in Western Europe as well as in the United States.   – We are now taking an important step forward towards increasing the utilization of our market-leading mixed reality displays, without the need for special glasses. Our strong partner-focus remains intact, and we see our rentals to end-clients as a way of supporting our partners in geographical regions where they are not yet established to complete the rental themselves, says Clas Dyrholm.  For more information about Realfiction, please contact:  Clas Dyrholm, Founder and CEO  Telephone: +45 25 22 32 81  E-mail: clas@realfiction.com   www.realfiction.com    Certified Adviser   Sedermera Fondkommission is the company’s Certified Adviser.   This information is information that Realfiction Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on November 14th, 2017. About Realfiction Holding AB Founded in Denmark in 2008, Realfiction is a leading mixed-reality solutions company, a market estimated to reach USD 80 billion by 2025. The company’s first product, Dreamoc, has been sold in over 10.000 units. DeepFrame, a new patent-pending product platform available as mixed-reality displays in larger and smaller formats, was made available to customers in September 2017. DeepFrame enables a wide range of new application areas for companies within entertainment, manufacturing and retail. The platform is also being developed for innovative consumer products. For easy access to Realfiction’s products, the company provides complete solutions that can be purchased, rented or leased in collaboration with a global network of distributors and content creators. Realfiction Holding AB’s share is publicly traded on Nasdaq Stockholm First North under the symbol “REALFI”.  The share’s ISIN code is SE0009920994.

Clas Ohlson increases sales in October 2017

Compared with the same month previous year, the net store portfolio was expanded by15 stores. At the end of the period, the total number of stores was 223. Sales in October is distributed as follows: +-------------------------+-------+-------+-----------------+------------------+|Countries, MSEK |October|October|Percentage change|Percentage change,|| |2017/18|2016/17| |local currency |+-------------------------+-------+-------+-----------------+------------------+|Sweden |313 |310 |1 |1 |+-------------------------+-------+-------+-----------------+------------------+|Norway |267 |270 |-1 |4 |+-------------------------+-------+-------+-----------------+------------------+|Finland |86 |78 |11 |12 |+-------------------------+-------+-------+-----------------+------------------+|Outside Nordic countries*|22 |24 |-7 |-6 |+-------------------------+-------+-------+-----------------+------------------+| |688 |681 |1 |3 |+-------------------------+-------+-------+-----------------+------------------+ *Effected by store optimization in the UK.  Total sales during the first six months of the fiscal year (May to October 2017) increases by 2 per cent to 3,782 MSEK (3,720). In local currencies, sales increases by 2 per cent versus previous year. The second quarter interim report 2017/18 will be published at 07:00 CET on Wednesday6 December 2017. The report will be presented on the same day at 08:30 CET in Clas Ohlson’s store at Drottninggatan 53 in Stockholm, Sweden. For more information, please contact:Sara Kraft Westrell, Director of Information and Investor Relations, phone +46 247 649 13 This is information that Clas Ohlson AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 7:00 am CET on 15 November 2017.


From left to right: Mary Keane Dawson (CEO), Adam Graham (CEO of parent company TMG), Adam Hopkinson (COO) LONDON: 15 November 2017 – TMG (The Marketing Group Plc) today announces the launch of TRUTH – the first media agency in the world to utilise blockchain smart contract technology. TRUTH will provide 100% transparency in a media industry described by one brand-side marketer as  “murky at best, and fraudulent at worst” .  In addition, TRUTH’s proprietary, media buying and planning platforms will ensure global best practice and complete GDPR compliance. TRUTH will be headed up by Mary Keane-Dawson who joined TMG earlier in 2017, and Adam Hopkinson who joins as COO from 1st December. TRUTH has been launched in response to the erosion of trust between advertisers, media agencies and media owners. The industry is ripe for innovation, where middlemen and the layers involved in media planning and buying can easily strip 80% of the value between brands and media owners. TRUTH’s use of blockchain technology revolutionises the traditional process, allowing for complete transparency for all involved.  TRUTH has commissioned research, alongside London Research, among CMOs and others with budget responsibility for programmatic advertising, which demonstrates demand for a new honest agency model. Initial findings reveal that 79% of those questioned are concerned about the level of transparency in programmatic advertising and over one third rate their trust in their agency as medium or low. The full research report will be published shortly. Mary Keane Dawson, CEO of TRUTH, said:    “By bringing blockchain technology into the media world we will build a cleaner media supply chain with 100% transparency. We want to put the client first and believe this is the best way to do that.” Commenting on the new agency, Adam Graham, CEO of parent company TMG, added:  “We are entering a new dawn in data driven advertising and TRUTH will be at the heart of that. We know from our research that CMOs are demanding change. We will be that change.” TRUTH launches with offices in London, San Francisco, Singapore and Sydney, providing a global solution for brands that want more transparency and better value. Adam Hopkinson appointed as COO of TRUTH Previous Anyclip EMEA MD, Adam Hopkinson will join TRUTH on 1st December 2017. Mary Keane-Dawson CEO of TRUTH said: “Adam joins us at an important time for TMG, as we start the next chapter of our network’s story. He will be at the heart of this exciting new venture and brings with him a huge array of skills and industry knowledge.” Adam Hopkinson commented: “I'm delighted to be joining Adam and Mary as Chief Operating Officer of TRUTH. I will be building out our offering within the existing infrastructure of TMG and bringing the service to current group clients as well entirely new clients, who are looking for a fresh alternative. “We all share the same vision for transparency of fees, efficiency of campaign delivery and open and honest service provision for advertisers. With TRUTH we are creating something amazing, much needed in the market, and very timely.”  -ENDS- About TRUTH Launched in 2017, TRUTH is a global media planning and buying service for advertisers. With offices in London, San Francisco, Singapore, Auckland and Sydney, TRUTH is a truly transparent agency that provides a single view across the value chain and a single clear fee for advertisers. What is a 'Blockchain'? A blockchain is a continuously growing list of records which are linked and secured, using cryptography, to produce an immutable, distributed ledger. Because blockchains are transparent and secure by design, they are highly suitable for use in creating smart contracts, transferring funds and documenting the provenance of a supply chain. Many experts believe that blockchain technology could have an effect as profound as that of the internet itself. About The Marketing Group plc (“TMG”) in brief TMG is building a global full-service marketing network, powered by technology, that provides a fresh alternative for global brands that want to see more bang for their buck. With offices in America, Europe, Asia and Australasia, TMG’s collaborative network of agencies provide a holistic service to deliver highly effective results.  The Marketing Group is listed on Nasdaq First North, Stockholm. www.tmg-plc.com. Mangold Fondkommission AB, +46 8-5030 15 50, is the company’s Certified Adviser and liquidity provider. Media contact for TRUTH Lydia Oakes, Bluestripe          M: 07710 244573 / lydia@bluestripemedia.co.uk


London – 15 November 2017 - The Marketing Group plc (“TMG” or the “Group” or the “Company”) is pleased to announce its financial results for the third quarter from 1 July 2017 to 30 September 2017. Third quarter highlights · Q3 2017 Turnover of €7.043 million (2017 year to date €19.59 million) · Q3 2017 Net Revenue of €4.259 million (2017 year to date €12.60 million) · Q3 2017 EBITDA of €679k (2017 year to date €1.45 million) Commenting, Adam Graham, TMG CEO, said,“Our continued focus on synergies and collaboration within the Group is yielding results. This strong organic growth provides solid foundations for further acquisitions and strategic initiatives.” CEO’s statementThe Group’s network is now gelling together well and, as such, further synergies are being unlocked. Trading performance for the quarter improved once more, with EBITDA coming in ahead of forecast at €679k and taking the EBITDA for the year to date to €1.45m. We are seeing more collaboration between our agencies around the world and an increased ability to provide a consolidated offering to clients. This is resulting in incremental new business wins and additional revenue being retained within the Group. This solid platform of organic growth provides the ideal foundations from which to launch new initiatives. Because of the talent we have, and the agile structure that we embrace, we can move quickly to capitalise on market opportunities. One such opportunity is the creation of a global media planning and buying network that provides a new level of transparency to clients. Today we announce the launch of TRUTH, our blockchain-enabled, global media agency that will provide previously unseen levels of transparency and value to brands, publishers and consumers alike. TRUTH will be led out of London by Mary Keane-Dawson and will leverage the existing media capabilities we have within the Group from DAE, One9Ninety, Rainmakers, and Channelzero. Alongside the roll-out of TRUTH, we will also continue to develop TEMBA, our internal collaboration platform, as a core part of our strategy of harnessing technology to provide a highly effective global marketing solution. As TEMBA evolves, it will unlock further opportunities to pull together best-in-class teams and load balance globally, to provide an unparalleled level of effectiveness and scalability. We are continuing to optimise the network and are very happy with the progress we are making. Future acquisitions will be selected on the basis of good strategic fit and additional value creation. There is still much to do but, as you can see, we are making good progress. This is an exciting time for TMG.Adam Graham, CEO The Group’s results for the 12 months ended 31 December 2017 will be announced on 28thFebruary 2018. For further information please contact:Adam Graham, CEOEmail: investorrelations@tmg-plc.com MediaLydia OakesPhone: +44 (0)7710 244573Email: lydia@bluestripemedia.co.uk Investor relationsTim MetcalfeMiles NolanPhone: +44 (0) 207 652 9789Email: investorrelations@tmg-plc.com

Eltel to sell its rail business operations in Finland

The purchase price amounts to EUR 8.5 million deducted by the cash generated from these operations during September 2017 - January 2018. The purchase price will be paid in the first quarter of 2018. The transaction is estimated to positively impact Group EBITA by approximately 4 million EUR in the first quarter of 2018. Closing of the transaction is expected to occur at the end of January 2018. In 2016, Eltel´s Finnish rail business operations generated net sales of EUR 28 million and currently employs approximately 120 people. In February 2017, Eltel decided that its strategic focus will be on the Group’s core businesses in Power and Communication with the geographical markets being in the Nordics, Poland and Germany. Eltel’s rail operations, classified as non-core operations, cover the Nordics countries. The divestment process of Eltel’s rail operations in Sweden, Denmark and Norway is still ongoing. For further information:Thomas RebermarkDirector – Group IR, Marketing & CommunicationsTel: +46 72 230 6945, thomas.rebermark@eltelnetworks.se About Eltel Eltel is a leading Northern European provider of technical services for critical infrastructure networks – Infranets – in the segments of Power, Communication and Other, with operations throughout the Nordics, Poland and Germany. Eltel provides a broad and integrated range of services, spanning from maintenance and upgrade services to project deliveries. Eltel has a diverse contract portfolio and a growing customer base of large network owners. In 2016, Eltel net sales amounted to EUR 1.4 billion. The current number of employees is approximately 8,400. Since 2015, Eltel AB is listed on Nasdaq Stockholm.

Clavister recruits Chief Strategy Officer from IBM and Google

November 15th, 2017, Örnsköldsvik, Sweden - Clavister, a leader in high-performance network security solutions, today announced the addition of Przemek Sienkiewicz as the new Chief Strategy Officer to the executive management team, effective immediately.  Sienkiewicz, a seasoned professional with experience from IBM where he has been their director for cloud and cognitive business—as well as creating and heading up Google’s enterprise business in some 30 countries in Europe. Previous to that, he was Sales Director for Oracle in EMEA and held sales positions in (amongst others) Lucent Technologies. He holds a master’s degree in Economy and Corporate Strategy from Economic University in Poznan, Poland.  “Having this kind of critical, strategic asset and competence join our team is a real strength to our business,” states Clavister President and CEO John Vestberg. “Przemek will help drive corporate strategy as well as build C-level relationships with key partners and much more,” he continues.  For his part, Sienkiewicz feels an affinity to the security industry, its potential and Clavister’s offering in it. “Clavister is really perfectly positioned to take off with the right set of structures and ambitions. So, to be able to use my knowledge and experience to grow with the company and attain its full capacity and market share is very exciting. I’m looking forward to deliver that business value to the company and to Clavister’s customers,” Sienkiewicz declares. 

Schörling & Partners AB publishes offer document

On 14 November 2017, Goldcup 15638 AB (u.n.c.t. Schörling & Partners AB) (“Schörling & Partners”) announced an unconditional cash offer to the shareholders of Melker Schörling AB (”MSAB”) to tender all their shares in MSAB to Schörling & Partners for SEK 569[1] %20FINAL.DOCX#_ftn1) per share (the “Offer”). Schörling & Partners has today published the offer document relating to the Offer. The offer document and an acceptance form are available on www.sochpartners.se and www.sebgroup.com/prospectuses. The offer document and the acceptance form will be distributed to shareholders in MSAB whose shares were directly registered with Euroclear Sweden AB as at 14 November 2017. Copies of the offer document and the acceptance form are provided free of charge upon request. Such request may be made by telephone +46 (0)8-639 2750. The acceptance period for the Offer runs from 16 November 2017 up to and including 14 December 2017. Settlement to those having accepted the Offer will occur weekly during the acceptance period, with the first settlement estimated on 24 November 2017. Schörling & Partners reserves the right to extend the acceptance period of the Offer as well as to postpone the date of settlement. Notice of such extension and/or postponing of the date of settlement will be announced by Schörling & Partners through press release in accordance with applicable laws and regulations. The information provided herein was submitted for publication on 15 November 2017, 8.00 a.m. CET. Information about the Offer Information about the Offer is made available at: www.sochpartners.se Schörling & Partners in brief Goldcup 15638 AB (u.n.c.t. Schörling & Partners AB) is a Swedish newly formed limited liability company, Reg. No. 559132-0402. Schörling & Partners is jointly owned by MSTAB, Reg. No. 556609-2168, Stefan Persson, UIE Malta Holding Ltd., Reg. No. C 57767 and Mikael Ekdahl AB, Reg. No. 556701-4112, and has its registered office in Stockholm, with address at Birger Jarlsgatan 13, 111 45 Stockholm, Sweden. Schörling & Partners has never conducted, and does not presently conduct, any business. The company’s sole purpose is to hold the MSAB shares, carry out the Offer and to take any measure necessary to finance and complete the Offer as well as to act as the parent company of MSAB. All owners of Schörling & Partners have previously been direct owners of MSAB, but have on 13 November 2017 transferred each of their respective shareholdings in MSAB to Schörling & Partners, in exchange for shares in Schörling & Partners, at an issuing price corresponding to the Offer Price. Following these transfers, which were conditional upon the Offer being made, MSTAB owns 92.9 percent of the shares in Schörling & Partners, Stefan Persson 5.2 percent, UIE Malta Holding Ltd. 1.8 percent and Mikael Ekdahl AB 0.1 percent of the shares in Schörling & Partners. The parties’ holdings in Schörling & Partners correspond to their previous mutual relative shareholding in MSAB. MSTAB is directly and indirectly owned by Melker Schörling, Sofia Schörling Högberg, Märta Schörling Andreen and the Schörling family’s charity foundation. Melker Schörling holds, directly and indirectly, a majority of the shares and votes in MSTAB. UIE Malta Holding Ltd. is a wholly owned subsidiary of United International Enterprises Ltd. which is controlled by Carl and Martin Bek-Nielsen and Mikael Ekdahl AB is controlled by Mikael Ekdahl. MSAB in brief MSAB is an active and long-term holding company listed on Nasdaq Stockholm (Large Cap) under the ticker code MELK. All of MSAB’s companies have a clear strategy and focus and a strong potential to further development. Today, the larger companies belong to the world-leading within each of their operation area. MSAB’s holdings consist of six listed companies, Hexagon, HEXPOL, AAK, ASSA ABLOY, Securitas and Loomis. MSAB’s largest holding is Hexagon where the company owns 26 percent of the capital and 47 percent of the votes. Through a long-term and active ownership, MSAB shall contribute to a continued good development of the holdings and create value for the shareholders of MSAB. Important information The Offer, pursuant to the terms and conditions presented in this press release, is not being made to persons whose participation in the Offer requires that an additional offer document is prepared or registration effected or that any other measures are taken in addition to those required under Swedish law and regulations. This press release and any related Offer documentation are not being distributed and must not be mailed or otherwise distributed or sent in or into any country in which the distribution or offering would require any such additional measures to be taken or would be in conflict with any law or regulation in such country – any such action will not be permitted or sanctioned by Schörling & Partners. Any purported acceptance of the Offer resulting directly or indirectly from a violation of these restrictions may be disregarded. The Offer is not being and will not be made, directly or indirectly, in or into, by use of mail or any other means or instrumentality of interstate or foreign commerce of, or any facilities of a national securities exchange of, Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States. This includes, but is not limited to facsimile transmission, electronic mail, telex, telephone, the Internet and other forms of electronic transmission. The Offer cannot be accepted and shares may not be tendered in the Offer by any such use, means, instrumentality or facility of, or from within Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States or by persons located or resident in Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States. Accordingly, this press release and any related Offer documentation are not being and should not be mailed or otherwise transmitted, distributed, forwarded or sent in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States or to any Australian, Hong Kong, Japanese, Canadian, New Zealand, South African or U.S. persons or any persons located or resident in Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United State. Any purported tender of shares in the Offer resulting directly or indirectly from a violation of these restrictions will be invalid and any purported tender of shares made by a person located in Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States or any agent, fiduciary or other intermediary acting on a non-discretionary basis for a principal giving instructions from or within Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States will be invalid and will not be accepted. Each holder of shares participating in the Offer will represent that it is not an Australian, Hong Kong, Japanese, Canadian, New Zealand, South African or U.S. person, is not located in Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States and is not participating in such Offer from Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States or that it is acting on a non-discretionary basis for a principal that is not an Australian, Hong Kong, Japanese, Canadian, New Zealand, South African or U.S. person, that is located outside Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States and that is not giving an order to participate in such offer from Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States. Schörling & Partners will not deliver any consideration from the Offer into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States. This press release is not being, and must not be, sent to shareholders with registered addresses in Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States. Banks, brokers, dealers and other nominees holding shares for persons in Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States must not forward this press release or any other document received in connection with the Offer to such persons. For purposes of this section “United States” and “U.S.” means the United States of America, its territories and possessions (including Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa, Wake Island, and the Northern Mariana Islands), any state of the United States of America and the District of Columbia. This press release has been published in Swedish and English. In the event of any discrepancy in content between the two language versions, the Swedish version shall prevail. ---------------------------------------------------------------------- [1] %20FINAL.DOCX#_ftnref1) If MSAB pays dividends or makes any other distributions to the shareholders, for which the record date occurs prior to settlement of the offer price, the offer price will be reduced accordingly.

NeuroVive presents TBI clinical study results at Nordic Neurotrauma Conference

The study, which includes evaluation of pharmacokinetic parameters and safety in a TBI-population, is NeuroVive’s first patient study with NeuroSTAT. NeuroVive has previously presented topline results from the study, which indicated that adequate, dose-dependent concentration levels can be measured in blood samples and that NeuroSTAT reaches its target organ, the central nervous system (CNS). Furthermore, the results showed no unexpected safety signals. The detailed additional analysis of the data to be presented by Dr. Kelsen confirm the previous topline results. ”We very importantly reached the study’s primary objectives: to demonstrate safety and to clarify the pharmacokinetics of NeuroSTAT at two separate dose levels (5 and 10 mg/kg/day) in patients with severe TBI. The 5-day continuous infusion of NeuroSTAT resulted in predictable blood concentrations of ciclosporin and cerebrospinal fluid measurements confirmed that it reaches the brain,” said Dr. Jesper Kelsen, M.D., Ph.D., at the Department of Neurosurgery at Rigshospitalet in Copenhagen, Denmark, and the CHIC study’s Principal Investigator. “This is an important milestone in the NeuroSTAT program which enables us to proceed as planned to develop a new treatment for patients with severe brain injuries where there is a large unmet medical need. Brain injuries cause significant personal suffering to patients and relatives, and a huge direct and indirect cost to society. The need to advance care in this area is highlighted by the gathered international experts here at the NNC,” commented Magnus Hansson, M.D., Ph.D., Chief Medical Officer, NeuroVive. NeuroVive is also a proud sponsor of the Bertil Romner Award, a prize awarded at the NNC in memory of the neurosurgeon Bertil Romner, a pioneer and a visionary in neurotrauma research. Bertil Romner and NeuroVive designed the CHIC study, and he served as the study’s initial Principal Investigator. The prize is awarded an abstract of particular scientific value, presented at the conference with clarity and enthusiasm. For more information please contact: Daniel Schale, Director of Communications, NeuroVive +46 (0)46-275 62 21, ir@neurovive.com NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) info@neurovive.com, www.neurovive.com About the Phase IIa clinical study, CHIC at Rigshospitalet in Copenhagen The phase II CHIC (Copenhagen Head Injury Ciclosporin) study was an open label study. The primary objective with the study was to establish safety and to characterize the pharmacokinetic profile of two dosing regimens of NeuroSTAT in severe Traumatic Brain Injury (TBI) patients. In addition, exploratory measurements to evaluate the efficacy of NeuroSTAT at mitochondrial level, and studies on how NeuroSTAT affects various biochemical processes after a brain injury, were conducted. Principal Investigator for the study is Jesper Kelsen, MD, PhD, Specialist in Neurosurgery, Department of Neurosurgery, Rigshospitalet, Copenhagen University Hospital. About Nordic Neurotrauma Conference (NNC) The NNC, hosted by the Scandinavian Neurotrauma Committee (SNC), is a multidisciplinary meeting place for clinicians and researchers interested in the exciting field of neurotrauma. Neurotrauma injuries are still amongst the most common indications to seek emergency care and account for the highest mortality in younger adults. The brain is still relatively poorly understood and current efforts aim to improve our understanding of the mechanisms and care of brain injuries. About TBI Traumatic brain injury (TBI) is caused by external violence to the head resulting in immediate damage to nerve cells. The damage continues to worsen for several days after the trauma, which in many cases has a significantly negative effect on the overall injury. At present, there are no approved treatments for the prevention of these secondary injuries. In the US, some 2.2 million people are affected annually, causing more than 50,000 deaths and 280,000 hospitalizations. The direct and indirect costs associated with TBI are an estimated USD 60 billion, and a large number of patients suffer moderate to severe functional disabilities requiring intensive care and various forms of support (www.nih.gov). The aim is that better preventive therapies for secondary brain damage, such as NeuroSTAT, will lead to higher survival rates, and significantly improve quality of life and neurological function of patients post-TBI. About NeuroVive NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

Interim Report January - September 2017 Storytel AB (publ)

Key figures for the Streaming division and Print Publishing currency: Q3, 2016 Q4, 2016 Q1, 2017 Q2, 2017 Q3, 2017 Q4, 2017thousand SEKTotal: Forecast1StreamingRevenue 135 703 147 399 155 660 167 008 197 881 208 000Contribution 29 269 32 684 32 133 27 847 27 784Profit 2 Contribution 21,6% 22,2% 20,6% 16,7% 14,0%MarginPaying 341,5 360,2 381,2 423,2 503,9 533,0subscribersSubscriber 49,9 18,7 21,0 42,0 80,7 29,1-base change Streaming,SwedenRevenue 86 889 91 557 96 177 101 365 113 709 118 000Contribution 29 464 27 073 32 678 31 257 32 872ProfitContribution 33,9% 29,6% 34,0% 30,8% 28,9%MarginPaying 219,9 230,8 241,4 255,8 282,3 293,0subscribersSubscriber 26,2 10,9 10,6 14,4 26,5 10,7-base change Streaming,other markets3Revenue 48 814 55 842 59 483 65 643 84 172 90 000Contribution -195 5 611 -545 -3 410 -5 088ProfitContribution -0,4% 10,0% -0,9% -5,2% -6,0%MarginPaying 121,6 129,4 139,8 167,4 221,6 240,0subscribersSubscriber 23,7 7,8 10,4 27,6 54,2 18,4-base change PrintPublishing 4Revenue 133 179 189 258 104 137 111 969 132 619Contribution 48 544 74 367 37 543 37 840 47 905Profit 5Contribution 36,45% 39,29% 36,05% 33,80% 36,12%Margin 1  Forecast based on information available at time of reporting 2  Contribution Profit is defined as streaming revenue minus costs for content and marketing 3  Storytel Norway included in figures @ 100%, In the consolidated accounts it is reported according to the principle of proportional consolidation. 4  Print Publishing refers to physically printed editions. People’s Press is part of the Group from Q2, 2017. In the table above People’s Press is included in all past quarters, to allow for comparability. I In Group Accounts, all acquisitions are included from date of acquisition. Internal transactions have been redacted. Barnens bokklubb not included in table. 5  Contribution Profit is defined as revenue minus cost per sold unit, distribution costs, and sales and marketing costs. Comments from the CEO Thanks to Storytel’s ongoing growth, we welcomed a record number of new subscribers, as per usual, to our service this past summer –– during Q3 our customer base increased by 80,000 satisfied new listeners, as compared to 50,000 new listeners in Q3, 2016. On the whole, Storytel’s rate of growth is rapidly rising, with rates of increase in Norway and Denmark almost at the level of Sweden’s. Thanks to these three profitable markets with high growth, we are able to continue investing and growing in new markets. Our subscriber bases in The Netherlands, Poland, and Finland increased according to plan in Q3, 2017, and we have reason to believe these markets will provide an excellent foundation for expansion in 2018. We plan to make significant investments in marketing in Russia and Spain (our service went online in the latter market in October), and we expect these efforts to bear fruit during the coming year. The forecast for Q4, 2017 looks positive in all our markets. In Sweden we have nearly 300,000 subscribers, and in total more than 530,000, which will generate up to 210 MSEK in streaming revenues during Q4, 2017. During 2017 as a whole, we estimate our streaming revenues will total approximately 730 MSEK, which is an increase of 47% compared to 2016 as a whole. Our goal is to be the world’s most successful and innovative audio-book service, with the ambition of always being the most popular provider in each of our markets. This demands strong regional teams who take advantage of the benefits of being part of a multinational company. One example of our desire to be each market’s top service can be seen Denmark, where our two major acquisitions (Mofibo and People’s Press) lay the foundation for strong growth and the advantageous position we now enjoy in that country. Audiobooks are riding a global wave of listening and streaming services. Increasing numbers of people are listening to podcasts and audiobooks, with individual sales-plans tending to be recast as subscription services. Storytel’s unique position allows us to capitalize on these trends. Based on our Swedish, Norwegian, and Danish markets, we could already choose to switch gears and turn a profit with an EBITDA-margin of 15-20%; the reason we haven’t slowed the pace of growth is that we see the potential to build and expand in these markets as well, for many years to come. Since this past summer we have been continually hiring new staff at our offices in Stockholm and Copenhagen, in order to assure that our global teams for marketing, expansion, content, IT, innovations, human resources and finance have the capacity to assist all of our new teams around the world. These are exciting times, and great demands are being placed on our organization. Therefore we have set up a new leadership group within streaming, whose focus is to guarantee strong expansion and appropriately sized teams on the ground –– who are still nimble and flexible enough to create new content, new IT solutions, and new ways of doing business. During the next few years we plan to rapidly expand internationally, building up the company with the express ambition of being the top streaming service in each new market. This strategy will require significant investments during the next few years, which is the main reason why we made a share issue of 200 MSEK in September. These funds will be used exclusively to increase our list of titles in new language markets, as well as investing in stronger marketing and in certain cases making minor acquisitions. During 2018 we plan to invest app. 200 MSEK in producing more than 5,000 high-quality audiobooks in fifteen different languages in order to assure our service remains attractive in existing regions, and to make new markets more viable. All investments in audiobook production, except prepaid royalties are expensed when they occur in the profit and loss statement, hence not capitalized in the balance sheet. Our goal is 40% annual growth in streaming revenues and increased investments in audiobook production. During 2018, we therefore foresee EBITDA-level margin losses at 5-10 % of our turnover. Our solid financial foundations make this strategy possible. Nonetheless we always prioritize caution and can, if necessary, lessen the pace of expansion and content-investments if we perceive negative local or global trends. The biggest publishing event of the year was September 7th, when Norstedts released the fifth book in the Millennium-series about Lisbeth Salander –– five weeks later, a million books had already been sold worldwide. The popularity of Elena Ferrante’s Naples-quartet has continued, selling 700,000 copies in Sweden since the first book was released two years ago. In terms of books for young readers, Rabén & Sjögren has been very successful with Handbok för superhjältar (The Superhero Handbook) and Fyr 137 (Lighthouse 137) by Ingelin Angerborn. In Denmark our publisher People’s Press released Camilla Läckberg’s latest novel Häxan (The Witch), which has sold very well. Our publishers’ digital sales (mainly through Storytel’s service) are growing very strongly, and all our imprints are increasing their production of audiobooks. The publishing division’s profitability continues to hold solid, with a profit margin of 6-7%. Every imprint is now operating in the black, with Massolit (formerly in the red) now quite profitable thanks to bestsellers by among others Jenny Colgan. Most annual publishing profits are normally made in the final quarter (Q4), thanks to the holiday season. Financial information Accounting principles Storytel Group and its parent company comply with the Swedish law regarding yearly statements of accounts, as well as BFNAR 2012:1 (Swedish Accounting Standards Board standard 2012:1) concerning annual statements of accounts and group accounts at the K3 tier. The registered parent company is Storytel AB (publicly traded). Storytel A.S. (Norway) is half-owned by Cappelen Damm and is reported here according to the principle of proportional consolidation. Wholly owned subsidiaries are included in the group statement of accounts from their time of registration or acquisition. This report has not been audited by the company’s accountants. Revenues and profits for period (compared to Q3, 2016) The group’s total turnover for Q3, 2017 was 308,778 (237,216) TSEK. Within the Streaming division, Sweden accounted for app. 57.5% (64.0%) and other markets for app. 42.5% (36.0%). Cappelen Damm owns 50% of Storytel A.S. in Norway, which is reported here according to the principle of proportional consolidation. The table on page two includes all subscribers and revenue in Norway, which is included under Streaming, other markets, which is why reported revenue for the table on page two is higher than in the statement of accounts, in order to give a truer indication of revenue per subscriber. The group’s Unit-sale costs during Q3, 2017 totaled 185,158 (139,276) TSEK. Unit-sale costs include costs for the actual production of audiobooks, Cost of Goods Sold of physical books, wharehousing and distribution costs, and royalties paid to other publishers and copyright owners. The contribution margin is stable –– around 40% in both Q3, 2017 and Q3, 2016. Other external costs for the group during Q3, 2017 totaled 78,316 (41,733) TSEK. The greatest external cost was marketing, which tends to be relatively high in Q3; Storytel makes its greatest marketing efforts during the summer, which is the quarter with the most new subscribers. Other significant costs included rental payments, tech services, and consultants. Staffing costs for the group in Q3, 2017 totaled 47,841 (33,490) TSEK. Staffing costs for Publishing have been level, while costs in Streaming have increased in relationship to revenues due to the demands of expansion. Profits before depreciation for the group for Q3, 2017 totaled -2,715 (19,694) TSEK. The dip in profits compared to Q3, 2016 is mainly due to increased marketing efforts; Storytel is now serving eight countries, and marketing costs tend to be higher compared to turnover the first few years. Compared to Q2, 2017, the group EBITDA has improved, thanks mostly to Print Publishing’s strong quarter which contributed to earnings in Q3, 2017. Depreciation primarily involves depreciation attributable to goodwill and other extra value identified in connection with acquisitions. The largest asset items are connected to the acquisition of Norstedts, Mofibo, and People’s Press. Depreciation from these three purchases totalled app. 11 MSEK per quarter (People’s Press calculated in from Q2, 2017). Other depreciation primarily concerns the purchasing and development of IT-systems. Earnings from holdings in associated companies are related to a reduction in shares in Pocketförlaget publishers which during Q3, 2017 were sold to Piratförlaget publishers, for a lower price than their book value. Net Financial Items includes both interest income and interest expenses, as well as realized and unrealized exchange differences. Interest expenses from bank loans totaled app. 2 MSEK for Q3, 2017. Earnings per share, after taxes, in Q3, 2017 totaled -0,45 SEK, calculated as earnings for the period after taxes, divided by the average number of shares during the period. Group: Financial position and cash-flow as of Sept. 30th, 2017 (compared to Dec. 31st, 2016) At the end of the period, the group had 281,594 (129,561) TSEK in liquid assets. Solvency was 35.9% (23.8%). Equity totaled 345,631 (172,472) TSEK, an increase related to Storytel’s share issue in worth 200 MSEK in September. Non-current liabilities to loaning institutions totaled 142,020 (155,161) TSEK. Amortization of bank loans started in 2017; the portion that will be amortized during the next twelve months is considered a short-term liability and totals ca. 45 MSEK. During Q2, an acquisition loan of 20 MSEK was taken on in order to help finance the purchase of People’s Press. Number of shares and Share-Capital (as of September 30th, 2017)There were 51,510,040 registered shares in issuance at the end of the period, divided between 635 A-shares and 51,509,405 B-shares. Share-capital totaled 25,755,020 SEK as of September 30th, 2017. Post-period activity In October Storytel launched in Spain; the service is now available in eight countries. On the 19th of September, Storytel contracted to acquire three companies –– in Bulgaria, Turkey, and Iceland. After the close of the quarter, each of these companies was acquired accordingly, and will be transformed into streaming companies under the Storytel banner. Prior to launching local services, our focus will be to invest in audio-book productions in order to assure rich content.   Date of next reporting The end-of-year report for 2017 will be released on February 26th, 2018. For more information, please contact: Jonas Tellander, CEO: +46 70 261 61 36 Sofie Zettergren, CFO: +46 70 509 98 08

Live the high-life in Play’n GO’s new slot Fu Er Dai

15th November, 2017 – Leading mobile slots specialist Play’n GO has launched Fu Er Dai, a lavish slot inspired by the designer lifestyles of China’s super-rich. Players will enter a world of flash gold watches, expensive cell phones and other luxury items in the five-reel, 10 pay line slot. A girl with a dragon tattoo will occasionally present herself on the gameboard, covering an entire reel, helping players to further wins. These will be enhanced when two appear simultaneously, with players granted five free Win Spins, and at least one guaranteed to hit a winning combination. Developed in Play’n GO’s standard HTML5, players will experience the usual intricate graphics and realistic sound effects across all devices. Johan Törnqvist, CEO of Play’n GO, said: “Fu Er Dai channels the extravagance of the lifestyle by the same name, and it can transport our players to a new world of luck, lavishness and luxury. “We’re sure players will love escaping to the decadent world of the Chinese nouveau riche which will be brought to life by our usual striking graphics and immersive soundscape.” Fu Er Dai continues Play’n GO’s strategy of developing a diverse game portfolio across various genres and game types, suitable for operators and players around the world. Recent Asian-inspired releases Prosperity Palace, Big Win Cat, and the much-anticipated sequel Reactoonz, have already proven popular with a diverse customer base since going live.

MIPS granted preliminary injunction against POC in Germany

MIPS has been granted an ex parte preliminary injunction in Germany to restrain infringement of MIPS’ patent EP (DE) 2 440 082 by POC Sweden AB through its sales in Germany of products incorporating the Shearing Pad INside, or “SPIN”, claiming to be a rotational impact protection system. The order was granted by the court ex parte. This means that there was no hearing, POC was not given the opportunity to make submissions and there was no detailed argumentation relating to infringement and validity.[JG1]   MIPS is in the process of executing the order against POC. POC is permitted to appeal against the order. POC is currently a customer to MIPS but represents a minor portion (less than 1% of net sales) of MIPS’ total sales. This information is of such nature that MIPS AB (publ) is obliged to disclose in accordance with the EU’s Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 15th November 2017 at 12.15 a.m. CET.   For additional information Johan Thiel, President and CEO. +46 73 399 65 88 or at johan.thiel@mipsprotection.com     About MIPS MIPS is a world-leader in helmet-based safety and the protection of the human brain. Based on an ingredient brand business-model, MIPS Brain Protection System (BPS) is sold to the global helmet industry. The BPS solution, which is patented in all relevant markets, is based on 20 years of research and development together with the Royal Institute of Technology and the Karolinska Institute, both located in Stockholm, Sweden.MIPS headquarter with 25 employees engaged in research and development, sales and administration is in Stockholm, where its product and technology test facility is also located. Production and manufacturing operations take place at sub-contractor facilities. On a rolling 12-month basis, Oct 2016/ Sep 2017, MIPS net sales amounted to MSEK 116.5 resulting in an adjusted EBIT-margin of 23.1%. Since its March 2017 IPO, MIPS is traded on the Nasdaq Stockholm stock exchange. For information, visit www.mipscorp.com. ----------------------------------------------------------------------  [JG1] What is the meaning of this? It could be interpreted as if though MIPS does not have an argument for infringement. Validity of what?


Oslo, 15 November 2017 - Axactor AB has entered into partnership with a large Spanish financial institution to take a majority position in two Spanish SPVs, containing more than 4,060 REO (Real Estate Owned) assets with an Appraisal Value in excess of EUR 228m. This transaction is an important milestone in Axactor's ambition to become a major contender in the growing secured/REO market in Spain. This deal shows that irrespective of size and type of asset, Axactor is adapting and developing its ability to service its clients in key markets, opening the possibility of several new transactions in the future. The investment will be made through a Luxemburg holding company in the process of being established, which will be controlled by Axactor. The company will initially be funded with equity from Axactor and funds from the SPV recently established by Geveran and Axactor. The portfolio acquisition combines well with Axactor's unsecured business. The secured portfolios/REO have significantly shorter payback periods than the unsecured portfolios, which are normally focused on repayment plans with much longer investment horizons. The short payback is expected to have a positive impact on Axactor's EBITDA in 2018 and 2019, supporting the business whilst it continues to build cashflow from its unsecured portfolio. "This agreement is an exciting step for Axactor, enabling us to become a major player in the Spanish REO market and further expand our recovery model.  By entering into a joint venture with a significant financial institution, we are able to learn from their best practices, and build skills that will be extremely valuable to the company going forward", says Endre Rangnes, CEO of Axactor AB. "The Axactor team in Spain is very enthusiastic to be working on this opportunity in the REO market. This clearly demonstrates the determination of the team to develop the business across all NPL segments. The team will be focusing on increasing the volumes in this new segment, as well as building REO expertise across the company as a whole", says Andrés López and David Martín, General Managers of Axactor Spain. Axactor has made important progress in implementing the operational functionality required to handle business in the secured market. The company is now ready to initiate the management of significant volumes of secured cases, and to support 3rd party clients with similar management. The combination of secured and unsecured business secures Axactor a strong position in the Spanish market. Axactor now looks to develop similar positions in other geographies where Axactor is present. "This transaction underlines the increased financial strength provided through the partnership with Geveran Holding, and shows how the two partners now have theopportunity to enter new market segments and enter into larger deals", says Endre Rangnes. For additional information, please contact: Endre Rangnes, CEO Axactor Mobile phone: +47 4822 1111 Email: endre.rangnes@axactor.com or Geir Johansen, CFO & Investor Relations, Axactor Mobile phone: +47 4771 0451 Email: geir.johansen@axactor.com www.axactor.com About Axactor Axactor Group specializes in both Debt Collection and Debt Purchasing across several countries, with operations in Italy, Germany, Norway, Sweden and Spain. The company has a Nordic base and an ambitious Pan-European growth strategy, which targets the market for non-performing loans (NPL) in Europe. This market is estimated to be about 1,500 billion euros across Europe providing significant opportunities for Axactor's future expansion. Axactor has approximately 900 employees.

Nordic Nanovector ASA – Financial Calendar

Oslo, Norway, 15th of November 2017 FINANCIAL YEAR 2017 Quarterly Report - Q3  22.11.2017 Quarterly Report - Q4  27.02.2018 Capital Markets Day    22.11.2017 FINANCIAL YEAR 2018 Quarterly Report - Q1  30.05.2018 Half-yearly Report       22.08.2018 Quarterly Report - Q3  21.11.2018 The dates are subject to change. The time and location of the presentations will be announced in due time. This information is published pursuant to the requirements set out in the Continuing obligations. For further information, please contact: IR enquiries: Tone Kvåle, Chief Financial Officer Cell: +47 91 51 95 76 Email: ir@nordicnanovector.com Media enquiries: Mark Swallow/David Dible/Marine Perrier (Citigate Dewe Rogerson) Tel: +44 207 638 9571 Email: nordicnanovector@citigatedr.co.uk About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugate (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications. Further information about the Company can be found at www.nordicnanovector.com

Nel ASA: Reference is made to previous stock exchange announcements made by Nel ASA (“Nel”) regarding acquisition of Proton Energy Systems, Inc.

(Oslo, 15 November 2017) Proton Energy Systems, Inc. (“Proton OnSite”) was acquired on a cash and debt free basis and assuming a normalized working capital. Pursuant to the transaction agreement, the purchase price was subject to adjustment based on the actual levels of net debt and working capital as per closing, to be settled by Nel issuing further shares to the selling shareholder of Proton Onsite, F9 Investments LLC ("F9"), or F9 transferring Nel shares to Nel, as the case may be. The number of shares shall in each case be calculated based on the originally agreed value of a Nel share in the transaction agreement of NOK 2.72. The post-closing adjustment has now been concluded. Pursuant to the result of the adjustment, F9 has today transferred 1,520,743 Nel shares to Nel. After the settlement of the adjustment amount, Nel holds 1,773,450 own shares and F9 holds 146,138,713 shares in Nel ASA (approx. 14.8% of the share capital). ENDS For additional information, please contact: Jon André Løkke, CEO, +47 9074 4949 Bent Skisaker, CFO, +47 468 21 693 About Nel | www.nelhydrogen.com       Nel is a global, dedicated hydrogen company, delivering optimal solutions to produce, store and distribute hydrogen from renewable energy. We serve industries, energy and gas companies with leading hydrogen technology. Since its foundation in 1927, Nel has a proud history of development and continual improvement of hydrogen plants. Our hydrogen solutions cover the entire value chain from hydrogen production technologies to manufacturing of hydrogen fueling stations, providing all fuel cell electric vehicles with the same fast fueling and long range as conventional vehicles today.

Nel ASA: Enters into exclusive partnership with Nikola – Awarded initial purchase order for two demo stations

(Oslo, 15 November 2017) Nel ASA (Nel, OSE:NEL) has received a purchase order from Nikola Motor Company (Nikola Motor) for two demo refueling stations to provide hydrogen to Nikola’s fleet of prototype hydrogen trucks. The purchase order is the initial part of an exclusive partnership aiming at developing low-cost renewable hydrogen production and fueling sites for the potential development of 16 large-scale sites with a capacity up to 32 tons of hydrogen per day. “We are very excited to announce our partnership with Nikola for a joint endeavor to develop mega-scale hydrogen fueling stations based on our new cluster design, which leverages Nel’s highly scalable electrolyzers in order to reduce the cost of hydrogen and achieve price parity with fossil fuels. Our initial two demo stations will each provide one ton of hydrogen to Nikola Motor’s prototype trucks and serve as design verification for Nel’s mega-scale concept. This solution will be jointly developed and scaled into the world’s most efficient network of low-cost hydrogen production and fueling sites,” says Jon André Løkke, Chief Executive Officer of Nel. Nikola Motor has entered into an agreement with Nel to work exclusively on all hydrogen stations involving electrolysis. The initial part of the partnership includes building two demo-stations for hydrogen fueling, which will serve the Nikola test fleet that will begin rolling out next year. For the following mega-stations, Nel will incorporate its clustering concept, where eight Nel A-485 electrolysers are integrated into one unit, to achieve lower CapEx levels. “We are building the world’s largest hydrogen network. Nel´s electrolyzers are well proven, and known in the industry for being very efficient and reliable, making them a natural backbone for the development of our mega-stations. We are beyond excited to work with the Nel team to deploy this groundbreaking technology as quickly as possible across the US,” says Trevor Milton, Chief Executive Officer of Nikola Motor.  Nikola has an initial target to build 16 of the mega-scale hydrogen stations between 2019-2021, with a minimum of eight units of the Nel A-485 electrolyzer per site. The solution is scalable to a maximum of 32 units of the Nel A-485 electrolyzer per site, equaling a production capacity of up to 32 tons of hydrogen per day. The initial purchase order has a value of USD 3.6 million and delivery of the demo stations is intended to start in the second half of 2018. ENDS For further information, please contact: Jon André Løkke, CEO, Nel ASA, +47 907 44 949 Bjørn Simonsen, VP Market Development and Public Relations, +47 971 79 821 Colleen Robar, +1 313-207-5960, crobar@robarpr.com (Nikola) About Nikola Motor Company | www.nikolamotor.com         Nikola Motor Company designs and manufactures electric vehicles, vehicle components, energy storage systems, and electric vehicle drivetrains. NMC is led by its visionary CEO Trevor Milton (twitter: @nikolatrevor), who has assembled one of the most talented teams in the country to bring the Nikola products to market. The company is privately-held. For more information, visit nikolamotor.com or Twitter: @nikolamotor. About Nel ASA | www.nelhydrogen.com         Nel is a global, dedicated hydrogen company, delivering optimal solutions to produce, store and distribute hydrogen from renewable energy. We serve industries, energy and gas companies with leading hydrogen technology. Since its foundation in 1927, Nel has a proud history of development and continual improvement of hydrogen plants. Our hydrogen solutions cover the entire value chain from hydrogen production technologies to manufacturing of hydrogen fueling stations, providing all fuel cell electric vehicles with the same fast fueling and long range as conventional vehicles today.

Insplorion is granted 500,000 SEK by Vinnova to investigate the possibility of using Insplorion's technique within water treatment

Insplorion applied for funding within EU's "SME 1 - Horizon 2020 Framework Program" in September. Thanks to high scores in the EU ranking system, Insplorion's application received a so-called "Seal of Excellence" which enabled financing through Vinnova's special announcement; "Runner up SME instrument 2017" The project aims at investigating and preparing for the possible commercialization of Insplorion's technology for monitoring of industrial water treatment processes, which would enable more efficient processes with cheaper production of clean water and more efficient use of purification chemicals and filters. The need has been identified, among other things, in discussions with Akzo Nobel, who wants to explore the possibility of using Insplorion’s technology to enable more efficient production of high quality water for use in their production.The need for more efficient water treatment processes is global and growing, where on-line monitoring during different purification steps is sought after. This project is expected to pinpoint within which niche Insplorion’s technology would provide the largest benefits and how large cost savings and reduction of environmentally harmful chemicals a better monitoring can provide. "The idea of an on-line instrument for the process industry has emerged from what we have learned from our fibre sensor development for batteries and how that knowledge can be combined with our instrument platform. There are still technical and market questions and we are very pleased that we have received this funding to help us answer these questions, before we initiate a new development project” commented Patrik Dahlqvist, CEO at Insplorion. Questions are answered by:Patrik Dahlqvist, CEO Insplorion AB, +46 723 62 32 61 or patrik.dahlqvist@insplorion.com

Electrolux Capital Markets Day 2017

“We’re very pleased with our improved operating margin performance, which provides a solid base to take the next steps towards targeted growth and over a business cycle reach Electrolux financial targets of at least 6% EBIT margin and 4% growth,” Jonas Samuelson said. “We will also share how Electrolux strategic framework connects our consumer experience focused business model with a clear company purpose – to shape living for the better – and look forward to showcasing how this is executed through a number of business cases.” The overall positive demand trend across most markets in 2017 is expected to continue in 2018. The European appliance market is expected to grow by 1-2% in 2018, with demand growth in most countries. Demand for appliances in North America remains favorable and is anticipated to grow by 2-3%. The market recovery in Latin America continues with an expected growth rate of 3-5%. The market for Australia is expected to grow 1-2% and the market outlook for Southeast Asia remains positive. The organic earnings contribution is expected to be positive for 2018 for the Group, as a result of mix improvements through continued portfolio management and product launches. In combination with volume growth, this will offset price pressure in the market. Net cost efficiencies are forecasted to be positive, despite increased spending on marketing and innovation in business areas focused on targeted growth. This will offset an expected increase in costs for raw materials. These raw material costs are currently forecasted to have a negative impact of SEK 1 billion, with a range of uncertainty of +/-200 million. The level of capital expenditure investments to drive targeted growth will increase over the coming three to four years, particularly in North America and Latin America. Investments will be focused on product architectures, automation and innovation. The capital expenditure for the Group in 2018 will increase to approximately SEK 6 billion. Changes in currencies will at current rates have a total negative transactional impact of SEK 150 million next year, while translational currency effects will be neutral overall. In addition to CEO Jonas Samuelson, presentations will be held by Anna Ohlsson-Leijon, CFO, Jan Brockmann, COO, Alan Shaw, Head of Major Appliances North America, Ola Nilsson, Head of Home Care & SDA, Lars Hygrell, CMO, David Cronström, Head of Strategy & Ecosystem, and Alberto Zanata, Head of Professional Products.

Starbreeze AB (publ) Q2 report 1 January 2017 – 30 September 2017

Today at 10.00 am CET, Starbreeze CEO Bo Andersson Klint and CFO Sebastian Ahlskog will host a live stream and present the report on Starbreeze Twitch channel: https://www.twitch.tv/starbreeze THIRD QUARTER 2017 · Net sales amounted to SEK 77.7 million (102.7 including non-recurring revenue of SEK 32.5 million). · PAYDAY generated SEK 24.4 million (20.9) and Dead by Daylight accounted for SEK 47.3 million (49.2) of net sales. · EBITDA amounted to SEK -21.9 million (19.2). · The loss before tax was SEK -35.3 million (11.0). · Basic and diluted earnings per share were SEK -0.11 (0.08). · Listing on Nasdaq Stockholm Main Market · Agreement signed to be lead partner to the new VR center in Dubai. · New loan financing of SEK 150 million from Nordea. · Agreements after the period included a new financing plan for StarVR Corp. and finalization of the acquisition of Dhruva Interactive. JANUARY–SEPTEMBER 2017 · Net sales increased by 5 percent to SEK 257.7 million (246.1). · PAYDAY generated SEK 99.9 million (124.5) and Dead by Daylight accounted for SEK 134.0 million (89.1). · EBITDA amounted to SEK -59.9 million (42.4). · The loss before tax was SEK -108.3 million (23.6). · Basic and diluted earnings per share were SEK -0.33 (0.11). · Cash and cash equivalents at the end of the period amounted to SEK 431.5 million (376.0). CEO Bo Andersson Klint remarks on the report: LEVELING UP STARBREEZE This quarter marked an extraordinary event for Starbreeze: we moved lists to be traded on Nasdaq Main Market. Starbreeze, as one of northern Europe’s first independent listed game studios has finally taken the big leap as the first AAA game developer on the main market. In and of itself, the listing is a quality stamp that gives us better access to Swedish and international capital markets and its institutional investors. This is a legacy the company has carried for 17 years and as the company turns 20 next year, we hope to continue to add shareholder value over the next decade and beyond. 11 PERCENT GROWTHNet sales for the third quarter reached SEK 77.7 million, an increase by 11 percent excluding non-recurring revenue last year. PAYDAY and Dead by Daylight generated revenues on par with the third quarter of 2016, even though the games are one year older. Our Games as a Service is still delivering and generating revenue. However, RAID: World War II has so far underperformed our expectations. We had expected a larger contribution from the game as of this quarter, although we knew it takes time and is riskier to build a new IP. We are working closely with the team at Lion Game Lion to improve and update the game according to our Games as a Service concept. We are looking at various components of the game and its market conditions and will be tweaking RAID: World War II over the next few months. EXPANSIVE PHASE ENTAILS SHORT-TERM IMPACT ON PROFITABILITYWe are in an expansive phase of ongoing initiatives in all business areas. Compared to last year, we have significantly higher activity in our core business, with expanded teams in own game development and a higher number of publishing titles. Costs are increasing, but at a slower rate than last year, and have declined compared to last quarter. Ongoing initiatives are having short-term impact on profitability and cash flow and we are reporting EBITDA of SEK -21,9 million for the third quarter, compared to SEK 19.2 million for Q3 2016. Cash flow from operating activities was strong, however, at SEK 59.6 million (37.0) for the quarter. INITIATIVES ARE POWERING SUBSTANTIAL VALUE CREATIONWe are investing in creating substantial value for our shareholders. In order to more clearly demonstrate our ambitions, we published new financial goals ahead of the listing on Nasdaq Stockholm. One of our targets is to achieve revenues of at least SEK 2 billion in 2020, not including PAYDAY 3. The majority of the revenues will be generated by our own game development. We also see tremendous growth potential in a continued expansion of the publishing game portfolio, new platforms like VR and new geographical markets. We also expect significantly higher profitability because our business model is scalable in several dimensions, with rising revenues and a relatively constant cost base. Our target is to generate positive EBITDA for the fourth quarter of 2018 and for every subsequent quarter on an annual basis. Our targets reflect our current quest to level up Starbreeze. FOCUS ON OWN GAME DEVELOPMENTAlthough we greatly believe our Publishing arm as well as our initiatives in Virtual Reality will be fruitful and a powerful additive to our revenue mix, the greater margins will in the medium term be found within our own development. We will continue to develop games where the gameplay sets the stage for ongoing development and new updates for the lifetime of the game. Accordingly, our primary focus is to ensure that the organization has the capacity to develop major game titles while delivering a steady stream of new content that enhances previously released games to extend their lifetime. The plan is to have at least three parallel development teams and to optimize team staffing for ongoing game projects. THE PUBLISHING BUSINESS IS WIDENING THE GAME PORTFOLIOWe will continue expanding the game portfolio in the Publishing business as we see positive effects from greater scalability through lower risk per game in the development phase and reduced use of internal resources per game. Greater scalability means that we are able to expand the portfolio to bring more games to the market in parallel and over time. With a broader portfolio of games produced by external teams, the risk factor will be mitigated if a project does not perform as we have initially wished. We have several proven strong titles in our Publishing portfolio to look forward to, including notable IPs such as Psychonauts 2 and System Shock 3. PARTNERING IN VR VENTURESThe questions we are asked most often about our VR ventures is why we – a game company – should engage in hardware production and how we can compete with other tech giants. Starbreeze remains fully committed to its virtual reality expansion and the answer is twofold. One, we firmly believe virtual reality is one of the emerging techs that is here to stay and we aim to be one of the future key stakeholders in creating immersive experiences, now and in the future. Secondly, we found that while the consumer market was alluring, the B2B market has great potential where we have an opportunity to take a strong position. Finding the right partner to bring the product to market has been key, and with our collaboration with Acer and through the creation of the StarVR joint venture, we’re well positioned to take market share in the B2B space. With the Dubai project getting closer to its launch, we’ll be able to finally show the realization of what a 21st century theme park, all in VR, could be like. With 7,000 m2 of total space and millions of people walking by the location every year, we’re set to take virtual reality arcades to the next level. As lead supplier we will initially have seven experiences in the center. We remain dedicated to our VR venture. We are looking to be smart about our investments and make sure we get maximum benefit from all of them. We have driven design and technical innovation within the framework of our VR partnership with Acer. The time is now right to gear up the investment in the joint venture company and get the headset onto the B2B market and into VR centers. This phase is capital intensive and Acer will be taking on a larger share of the financing and, accordingly, a larger stake in the joint venture. With Acer as our strategic partner and with their financial muscle, we can focus our resources on our core business – Content is still king!

Swedbank in top when Fair Finance Guide ranks Swedish banks’ guidelines for sustainability 2017

Once a year, Fair Finance Guide reviews the banks’ guidelines concerning requirements on companies they finance or invest in, and how transparent they are in reporting their sustainability work. “In Swedbank we work hard on integrating sustainability aspects into the business. This because we are convinced that this is how we build long-term financial value, and in the long run how we promote a sound and sustainable economy for the many households and companies. The fact that our sustainability guidelines now ranks best in comparison with other banks shows that we are doing the right thing and it gives energy as we continue to work”, Birgitte Bonnesen, President and CEO at Swedbank says. Fair Finance Guide ranking is based on the banks’ official guidelines and it takes clear statements or references to existing frameworks to get points. The review shows that Swedbank’s biggest improvements lie in the area of human rights, forestry and anti-corruption. “Swedbank wants to make it easier for people and companies to make sustainable choices. We constantly and systematically review our guidelines to create tools that provide better insight in different industries’ sustainability challenges. Besides, five of Swedbank Robur's sustainability funds recently managed the stringent requirements for eco-labeling, which makes it easier for savers to find and choose funds that affects companies in a more sustainable way”, Fredrik Nilzén, Head of Group Sustainability at Swedbank says. The organisations behind Fair Finance Guide are Swedish Consumers Association, Fair Action, Amnesty International, Diakonia and Swedish Society for Nature Conservation. The initiative is funded with support from The Swedish International Development Cooperation Agency. For more information:Fredrik Nilzén, Head of Group Sustainability, Swedbank, +46 76 773 19 26Josefine Uppling, Head of Press Office, Swedbank, +46 76 114 54 21

Volvo Group unveils new innovative transport solution to drive safety and productivity

The Volvo Group has been conducting research into autonomous transport solutions for several years. The company has demonstrated concept vehicles for applications in confined areas like mines and quarries. Now Volvo Group takes the next step towards the future with an autonomous concept truck for hub-to-hub transportations in semi-confined areas like harbours and dedicated lanes on highways. Autonomous solutions bring benefits and serve the needs of both the customer and of society. This pioneering truck, based on an existing FH platform, navigates and operates entirely autonomously using Lidar and GPS technology to continuously read its surroundings, navigating around fixed and movable obstacles while gathering data via its on-board transport system in order to further optimize its route, traffic safety and fuel consumption. This truck requires no manual supervision, but rather is part of the customer’s total transport solution that controls the entire delivery process. “Although this technology may be years away from production, it will undoubtedly influence our future offering and has the potential to develop smart societies for the future. No matter what type of solution we develop, safety is always our primary concern and this applies to all our self-driving projects” says Martin Lundstedt, President and CEO at Volvo Group.  Watch the video with the self-driving truck  Read more at our web site  16 November 2017 For further information, please contact Anna Arbius at +46 (0)31 322 2993 For more stories from the Volvo Group, please visit www.volvogroup.com/press. The Volvo Group is one of the world’s leading manufacturers of trucks, buses, construction equipment and marine and industrial engines. The Group also provides complete solutions for financing and service. The Volvo Group, which employs about 95,000 people, has production facilities in 18 countries and sells its products in more than 190 markets. In 2016 the Volvo Group’s sales amounted to about SEK 302 billion (EUR 31,9 billion). The Volvo Group is a publicly-held company headquartered in Göteborg, Sweden. Volvo shares are listed on Nasdaq Stockholm. For more information, please visit www.volvogroup.com. 

Stockmann refinances its long-term credit facilities, considers the issuance of new notes and announces a consent solicitation of its notes due 2018

STOCKMANN plc, Inside Information 16.11.2017 at 11.45 EET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Stockmann plc (the "Issuer" or "Stockmann") has agreed on the refinancing of its long-term credit facilities. A EUR 650 million secured term and revolving credit facilities agreement has been signed with OP Corporate Bank plc, Danske Bank A/S, Nordea Bank AB (publ), Finnish Branch, DNB Bank ASA, Svenska Handelsbanken AB (publ) and Swedbank AB (publ) acting as arrangers. The new credit facilities are to replace the existing EUR 700 million bilateral credit facilities. EUR 150 million of the new credit facilities will mature in March 2018 and the remaining facilities in January 2021. The new facilities as well as the New Notes (as defined below) are to be secured by property mortgages and a pledge over certain shares. In addition, a share pledge related to the Nevsky Centre property is granted for the new credit facilities. The new facilities include financial covenants related to equity ratio and leverage. Stockmann has also undertaken to enter into measures resulting in obligations to prepay by no later than January 2019 an aggregate amount of EUR 150 million with respect to the term loans under the new facilities. Issuance of new senior secured notes Subject to market conditions, the Issuer intends to issue new senior secured notes (the “New Notes”). Stockmann has mandated Danske Bank A/S, Nordea Bank AB (publ) and OP Corporate Bank plc (together, the “Coordinators”) together with DNB Bank ASA, Svenska Handelsbanken AB (publ) and Swedbank AB (publ) (together with the Coordinators, the “Lead Managers”) to arrange investor meetings in respect of the issuance of the New Notes. The net proceeds from the issue of the New Notes would be used by Stockmann primarily to refinance its outstanding EUR 150 million 3.375 per cent notes due 2018 (ISIN: FI4000051057) (the "Notes") and the remaining proceeds to refinance other existing indebtedness of Stockmann. The availability of the new credit facilities is conditional on the issuance of New Notes in a minimum principal amount of EUR 200 million and the successful completion of the consent solicitation of the Notes. Consent Solicitation with respect to notes due 2018 Stockmann is soliciting consents from all holders (the “Noteholders”) of the Notes to approve certain modifications (the “Proposal”) to the terms and conditions of the Notes (the “Consent Solicitation”). The Consent Solicitation is subject to the terms and conditions and restrictions set out in the consent solicitation memorandum dated 16 November 2017 (the “Consent Solicitation Memorandum”). Capitalised terms used herein shall have the meaning ascribed to them in the Consent Solicitation Memorandum. The Issuer is not permitted, pursuant to the terms and conditions of the Notes, to refinance the Notes ahead of maturity and extend security to the New Notes. Therefore, in order to permit the refinancing of the Notes through the issuance of the New Notes, the Issuer is requesting that Noteholders approve the Proposal at the noteholders’ meeting (the “Noteholders’ Meeting”) in order to permit an early redemption of the Notes (the “Early Redemption”) at a redemption price (the “Redemption Price”) calculated by reference to a fixed purchase yield of 0.58 per cent, as described in the Consent Solicitation Memorandum. The expected Early Redemption Settlement Date is 12 December 2017, and the last possible Early Redemption Settlement Date is 31 January 2018. For information purposes only, the Redemption Price on the expected Early Redemption Settlement Date (12 December 2017) is expected to, when determined in the manner described in the Consent Solicitation Memorandum, be EUR 1,007.38 per each EUR 1,000.00 in principal amount of Notes. Any accrued and unpaid interest will also be paid in respect of the Notes. A Noteholder who delivers a valid Voting Instruction in favour of the Proposal before 4:00 p.m. (Finnish time) on 24 November 2017 (the "Early Consent Fee Deadline") will also be eligible to receive an early consent fee of 0.20 per cent in respect of the Notes for which a vote has been cast (the "Early Consent Fee") and a priority in the allocation of the New Notes (please see section "Priority in the allocation of the New Notes" below for further details of the allocation). If the Early Redemption Settlement Date occurs as expected on 12 December 2017, EUR 1,009.38 per each EUR 1,000.00 in principal amount of Notes (plus accrued and unpaid interest) would be paid to Noteholders who qualify for the Early Consent Fee (i.e., both the Early Consent Fee and the Redemption Price). The Voting Instruction should be sent to the Tabulation Agent by email to the email address: is.operations.fi@nordea.com or by regular mail to the address provided further below. Noteholders who (i) do not vote; (ii) vote in another manner, for example in person or by being represented by proxy (other than a Voting Instruction to the Tabulation Agent) at the Noteholders' Meeting (or at an adjourned Noteholders' Meeting, if any) or by Voting Instructions in favour of the Proposal but after the Early Consent Fee Deadline; or (iii) vote against the Proposal will not be eligible to receive the Early Consent Fee, but all Noteholders will receive the Redemption Price if the Early Redemption occurs. The Noteholders’ Meeting will be held at the premises of Nordea at Aleksis Kiven katu 7, Helsinki, Finland at 9:00 a.m. (Finnish time) on 28 November 2017. The Proposal will be approved if a quorum of two or more Noteholders present holding at least 50 per cent of the principal amount of Notes outstanding is achieved at the Noteholders’ Meeting and Noteholders representing at least 2/3 of the votes cast at the Noteholders’ Meeting vote to approve the Proposal. Payment of the Early Consent Fee will take place, if the Proposal is passed at the Noteholders’ Meeting and the Early Redemption occurs and will be paid no later than 10 days following the Early Redemption Settlement Date. Noteholders are advised to read carefully the Consent Solicitation Memorandum for full details of and information on the Early Redemption and the procedures for participating in the Consent Solicitation. The final deadline for submission of a valid Voting Instruction is 4:00 p.m. (Finnish time) on 27 November 2017. Noteholders will be notified of the Redemption Price and the Early Redemption Settlement Date via a stock exchange release. Any Early Redemption will be conditional on the issue of the New Notes in the minimum principal amount of EUR 200 million. Priority in the allocation of the New Notes A Noteholder who wishes to subscribe for New Notes in addition to participating in the Consent Solicitation may receive priority in the allocation of the New Notes (the “New Issue Allocation”). The New Issue Allocation may be given for an aggregate principal amount of New Notes up to the aggregate principal amount of Notes subject to a Noteholder’s valid Voting Instruction in favour of the Proposal before the Early Consent Fee Deadline, where an allocation of New Notes is also requested. Noteholders should contact any of the Solicitation Agents to obtain a unique reference number in respect of the New Issue Allocation. If any Noteholder wishes to subscribe for New Notes, it must make an application to subscribe for such New Notes to any of the Coordinators of the New Notes. To receive copies of the Consent Solicitation Memorandum or for questions relating to the Consent Solicitation, please contact any of the Solicitation Agents. Solicitation Agents:Danske Bank A/STel.: +358 10 513 8794 / Email: liabilitymanagement@danskebank.dk  Nordea Danmark, filial af Nordea Bank AB (publ), SverigeTel.: +45 6161 2996 / Email: NordeaLiabilityManagement@nordea.com OP Corporate Bank plcTel.: +358 10 252 1668 / Email: liabilitymanagement@op.fi Tabulation AgentNordea Bank AB (publ), Finnish BranchIssuer ServicesAleksis Kiven katu 3-5VC 215FI-00020 NordeaFinlandEmail: is.operations.fi@nordea.com Paying Agent:OP Corporate Bank plcTel: +358 10 252 7740 / Email: yhtiotapahtumat@op.fi Further information: Kai Laitinen, CFO, Stockmann, tel. +358 9 121 5800Nora Malin, Director, Corporate Communications, Stockmann tel. +358 9 121 3558 www.stockmanngroup.com STOCKMANN plc Lauri VeijalainenCEO Distribution:Nasdaq HelsinkiPrincipal media DisclaimerThis announcement is for information purposes only and is not to be construed as an offer to purchase or sell or a solicitation of an offer to purchase or sell with respect to any securities of Stockmann. Furthermore, this announcement does not constitute an invitation to participate in the Consent Solicitation in any jurisdiction in which, or to any person to or from whom, it is unlawful to make such invitation or for there to be such participation under applicable securities laws. No actions have been taken to register or qualify the New Notes, or otherwise to permit a public offering of the New Notes, in any jurisdiction. The distribution of this announcement may, in certain jurisdictions, be restricted by law. Any offering material or documentation related to the New Notes may be received only in compliance with applicable exemptions or restrictions. This announcement and any such offering material or documentation may not be distributed or published in any jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction or would require actions under the laws of such jurisdiction. In particular this announcement and any such offering material or documentation may not be distributed in the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or any other jurisdiction in which it would not be permissible to offer the New Notes and this announcement and any related material concerning the issuance of the New Notes may not be sent to any person in such jurisdictions. Persons into whose possession this announcement or any such offering material or documentation may come are required to inform themselves of and observe all such restrictions. Neither Stockmann nor Lead Managers nor their representatives accept any legal responsibility for any violation by any person, whether or not the persons contemplating investing in or divesting Stockmann's securities including the New Notes are aware of such restrictions. Any securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and any such securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account or benefit of any U.S. person (as such terms are defined in Regulation S under the Securities Act). Stockmann has not authorised the offering of the New Notes to the public in any member state of the European Economic Area (the "EEA"). All offers of the New Notes in the EEA will be made pursuant to an exemption under the Prospectus Directive (Directive 2003/71/EC as amended), as implemented in the member states of the EEA (each, a "Relevant Member State"), from the requirement to produce a prospectus under the Prospectus Directive for offers of securities. An offer to the public of the New Notes may not be made in that Relevant Member State, except that an offer of the New Notes to the public in that Relevant Member State may be made under the following exemptions from the Prospectus Directive, if they have been implemented in that Relevant Member State: (a) to any legal entity which is a qualified investor as defined in the Prospectus Directive; (b) to fewer than 100, or, if the Relevant Member State has implemented the relevant provisions of the 2010 PD Amending Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive; or (c) in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall result in a requirement for Stockmann or the Lead Managers to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. The expression an "offer to the public" in relation to the New Notes in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase any securities, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State, the expression “2010 PD Amending Directive” means Directive 2010/73/EU amending the Prospectus Directive. This communication does not constitute an offer of the securities to the public in the United Kingdom. No prospectus has been or will be approved in the United Kingdom in respect of the New Notes. This communication is being distributed to and is directed only at (i) persons who are outside the United Kingdom or (ii) (a) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (b) persons falling within Article 49(2)(a) to (d) of the Order, or other persons to whom they may be lawfully communicated (all such persons together being referred to as “Relevant Persons”). Any investment activity to which this communication relates will only be available to and will only be engaged with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or any of its contents. The information provided in this announcement is not intended to constitute an offer or solicitation to purchase or invest in the New Notes described herein. The New Notes may not be publicly offered, sold or advertised, directly or indirectly, in, into or from Switzerland and will not be listed on the SIX Swiss Exchange Ltd. (“SIX Swiss Exchange”) or on any other stock exchange or regulated trading facility in Switzerland. Neither this announcement nor any other offering or marketing material relating to the New Notes constitutes a prospectus as such term is understood pursuant to article 652a or article 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange or any other regulated trading facility in Switzerland, and neither this announcement nor any other offering or marketing material relating to the New Notes may be publicly distributed or otherwise made publicly available in Switzerland. In respect of the Consent Solicitation, this announcement must be read in conjunction with the Consent Solicitation Memorandum. If you are in any doubt as to the action you should take, you are recommended to seek your own financial advice immediately from your stockbroker, bank manager, legal counsel, accountant or other appropriately authorised independent financial advisor.

Axel Johnson International acquires AHD Aandrijftechniek in The Netherlands

To the left Bob Stijsiger, Managing Director of AHD Aandrijftechniek B.V and to the right Jan Verduin, Managing Director of Spruit Transmissies B.V Axel Johnson International’s business group Industrial Solutions is increasing its market presence in the Benelux countries through the acquisition of AHD Aandrijftechniek B.V. AHD has been active in the maintenance, repair and overhaul segment in The Netherlands, Belgium and Luxemburg for 25 years. It sells, maintains and services industrial gearboxes, brakes, couplings and propeller shafts to large and small customers, most notably Tata Steel. AHD will join forces with Spruit Transmissies B.V., a technical distributor of power transmission parts within Industrial Solutions. “This is an important step for Spruit,” says Ola Sjölin, Managing Director of Industrial Solutions, Axel Johnson International, “The transaction shows our confidence in the Dutch and Benelux market and in Spruit’s ambition to grow. AHD and Spruit will continue to work together with a high degree of freedom, which is in line with Axel Johnson International’s values.” AHD and Spruit have had a business relationship for many years and both companies see immediate benefits from the transaction, which closed October 26. The aim is to integrate AHD gradually into Spruit’s operational systems whilst keeping the trade name intact for a longer period. “The products that AHD has in its portfolio are a good complement to our current product groups, providing us with the opportunity to offer our customers a more complete package of products, plus on-site service,” says Jan Verduin, Spruit’s Managing Director. AHD will ensure continuity for partners and employees, with experienced engineers from AHD joining Spruit’s team. “Joining Spruit is a strategic step for us,” says Bob Stijsiger, Managing Director of AHD, who will continue as technical service manager in the new organisation. “The support of a larger group provides us with opportunities to expand our customer base in the region and to take on larger projects. For myself, I can fully focus on servicing our customers.” Spruit Transmissies is a technical distributor and problem solver in transmission products, selling premium products to independent retailers, as well as to OEM and MRO customers in the Benelux area. Its headquarters is in Alkmaar, north of Amsterdam, where it has about 25 employees and its own workshop. The company was founded in 1981 and has annual sales of approximately EUR 6 million. It has a very strong name as supplier in Holland, Belgium and the neighbouring regions. Axel Johnson International acquired it in 2014. AHD Aandrijftechniek BV is headquartered halfway between Rotterdam and Amsterdam in Alphen, where it has three employees. It has annual sales of approximately EUR 600,000. AHD is well known in the market for the quality of their service and for providing special solutions for customers. The company was founded in 1991 as a supplier and MRO specialist in the power transmissions market.   For further information, please contact: Hans Glemstedt, Head of Strategy and M&A, Axel Johnson International, +46 (0)8 453 77 41, hans.glemstedt@axinter.com Ola Sjölin, Managing Director Industrial Solutions, Axel Johnson International, +46 (0)8 453 77 25, ola.sjolin@axinter.com Jan Verduin, Managing Director of Spruit Transmissies B.V+31 (0)72 541 20 08, JVerduin@spruit.nl  

Instalco expands in Finland through the acquisition of Telefuusio

Telefuusio was founded in 2008 by Ruslan Vassiljev and currently employs 28 people. The company is specialised in telecom installations, such as fibre, server rooms and entrance systems, with customers primarily in the private sector and within commercial properties. For the financial year of 2016/17, the company’s net sales amounted to approx. SEK 35 million. “Telefuusio is an excellent addition to Instalco and will complement our existing companies in Helsinki in a good way. We see great opportunities for increased cooperation between our Finnish units and to continue our growth in the market”, says Robin Boheman, Head of Business Development and the Finnish business area of Instalco. Telefuusio’s founder Ruslan Vassiljev will remain as CEO of the company. ”It is very exciting to become part of Instalco’s successful group of companies. Through the deal, we will be able to cooperate with the other units while also getting a stable platform for our business and employees”, says Ruslan Vassiljev. Instalco acquires 100% of the shares in Telefuusio Oy with completion today, 16 November 2017. For more informationRobin Boheman, Head of Business Development and business area Finland, Instalcophone +46 73 336 71 42, e-mail robin.boheman@instalco.se Adrian Westman, Head of Investor Relations, Instalcophone +46 73 509 04 00, e-mail adrian.westman@instalco.se  Instalco is one of the leading installation companies in the Nordic region, active in the areas of heating, plumbing, electricity, cooling and industrial solutions. We work closely with customers, offering all the advantages of a local company, along with efficient collaboration and leadership. The operations are conducted through approximately 30 leading and highly specialised local companies, with the support of a small central organisation. Instalco is listed at Nasdaq Stockholm under the ticker INSTAL. For further information, visit www.instalco.se.

European Medical Device Firm BrainCool AB (publ) Establishes US Headquarters and Adds Bryan Nicholson as VP Operations

FOR IMMEDIATE RELEASEDate: November 16, 2017Contact: Martin Waleij, +46 733 93 70 76, martin.waleij@braincool.se; Lisa Owens, 210-601-6647, LisaMMOwens@gmail.com November 16, 2017 – Lund, Sweden and Annapolis, Maryland, US. Swedish medical device firm BrainCool AB (publ) has established a US subsidiary, BrainCool, Inc ., headquartered in Annapolis, Maryland, and added Bryan Nicholson as its US Vice President of Operations. Nicholson will lead operations for the company as it grows the North American market for its IQool® System which was cleared by the US FDA in May of 2017. He will also serve as Global VP of International Sales for the company’s full portfolio of therapeutic hypothermia and temperature management products in the EU. Mr. Nicholson is an experienced executive in the medical device industry with a focus on hypothermia and targeted temperature management solutions, building sales and support operations in the US. Most recently he served as Vice President of Sales North America for LKC Technologies. He previously held positions with Cryothermic Systems, Inc., Bayer Healthcare, Sanofi-Aventis and with Medivance, CR BARD as National Account Manager specializing in targeted temperature management for the Arctic Sun device.  BrainCool´s CEO, Martin Waleij commented, “The addition of Bryan Nicholson to the team will support our international growth plan as BrainCool products continue to gain acceptance. His significant commercial and operational experience, including in-depth knowledge of the hypothermia and temperature management market, will help BrainCool promote adoption of the IQool® System in the US.”  “Temperature management is an emerging market globally and BrainCool’s portfolio of innovative products is unmatched by the currently available devices today,” commented Nicholson. “The IQool® System offers a novel and unique alternative for US-based clinicians to cool patients when clinically indicated.”  The IQool® System is a next-generation precision surface cooling system intended for temperature management with a focus on three independent anatomical zones: head/neck, thigh and torso. The IQool® System quickly and effectively cools adult patients when clinically indicated using easy-to-apply non-stick adhesive pads prefilled with BCCOOL (a non-toxic and bacteria-static cooling agent) that are attached to an automated chiller. The IQool® engages within seconds, allowing clinicians in a variety of settings to manage patient temperature quickly and effectively. The product received 510(k) clearance from the US Food and Drug Administration (FDA) in May of 2017, with an indication for use of temperature reduction in adult patients when clinically indicated. Based in Lund, Sweden, Europe, BrainCool AB (publ) (AktieTorget: BRAIN) is a publicly traded medical device company focused on next-generation temperature management systems. The technology platform both cools and warms patients using focused anatomical zones as opposed to whole body applications such as cooling blankets. BrainCool dramatically advances the temperature management standard of care by delivering a physically-targeted, speed-driven temperature management system designed to be easy to use and effective. The company currently markets a number of CE-marked devices in Europe addressing therapeutic hypothermia for cardiac arrest and stroke (BrainCoolTM and RhinoChillTM), with products focused on concussion and traumatic brain injury and pain management within the oncology and migraine spaces currently in clinical development. ### This information is information that BrainCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on November 16, 2017. 

Arcam announces outcome of rights issue

Those who were registered by Euroclear Sweden AB as shareholders in Arcam on the record date October 19, 2017, had preferential right to subscribe for new ordinary shares in the rights issue. For each share held in Arcam one (1) subscription right was received. Five (5) subscription rights entitled to subscription of one (1) new ordinary share at a subscription price of SEK 240. In addition, subscribers who subscribed for ordinary shares with subscription rights, were offered to subscribe for ordinary shares without subscription rights. Those who have subscribed for ordinary shares without subscription rights will be allotted shares according to the principles outlined in the prospectus. Notification regarding allocation of ordinary shares to subscribers who have been allotted shares without subscription rights are expected to be distributed on November 17, 2017. Subscribed and allocated ordinary shares shall be paid in cash at the latest on the settlement day, November 21, 2017, in accordance with the instructions on the settlement note. Nominee registered shareholders will receive notification regarding allocation of ordinary shares in accordance with the respective nominee’s procedures. Only those who are allotted ordinary shares will be notified. Through the rights issue Arcam’s share capital will increase by approximately SEK 4,109,286 to approximately SEK 24,855,873 and the total number of shares will increase by 4,109,286 ordinary shares to 24,855,871 shares, where 24,655,871 comprise of ordinary shares and 200,000 comprise of preference shares of series C, when the rights issue is registered by the Swedish Companies Registration Office. The new ordinary shares subscribed with subscription rights are expected to start trading on Nasdaq Stockholm on November 21, 2017. New ordinary shares subscribed for without exercise of subscription rights are expected to start trading on Nasdaq Stockholm on November 24, 2017. Advisors in connection with the rights issue Söderlind & Co AB is financial advisor to Arcam and Baker McKenzie is legal advisor relating to the Rights Issue. Important information This announcement is not and does not form a part of any offer for sale of securities. Copies of this announcement are not being made and may not be distributed or sent into the United States, Australia, Canada, New Zealand, Hong Kong, Japan, South Africa or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States. Any Offering of securities referred to in this announcement will only be made by means of a prospectus. This announcement is not a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus. In any EEA Member State other than Sweden that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). This communication must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe,” “expect,” “anticipate,” “intends,” “estimate,” “will,” “may,” "continue," “should” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. 

THQ Nordic acquires Biomutant® developer Experiment 101

Biomutant is an open world, post-apocalyptic kung-fu fable action role-playing game. The game was first announced at Gamescom in August 2017, receiving strong reception with fans and the gaming media. The total consideration paid for all shares is SEK 75.3 million paid to the sellers Goodbye Kansas and Stefan Ljungqvist[1] . SEK 10.0 million of the consideration is paid by issuance of new THQ Nordic B shares, with a 3-year lock-up, to Stefan Ljungqvist1, subject to decision by the next general meeting in THQ Nordic. The remaining consideration is paid in cash upon closing. The parties have agreed an earnout based on Biomutant´s financial performance. The earnout will be calculated as a small percentage of THQ Nordic’s net proceeds from Biomutant during the first 36 months after release, after deduction of 150% of both total consideration paid and game development costs. The consideration paid will mainly be booked in the group balance sheet as ongoing game development as well as IP rights for the Biomutant franchise. Lars Wingefors comments: “We saw significant potential in Experiment 101 and Biomutant, under Stefan Ljungqvist’s leadership, early in the development 2016. After the strong reception Biomutant received at its announcement at Gamescom 2017, we are excited to have been able to acquire Experiment 101 and Biomutant. Our aim is to build Biomutant into one of our major franchises. The recruitment of Stefan Ljungqvist and his talented team brings important new power to THQ Nordic. In addition to continue leading the Biomutant franchise, Stefan will advise on our strategy, future acquisitions and further game development projects.” ---------------------------------------------------------------------- [1]  To Stefan Ljungqvist´s wholly-owned company Boston Front AB 

Coor upgrades digital interface for superior customer experiences

With the aim of enhancing the customer’s experience and increasing availability, Coor has executed dedicated initiatives to enhance its largest digital customer platforms. Coor Service Portal is a customer portal that many of its customers use Nordic wide. The portal is fully responsive and embedded in a responsive cloud-based solution that is easily accessible from all types of device (PCs, tablets and mobiles). It enables Coor’s end-users to find information, manage cases, place orders or make bookings. The portal is linked to Coor’s CRM system, which supports automated workflows and makes cases fully traceable. FOOD by Coor Portal is a dedicated restaurant portal. Apart from menu information, it also has functionality to order food and related products to take away. “As the leading service provider in the Nordics, it’s important that we have a good understanding of how to use new technology on our deliveries. The ability to offer our customers really good, state-of-the-art customer platforms is part of these efforts. Users should experience Coor as a provider that adds value, which these platforms contribute to,” commented Rikard Wannerholt, Coor’s Head of Operational Development & Transformation. Both platforms have gone live in parts of Coor’s business, and will be rolled out during 2017. For more information, images etc., please visit www.coor.com or contact: Rikard Wannerholt, Head of Operational Development and Transformation+46 10 559 59 35, rikard.wannerholt@coor.com Sofie Schough, acting Communictions Director+46 10 559 59 83, sofie.schough@coor.com